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In South Africa, there is a lack of national surveillance for Campylobacter. 
Campylobacter infections particularly those caused by Campylobacter jejuni and 
Campylobacter coli, cause a significant proportion of all diarrhoeal cases.  Although 
diarrhoea caused by Campylobacter is short-lived, belligerent clinical manifestations 
include C. jejuni-induced Guillain-Barré Syndrome (GBS) which can cause considerable 
morbidity. Improvements in molecular subtyping methodologies, such as multi-locus 
sequence typing (MLST) and whole genome sequencing (WGS) based applications 
have been successfully applied in the field of molecular epidemiology of Campylobacter. 
Our study proposed to improve the molecular epidemiological understanding of 
Campylobacter in South Africa using polymerase chain reaction (PCR), WGS, and 
MLST. Antimicrobial susceptibility profiles of Campylobacter were also investigated. 
Furthermore, the prevalence of Campylobacter in stool specimens of children (<5 years) 
with acute diarrhoea and from patients with symptoms of acute flaccid paralysis (AFP) 
was investigated. A multiplex real-time PCR targeting C. jejuni and C. coli was used to 
screen a total of 2,341 samples from clinical isolates and clinical specimens associated 
with various existing surveillance programs. Antimicrobial susceptibility was performed 
using the Etest method. C. jejuni isolates were further subtyped using MLST based on 
the analysis of WGS data. In all surveillance programs, C. jejuni was the most 
predominant species of Campylobacter detected (>77%). Isolates had low prevalence of 
antimicrobial resistance to erythromycin (10%) and azithromycin (14%), however, 
ciprofloxacin (53%) and tetracycline (53%) resistance was notable. It was male (54%) 
children of less than five years of age (35%) who were more frequently associated with 
campylobacteriosis. A total of 33 different sequence types (STs) were identified through 
MLST; ST-227 and ST-572 were the most common STs. A total of five different clonal 
complexes grouped all typable isolates, with ST-206 complex and ST-21 complex being 
the most common clonal complexes. Strains with new unassigned STs of novel 
combinations of known alleles (n=8) and novel alleles were identified (n=1).  Multiplex 
real-time PCR proved effective to detect and discriminate Campylobacter species. C. 
jejuni was the most isolated species during the course of the study. The application of 
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MLST reflected the genetic diversity that exists in C. jejuni strains. The current 
underrepresentation of Campylobacter burden of disease in South Africa may improve if 
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Chapter 1: Introduction and Literature review 
 
 
1.1.       Introduction 
Campylobacteriosis is a disease caused by species of Campylobacter, particularly 
Campylobacter jejuni and Campylobacter coli. These infections are a major leading 
cause of gastrointestinal disease globally, with recent incidence rates that are higher 
than those caused by Salmonella in developed countries (Acheson and Allos, 2001; 
Samuel et al., 2004). Although gastrointestinal diseases associated with species of 
Campylobacter are rarely fatal, significant proportion of diarrhoeal cases are 
reported annually, which result in significant burden on health care systems and a 
major cause of economic loss globally (Sheppard et al., 2009). Common sources of 
Campylobacter infection have been defined, however, how these sources contribute 
to human infection remains incompletely addressed and reported cases of infection 
continue to increase (Tenkate and Stafford, 2008; Sheppard et al., 2009).  
 
Belligerent clinical manifestation of Campylobacter includes post-infectious 
manifestation of C. jejuni infection resulting in Guillain-Barrè Syndrome (GBS) which 
can cause considerable morbidity (Acheson and Allos, 2001; Friedman et al., 2004). 
Another emerging issue is the global increase of Campylobacter species resistant to 
clinically recommended antimicrobials (Wimalaratha et al., 2013). National 
Campylobacter surveillance programs established in developed countries are not as 
they should be in many developing countries; a situation that compromises incidence 
values for a defined population (Coker et al., 2002). Irrespective of the lack of 
incidence data from national surveys, case-control community-based studies showed 
incidence estimates of 40, 000 to 60, 000 per 100, 000 for children of less than five 
years of age (van Vliet and Katley, 2001; Coker et al., 2002; Galate and Bangde, 
2015). The report demonstrated that campylobacteriosis is often a paediatric disease 





1.2.       The historical emergence of the genus Campylobacter  
In 1886 Theodor Escherich first described non-culturable spiral shaped bacteria 
which were observed in the colons of infants who died of a disease he named 
“cholera infantum” (Samie et al., 2007). Following Theodor Escherich’s observations, 
Campylobacter was first identified in the uterine mucus of a pregnant sheep in 1902 
by two British veterinarians (Silva et al., 2011). Initially campylobacters were referred 
to as “Vibrio like” organisms until 1963 when Sebald and Vèron proposed 
‘Campylobacter’ as the genus based on their curved-rod like shape [Figure 1.1], low 
DNA base composition, microaerophilic growth requirement, and their non-
fermentive metabolism (Hèbert et al., 1983; Vandamme and Ley, 1991; Samie et al., 
2007; Silva et al., 2011; Galate and Bangde, 2015). With on-going advances in 
diagnostic arsenals, selective media founded the initial routine detection of 
Campylobacter in clinical laboratories (Acheson and Allos, 2001; Moore et al., 2005). 
 
 
Figure 1.1: Scanning electron micrograph showing the curved/rod shape and bipolar 




1.3.       Taxonomy 
The family Campylobacteraceae which was first proposed in the early nineties 
consists of two genera; Campylobacter and Acrobacter (Vandamme et al., 1991; van 
Vliet and Katley, 2001; Silva et al., 2011; Galate and Bangde, 2015). The genus 
Campylobacter, first proposed in 1963 by Sebald and Vèron, was derived from a 
Greek word which described a curved rod (Moore et al., 2005; Samie et al., 2007). 
Currently, the genus Campylobacter consists of 26 species of which 19 have been 
isolated from humans and 10 subspecies of which nine are from humans, however, 
the taxonomic structure of the family Campylobacteraceae remains controversial 
with the on-going discovery of organisms that fall under the family (Lastovica, 2006; 
Debruyne et al., 2008; Galate and Bangde, 2015;). According to Debruyne et al., 
(2008), there are only 14 species of Campylobacter that are validly described (Silva 
et al., 2011; Galate and Bangde, 2015). 
 
1.4.        Microbiology 
Campylobacter species are fastidious, gram-negative bacilli that are morphologically 
spiral or curved (Acheson and Allos, 2001; Mason et al., 2013). The morphology of 
Campylobacter is comparatively very small, about 0.2 to 0.5 µm wide and 0.5 to 8 
µm long (Silva et al., 2011). Campylobacter species are motile by means of unipolar 
or bipolar flagellae [Figure 1.1] (Acheson and Allos, 2001). These thermophilic 
species of bacteria thrives well at higher body temperatures, ranging from 37 
degrees Celsius (°C) to 42°C (Pendleton et al., 2013). They require longer incubation 
periods for optimum growth, ranging from 48 hours to 96 hours microaerophilically, 
depending on the specific species (Perez-Perez and Blaser, 1996). Campylobacter 
species are non-fermenting organisms due to their incapability to ferment or oxidize 
common carbohydrate substrates (Galate and Bangde, 2015). However, they are 
oxidase positive and they reduce nitrates. Spirally shaped Campylobacter have been 
reported to transition into coccoid forms when exposed to atmospheric oxygen levels 
or other environmental stresses (Cappelier et al., 1997). Viable non-culturable (VNC) 
has been used to describe the coccoid transitioned state, and it is suggested to be a 
dormant state necessary for survival under un-optimal environmental conditions for 
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Campylobacter growth (Cappelier et al., 1997; van Vliet and Katley, 2001). Although 
Campylobacter requires special growth conditions, the bacterium may survive on 
food or in the environment for a couple of days (Schielke et al., 2014).  
 
1.5.       Species of Campylobacter   
The emergence of species within the genus Campylobacter over the last three 
decades has indicated their pathogenic clinical importance (Acheson and Allos, 
2001; Moore et al., 2005). Campylobacter species have been implicated as 
aetiological agents for veterinary diseases, such as diarrhoea in cattle and septic 
abortion in cattle and sheep, and more recently as significant clinical pathogens, 
particularly of human public health concern (Moore et al., 2005; Silva et al., 2011). 
Campylobacter is a major food and waterborne pathogen where foods of animal 
origin, particularly poultry, have been identified as significant sources of 
Campylobacter infection (Acheson and Allos, 2001). C. jejuni and C. coli are species 
of major public health importance of the genus Campylobacter (Perez-Perez and 
Blaser, 1996; Persson and Olsen, 2005; Chokboonmongko et al., 2013; Ioannidou et 
al., 2013; Mason et al., 2013; Moore et al., 2005; Wagenaar et al., 2013 Schielke et 
al., 2014).  
 
Campylobacteriosis, the disease caused by a Campylobacter infection, which results 
in enteritis, is mainly caused by C. jejuni and to a lesser extent by C. coli (Wagenaar 
et al., 2013). C. jejuni has been found to account for over 80% of human cases, 
followed by C. coli, which accounts for most of the remainder (Gillespie et al., 2002; 
Vidal et al., 2016). Campylobacter species are invasive bacteria, capable of 
translocating and reaching the blood stream. In the 1950’s, association of human 
Campylobacter infections with blood cultures was rare, rendering campylobacters to 
be deemed opportunistic human pathogens, most likely to occur in patients who are 
immunocompromised, among the very young or the elderly (Acheson and Allos, 
2001; Moore et al., 2005). The rate of bacteraemia caused by Campylobacter remain 
as low as 1%, especially when contrasted with invasive infections caused by 
Salmonella (Acheson and Allos, 2001; Moore et al., 2005; Wagenaar et al., 2013). 
Reports on other Campylobacter species such as C. lari, C. upsaliensis, and C. fetus 
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have been documented as causative agents for human diseases. However, these 
reports of non-C. jejuni/C. coli infections globally accounts for a small fraction of all 
Campylobacter infections (Wagenaar et al., 2013). 
 
This has resulted in studies conducted to only focus on epidemiological studies 
involving C. jejuni and C. coli (Acheson and Allos, 2001; Moore et al., 2005; 
Wagenaar et al., 2013). Biotypes and serotypes of C. jejuni and C. coli have been 
identified and the congruency between biotypes and serotypes extracted from 
humans and animals show that campylobacteriosis is zoonotic (Perez-Perez and 
Blaser, 1996; Colles and Maiden, 2012). Studies aimed at understanding the 
epidemiology of Campylobacter species have identified C. jejuni and C. coli as the 
major causative agents of sporadic gastroenteritis in humans (Lee and Newell, 
2006). However, knowledge founding the pathophysiology of the organisms is poorly 
understood (Parkhill et al., 2000).  
 
1.6.        Epidemiology 
 
1.6.1. Burden of diarrhoeal diseases   
Diarrhoeal diseases pose a major public health problem in Republic of South Africa 
(RSA) making it the third leading cause of death in the country (Van Derslice and 
Briscoe, 1993; Nannan et al., 2012). In Africa, it is estimated that 3.552 million 
children of less than five years of age die each year, with diarrhoea accounting for 11 
% of these deaths (Mason et al., 2013). The disease is associated with high 
morbidity, mortality, and economic loss for families and communities. The World 
Health Organization (WHO) report has estimated that around one billion people lack 





1.6.2. Prevalence of Campylobacter diarrhoeal diseases 
The increase in incidence of human campylobacteriosis globally has attracted the 
attention of the WHO (Coker et al., 2002). However, the true estimates of incidence 
of diarrhoeal diseases caused by Campylobacter are poorly known. Various 
approaches are being investigated and implemented which may potentially reflect 
the true incidence of human campylobacteriosis (WHO, 2013). The rate at which 
human campylobacteriosis cases are escalating have been reported to be 
numerically greater than those of salmonellosis and shigellosis (Acheson and Allos, 
2001). In developing countries, Campylobacter is one of the commonly isolated 
bacteria from faeces of infants due to contaminated food and/or water (Mason et al., 
2013). These findings suggest the need for more studies aimed at understanding the 
epidemiology and control of campylobacteriosis which is still far from clear (Coker et 
al., 2002; Nylen et al., 2002; Klena et al., 2004). The limiting factor in developing 
countries is the lack of established national surveillance programs for 
campylobacteriosis, regardless of the pervasiveness of the disease. National 
surveillance programs for Campylobacter have been established in developed 
countries (Tauxe et al., 1988; WHO, 2013).    
 
I. Incidence of Campylobacter in developed countries 
 
Campylobacter species fall among the most prevalent bacterial enteric pathogens 
isolated in developed countries (Tauxe et al., 1988). Majority of the published 
literature reports incidence and prevalence estimates of campylobacteriosis from 
developed countries, with a few reports from developing countries [Figure 1.2]. While 
the incidence of campylobacteriosis is high, most illnesses occur sporadically, and 
cases are rarely (typically <1%) associated with outbreaks (Taboada et al., 2013). It 
has been reported that outbreaks or smaller case clusters do occur far more 
frequently than previously conceived to occur [Figure 1.3] (Taboada et al., 2013; 
Kaakoush et al., 2015).  Literature collected from the year 2007 to 2013 has shown 
majority of Campylobacter outbreak cases to be associated with poultry products 
and contaminated water [Figure 1.3] (Kaakoush et al., 2015). Other sources of 
Campylobacter outbreaks discovered during those years included ingestion of 
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mud/food, unpasteurized milk, animal contact, and sexual interactions (Kaakoush et 
al., 2015). Campylobacteriosis is a commonly reported zoonosis in the European 
Union (EU) and a commonly notified bacterial gastrointestinal disease in Germany 
(Schielke et al., 2014). The annual number of notified campylobacteriosis cases has 
increased in many European countries in recent years relative to other enteric 
pathogens such as Salmonella (Nylen et al., 2002; CDC, 2010; Schielke et al., 
2014). In the United States of America (USA), Campylobacter infection is the second 
commonest cause of bacterial enteritis after salmonellosis, with 2.4 million cases 
estimated to occur yearly (CDC, 2010). 
 
 
Figure 1.2: Incidence and prevalence data of campylobacteriosis extracted from 
literature published from studies conducted in developed and developing countries. 
Image adopted from Kaakoush et al., (2015). 
 
 
II. Incidence of Campylobacter in developing countries  
Campylobacter surveillance in developing countries is not what it should be as 
compared to developed countries; a situation that compromises incidence values for 
cases of campylobacteriosis for a population [Figure 1.2] (Coker et al., 2002; 
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Kaakoush et al., 2015). Compiled data from published literature has indicated 
research gaps existing in developing countries for Campylobacter (Kaakoush et al., 
2015). For instance in Africa, there are few collected published data reports on cases 
of campylobacteriosis in Kenya and Malawi [Figure 1.2], as well as Tanzania, and 
South Africa (Kaakoush et al., 2015). The Global Enteric Multicenter Study (GEMS), 
which enrolled children with moderate-to-severe diarrhoea residing in Africa and in 
Asia, found the detection of Campylobacter, which was based on conventional 
culture methods, to be scarce and restricted to Asian countries (Kotloff et al., 2013). 
Incidence estimates in developing countries are based on laboratory confirmed 
cases of sporadic Campylobacter infections as well as outbreak cases, from which 
laboratory-based surveillance of Campylobacter and other enteric pathogens are 
founded (Coker et al., 2002). In 2000, Oberhelman and colleagues reported 
Campylobacter isolation to range from 5 to 20% in developing countries; although 
some countries have reported increase in isolation and incidence rates since their 
initial report, which has been linked to improved diagnostic methods (Coker et al., 
2002; Galate and Bangde, 2015). 
  
 
Figure 1.3: Trends of Campylobacter outbreak cases from 2007 to 2013. Image 
adopted from Kaakoush et al., (2015). 
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III. Campylobacter confirmed cases in RSA 
 
There is insufficient literature describing the epidemiology of Campylobacter 
specifically in RSA, and as a result, values for burden estimates in the country do not 
exist. Studies that have been previously carried out are based on small sample size 
cases, carried out to give a snapshot of the prevalence of Campylobacter in RSA 
(Mason et al., 2013). In one of the studies, carried out by Mason et al., 2013, 
polymerase chain reaction (PCR) was used to examine Campylobacter species in 
adults and children with diarrhoea in RSA and the prevalence estimates were 12% 
and 7.5% respectively for C. jejuni & C. coli [n=225 samples; 34/225 children <5 
years of age]. Another study was carried out in Venda, Limpopo province, RSA, 
where 322 stool samples (n=255 hospital patients; n=67 asymptomatic pupils) were 
analyzed to detect the prevalence of Campylobacter species in the Vembe district. 
The prevalence of C. jejuni and C. coli was 10.2% and 6.5% respectively and 
significantly associated with diarrhoea among all the organisms detected in the study 
(Samie et al., 2007). In 1983, Richardson found 30% (n=60 children <2 years of age 
with diarrhoea; 18/60) positivity of C. jejuni infected children of less than nine months 
in Soweto, RSA. Preliminary unpublished data from a Rotavirus surveillance project 
in RSA has found approximately 13% positivity for Campylobacter in stool 
specimens of children (<5 years of age) with acute diarrhoea (NICD annual review, 
2014). These findings are much higher than previously thought, suggesting that the 
rates of Campylobacter infections have been previously underestimated in RSA. 
 
A study in Cape Town, RSA, conducted by Lastovica (2009) gave a more 
comprehensive standing of the epidemiology of Campylobacter, where during a 
period of five years 5 443 strains of Campylobacter were isolated from 
diarrhoeagenic stools of children using developed culture methodologies for the 
isolation of Campylobacter species. Of the isolated species of Campylobacter, 40% 
were C. jejuni (32.3% C. jejuni subsp. jejuni and 7.7% were C. jejuni subsp. doylei), 
and 24.6% was accounted for by C. concisus. The developed culture method 
permitted the isolation of non-C. jejuni/C. coli such as C. concisus which was the 
second most detected species of Campylobacter (Lastovica, 2006) . The few studies 
conducted in African countries have shown campylobacteriosis to be prevalent in the 
paediatric population (Kaakoush et al., 2015). Lastovica and colleagues (2006) 
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extensively described some of the confounding factors affecting the successful 
isolation of Campylobacter, such as underestimating the relative abundance of 
Campylobacter species, fastidious nature of the organism that was not accounted 
for, and unoptimal growth conditions suppressing growth of Campylobacter 
(selective media, temperature, atmosphere, and incubation periods). 
 
1.6.3.     Campylobacter and coinfections 
A study conducted by Mason et al., (2013) in Malawi demonstrated that in the non-
diarrhoeagenic group, 16% of the children with Campylobacter in the specimen also 
had a viral coinfection. Poor hygiene and sanitation as well as close proximity to 
animals in developing countries intensifies frequent acquisition of any enteric 
pathogen, an observation which has been previously reported from studies of 
coinfection with Campylobacter (Coker et al., 2002; Lèvesque et al., 2013; Mason et 
al., 2013). Coinfection of flocks with more than one strain of Campylobacter has 
been reported, and as a result coinfection of humans with more than one 
Campylobacter strain is identified in 5 to 10% of sporadic cases (Forbes et al., 
2009). 
 
1.6.4.      Risk factors and risk groups 
 
I. Seasonality as a risk factor 
Seasonality for campylobacteriosis in temperate and tropical countries differs 
(Acheson and Allos, 2001; van Vliet and Katley, 2001; Galate and Bangde, 2013). 
Summer and autumn Campylobacter peaks have been reported in temperate 
countries, although variation between and within countries have been reported 
(Nylen et al., 2002; Ekdahl and Andersson, 2004; Galate and Bangde, 2013). A 
study conducted in England and Wales showed Campylobacter peaks in spring, an 
observation which was consistent with results from previous studies (Louis et al., 
2005). In temperate countries, campylobacteriosis is reported to increase with 
increasing temperature (Louis et al., 2005). This observation is contrary to tropical 
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countries, where Campylobacter infections do not have a marked seasonal pattern 
(Ekdahl and Andersson, 2004).  
 
In the Southern part of Africa summer occurs from mid-October to mid-February, 
autumn from mid-February to April, winter from May to July, and spring from August 
to mid-October (Renssen, 2007). The weather in Africa can largely be classified as 
tropical; the lack of extreme temperature fluctuations, as well as the lack of 
surveillance for epidemics may be a contributing factor for the unrecognized 
Campylobacter seasonal peaks (Ekdahl and Andersson, 2004; Nylen et al., 2002; 
Galate and Bangde, 2013). In temperate regions, risk factors that are associated 
with campylobacteriosis in the summer months include animal contact, eating 
barbequed meals, drinking untreated water from streams and other natural sources, 
and most recently, flies have been postulated to be a risk factor, functioning as a 
mechanical vector (Nylen et al., 2002; Ekdahl et al., 2005). Studies have shown 
transfer of Campylobacter from the environment to flies with relative ease; in one 
such study, Campylobacter was isolated from 8% (4/49) of flies caught outside a 
broiler house in Denmark (Ekdahl et al., 2005). 
 
II. Sex as a risk factor 
Studies have reported that males and females differ in the way they respond to 
infections (Flanagan, 2014). The factors contributing to sexual dimorphism as far as 
infections are concerned include behavioural and physiological difference between 
males and females; however, there is scarcity of data supporting these viewpoints 
(Strachan et al., 2008). More recently, according to Olivier and William, (2010) the 
evolution of sex-specific immune defences play a role on how males differently 
perceive infections from females. As far as campylobacteriosis is concerned, 
tethered to paucity of data describing the epidemiology of the disease, explanations 
as to why males are more frequently implicated than females is less understood 
(Tauxe et al., 1988; Acheson and Allos, 2001). Although the significance to such 
findings has not yet an explanation, risk factors considered include differences in 
food handling practices and basic hygiene during food preparation, as well as the 




III. Age as a risk factor 
 
Studies aimed at identifying risk groups for campylobacteriosis have reported 
variation in age distribution of infected individuals; being highest among those under 
five years of age, young adults, and the elderly (Sebbald and Sharp, 1985; Samuel 
et al., 2004; Ekdahl et al., 2005; Mshana et al., 2009; van Vliet and Katley, 2001; 
Cody et al., 2012; Weinberger et al., 2013). Age risk groups differ in industrialized to 
developing countries (Acheson and Allos, 2001; Coker et al., 2002). In industrialized 
countries, two age risk groups have been identified; those aged <1 in years and in 
young adults (11-44 years), with a prevalence estimate of 1-13% among children 
with acute diarrhoea and 1.5 % among non-diarrhoeaic children (Mshana et al., 
2009).  
 
In developing countries, the prevalence of Campylobacter infections in patients with 
diarrhoea range from 5-35%, and are reported to be hyperendemic among the 
young, particularly those aged less than two years of age (Ayyagari et al., 1984; 
Acheson and Allos, 2001; Mshana et al., 2009; Sheppard et al., 2009). According to 
Miller et al., (2005) and Weinberger et al., (2013) detection rates of 
campylobacteriosis in developing countries forms a U-shaped curve, a suggestive 
trend arising from repeated exposure to Campylobacter species in early childhood 
which results in acquisition of protected immunity at older age. Another aspect is that 
asymptomatic infections occur commonly in children and adults, an unusual trend in 
developed countries (Acheson and Allos, 2001; Coker et al., 2002). Plausible risk 
factors associated with Campylobacter infections for individuals of different age 
groups have been documented, which include the lack of a fully developed immune 
system (infants), poor hygiene, and close proximity to pets and farm animals, travel, 
consuming contaminated high risk foods such as poultry, stress, weakened immunity 
due to diseases, and age-related deteriorating of immunity (Tauxe et al., 1988; 





1.6.5.     Pathogenesis 
 
I. Source and mode of transmission  
Meats, particularly of poultry origin, raw milk, and untreated water are well 
documented sources of human Campylobacter infections (Moore et al., 2005; 
Wagenaar et al., 2013; Fernandes et al., 2015). Approximately 50-70% of all 
Campylobacter infections are attributed to chicken consumption (Acheson and Allos, 
2001); which is not surprising in light of the frequency with which poultry products are 
consumed (Acheson and Allos, 2001; Moore et al., 2005) as well as the nearly 
universal contamination of chicken carcasses with Campylobacter during slaughter 
processes (van Vliet and Ketley, 2001; Wagenaar et al., 2013).  
 
Cross-contamination in the kitchen from contaminated meat to items that will not be 
cooked is considered a major pathway for transmission (Acheson and Allos, 2001; 
Wagenaar et al., 2013). The infectious dose ranges from 500-800 organisms which 
can be carried in approximately one drop of chicken juice (Acheson and Allos, 2001; 
van Vliet and Ketley, 2001; Schielke et al., 2014). Person-to-person transmission, 
which occurs through the faecal-oral route is uncommon (Acheson and Allos, 2001; 
Schielke et al., 2014; Galate and Bandge, 2015; Kaakoush et al., 2015). Human 
exposure from reservoirs has been linked to multiple pathways which include: (1) 
food, particularly poultry; (2) the environment; and (3) direct animal contact [Figure 





Figure 1.4: Pathogenesis of Campylobacter infection and the associated clinical 
manifestations. Abbreviations: inflammatory bowel diseases (IBD), and irritable 
bowel syndrome (IBS).Question marks represent conditions associated with 
campylobacteriosis, however with some degree of uncertainties. Image adopted from 
Kaakoush et al., (2015). 
 
II. Virulence  
Mechanisms by which Campylobacter species are virulent still remain largely 
undetermined (Perez-Perez and Blaser, 1996; Man, 2011; Galate and Bangde, 
2015). A possible reason contributing to this stagnancy is the lack of pathogenesis 
similarity between Campylobacter species and other enteric pathogens (Galate and 
Bangde, 2015). Advances in medical model technologies aided in unraveling 
mechanisms by which Campylobacter causes infection [Figure 1.5]. According to 
Dastia et al., (2010) as well as Cróinín and Backert, (2012) flagella-mediated motility, 
bacterial adherence to intestinal mucosa (Man, 2001), invasive capability, and the 
ability to produce toxins (particularly Cytolethal distending toxin (CDT), an important 
virulence factor for Campylobacter) have been identified as virulence (Galate and 
Bangde, 2015). Flagella are required for the colonization of small intestine, followed 
by the migration to the target organ, which is the colon (van Vliet and Ketley, 2001). 
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Invasion, which results in cellular inflammation, has been reported to result from the 
production of cytotoxins, which compromises the absorptive capacity of the 
intestines (van Vliet and Ketley, 2001). The ability of C. jejuni or C. coli to reach the 
intestinal tract is, in part, due to resistance to gastric acids and also to bile salts. 
Disease severity may depend on the virulence of the strain, as well as on the host’s 
immune condition (Silva et al., 2011; Galate and Bangde, 2015).  
 
A study conducted to investigate incidence of toxin producing human Campylobacter 
strains in RSA found strains that produce heat-labile cytotonic toxin (CTON) and 
various cytotoxins (CTOX). The study which included 22 Campylobacter strains 
reported that CTON was the most commonly found toxin in those strains that were 
toxin-producing (Bok et al., 1991). Low virulence has been reported in animals; 
however, some strains of both C. jejuni and C. coli have the ability to cause serious 
diarrhoeal illness in humans (Jonker and Picard, 2010). 
 
 
Figure 1.5: A model representation of the mechanisms of Campylobacter invasion of 
human intestinal epithelial cells and bloodstream translocation of the organism which 
subsequently causes haemolysis. Abbreviations: Interleukin 8 (IL8), Type IV 




1.6.6.     Clinical characteristics of campylobacteriosis  
Clinically, Campylobacter infections are indistinguishable from acute gastrointestinal 
infections caused by other bacterial pathogens (Acheson and Allos, 2001). Upon 
infection with C. jejuni and/or C. coli, susceptible subjects generally experience (after 
one to seven days) acute abdominal pain, often accompanied by fever, nausea and 
or vomiting, as well as general malaise (van Vliet and Ketley, 2001). Progression of 
symptoms is accompanied by either loose or watery profuse diarrhoea, which may 
contain mucous or blood (Acheson and Allos, 2001; van Vliet and Ketley, 2001; 
Perez-Perez and Blaser, 1996; Galate and Bangde, 2015). In developing countries, 
infection with C. jejuni and closely related organisms is less severe, without bloody 
diarrhoea, fever or fecal leukocytes (Perez-Perez and Blaser, 1996).  The disease is 
usually limited to a period of five to eight days, but may continue longer and bacterial 
shedding often persists after clinical symptoms have ended (van Vliet and Ketley, 
2001; Moore et al., 2005). Other clinical manifestations following campylobacteriosis 
are outlined in Figure 14. 
 
 
1.7.       Diagnosis, isolation, and identification of Campylobacter species 
1.7.1.    Phenotypic characterization of Campylobacter 
The principle encompassing definitive diagnosis of campylobacteriosis is based on 
the isolation of Campylobacter species from a stool culture (Blaser and Reller, 1981; 
Perez-Perez and Blaser, 1996; UK Standards for Microbiology Investigations, 2015). 
However, only a small percentage of individuals suffering from campylobacteriosis 
consult for medical care and have their infections culture-confirmed. Alternatively, 
when they do consult, they submit samples for culturing after they have started 
antibiotic treatment, which may make it even more difficult for a laboratory to grow 





I. Microscopic appearance  
Diagnosis can be carried out by direct examination of a stool sample using contrast 
microscopy or Gram’s strain (Blaser, 1997; Blaser, 2000). Direct examination 
provides a rapid presumptive diagnosis that must still be confirmed by stool culture. 
Observation of darting motility in fresh fecal specimens or of vibrio forms in Gram 
stain provides presumptive diagnosis for Campylobacter (Perez-Perez and Blaser, 
1996; UK Standards for Microbiology Investigations, 2015). 
 
II. Stool culture 
Sensitivity of Campylobacter species to oxygen and oxidizing radicals has been 
exploited to develop selective media for isolating Campylobacter from clinical 
specimens (Galate and Bangde, 2015). A number of selective agars have been 
developed, Preston, charchoal cefoperazone deoxycholate (CCDA) is one of the 
selective agars found to be effective because it permitted high yields of isolated 
Campylobacter strains at 42°C microaerophilically (Murray et al., 2007; Silva et al., 
2011). Another technique used in conjunction with primary isolation of 
Campylobacter species on selective media is the filtration method. The method is 
based on the principle that campylobacters, particularly C. jejuni and C. coli, can 
pass through membrane filters (0.45 µm to 065 µm pore size) with relative ease 
while other stool flora are constricted during filtration onto the surface of the media 
(Murray et al., 2007; Galate and Bangde, 2015). One of the limitations of the 
culturing method is that Campylobacter species are fastidious organisms, taking up 
to 72 hours to obtain growth, thus isolation methods for these organisms are not 
commonly used in routine laboratories (Murray et al., 2007). Most routine 
laboratories also lack differentiating tests, limiting species differentiation of cultures. 
 
III. Colonial morphology 
On CCDA selective media, culture positive colonies for Campylobacter appear either 
grey/white or creamy grey in colour and moist in appearance.  They may appear as a 
layer of growth over the surface of the selective agar. On blood agar, colonies are 
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translucent and moist in appearance (UK Standards for Microbiology Investigations, 
2015). 
 
IV. Serotyping schemes  
In the 1980’s two serotyping schemes for Campylobacter were developed in 
Canada; the Penner scheme, which is based on soluble heat-stable antigens; and 
the Lior scheme which detects variation in heat-labile antigens (Frost et al., 1998). 
The Penner scheme has been more widely used in the United Kingdom (McKay et 
al., 2001) and according to Coker et al., (2002) the Lior serotyping scheme has been 
used to determine subspecies of Campylobacter, particularly of C. jejuni and C. coli 
in laboratories in developing countries. Some of the limitations of the serotyping 
methods included nonspecific reactions as well as reproducibility problems (Frost et 




V. Immunological aspects of Campylobacter infections 
Serum immunoglobulin G (IgG), IgM, and IgA levels peak in response to infection, 
followed by a rapid decline after a few weeks post infection (Murray et al., 2007). In 
developing countries where individuals, both young and old, are constantly exposed 
to campylobacters in the environment, serum antibodies against Campylobacter 
species develop very early in life (Coker et al., 2002).  Antibody titers observed in 
children in developing countries have been found to be significantly higher than 
children in developed countries (Coker et al., 2002). Serum antibody assays vary in 
both sensitivity and specificity for detecting Campylobacter infections, therefore, 
should be interpreted with caution in diagnosis of Campylobacter infections (Coker et 
al., 2002). Serologic testing is a useful technique for epidemiological studies and it is 
not recommended for routine diagnosis, as test performance appears to be 






VI. Hippurate hydrolysis 
Hydrolysis of sodium hippurate is the test exploited to differentiate other species of 
Campylobacter from C. jejuni. A positive test with hippurate hydrolysis, along with a 
positive oxidase test from a culture positive strain grown microaerophilically at 42 °C, 
showing characteristic microscopic morphology of Campylobacter, should be 
reported as C. jejuni. For routine clinical purposes, no other tests need to be 
performed (Murray et al., 2007).  
 
VII. Alternative phenotypic methods 
Other rapid tests for the detection and confirmation of Campylobacter species 
include fluorescence in situ hybridization, and latex agglutination (Galate and 
Bangde, 2015). Several other rapid methods exploiting the phenotypic properties of 
























C. jejuni subsp. jejuni + - - - + + V V + 
C. jejuni subsp. 
Doylei 
V - - - V + - - + 
C. coli + - - V - + - + + 
C. fetus subsp. fetus + - - - - - - V + 
C. fetus subsp. 
venerealis 
V - - - - - - V V 
C. lari + - V - - - - V + 
C. upsaliensis - - - - - + - + + 
C. hyointestinalis 
subsp. hyointestinalis 
+ V - + - - - + + 
C. hyointestinalis 
subsp. lawsonii 
+ V + +ᵇ - - - + V 
C. lanienae + - - - - - ND + V 
C. sputorumᵇ bv. 
sputorum 
- + - + - - + V + 
C. sputorum bv. 
faecalis 
+ + - + - - + V + 
C. sputorum bv. 
paraureolyticus 
- + + + - - + V + 
C. helveticus - - - - - + ND - V 
C. hominis - +  ND - - - ND - + 
C. mucosalis - + - + - - - V V 
C. concisus - + - V - - + V V 
C. curvus - + - V V V + - + 
C. rectus V + - - - + + - + 
C. showae + + - - - V + - V 
             V ND - - - V ND - + 
     Positive reaction (+); negative reaction (-); variable reaction (V); not determined (ND); triple sugar ion (TSI). 
ᵇ   Srains of C. sputorum and C. hyointestinalis subsp. lawsonii normally produce large amounts of H₂S in triple sugar ion.  
ᶜ   Anaerobic growth only.  
 
 Table adopted from Murray et al., (2007).   
Table 1.1: Properties of Campylobacter exploited for phenotypic identification of species. 
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1.7.2.    Molecular characterization of Campylobacter  
The advent of molecular diagnostic technologies has circumvented the limitations of 
distinguishing between Campylobacter species based primarily on phenotypic 
properties commonly used in clinical laboratories (Klena et al., 2004; Carriço et al., 
2013). Various sequence-based typing methods have been exploited to identify 
differences between species of Campylobacter, particularly C. jejuni strains, which 
are frequently implicated with campylobacteriosis (Klena et al., 2004; Quiñones et 
al., 2008; Taboada et al., 2013). Molecular diagnostic methods also contribute in the 
search for associations between genotypes and hosts, subsequently linking hosts to 
the source of infection for epidemiological studies of pathogens (Schouls, et al., 
2003; Forbes et al., 2009). In almost all published sequence-based studies of 
Campylobacter, it is only a few isolates that have an identical genome, therefore 
Campylobacter isolates are reported to exibit genetic plasticity, which in essence is 
represented by a few clonal lineages (Pearson et al., 2003). The diversity of 
Campylobacter species is influenced by horizontal genetic exchange capabilities of 
the organisms (Cody et al., 2013). The diversity is thought to be primarily responsible 
for the different pathogenic properties of different isolates as seen in C. jejuni strains 
(Hofreuter et al., 2006). 
 
Since assays exploiting phenotypic properties of Campylobacter species are often 
atypical and difficult to read, more robust techniques for diagnosis and species 
subtyping exploiting the genome of Campylobacter have been developed (Klena et 
al., 2004; Carriço et al., 2013; Taboada et al., 2013). Methods that are used in 
current research and epidemiological studies to distinguish between strains of 
Campylobacter can be categorized into three groups: (I) methods based on PCR 
amplification of genomic targets; (II) methods based on restriction enzyme digestion 
of genomic DNA; and (III) methods based on single nucleotide polymorphisms 
(SNPs) (Taboada et al., 2013). For each of the listed method category, the examples 





1.7.2.1. Molecular diagnostic PCR for Campylobacter 
Quantitative real-time PCR (qPCR) has proven to be efficacious in determining the 
prevalence and epidemiological features of Campylobacter infections (Best et al., 
2003; Lund et al., 2004; Botteldoorn et al, 2008; Mason et al., 2013). Multiplex PCR 
assays targeting genes specific to species of Campylobacter have been developed 
(Linton et al., 1996; Best et al., 2003; Wierzba et al., 2008; Mason et al., 2013) 
Target genes include the mapA gene specific for C. jejuni and the ceuE gene 
specific for C. coli (de Boer et al., 2013). Isolates from different bacteria can be 
identified to genus and often also to species level by sequence analysis of the 16 
SrRNA gene. Thus, regions of the 16 SrRNA gene specific to all Campylobacter 
species have successfully been applied for the detection of Campylobacter with 
improved accuracy (Hasson et al., 2008).  
 
1.7.2.2.                Molecular subtyping used for Campylobacter 
 
I. Pulsed-field gel electrophoresis (PFGE) 
Molecular typing methods are in essence, developed to differentiate between 
isolates of the same species of bacteria, whereas, genotyping methods are used to 
identify the genetic relatedness between different strains of bacteria (Noormohamed 
and Fakhr, 2014). PFGE which is a primary method for typing foodborne pathogens 
was one of the first DNA based methods devised for typing Campylobacter species 
(Taboada et al., 2013; Noormohamed and Mohamed, 2014). PulseNet, which is 
concerned with the rapid detection of outbreaks, largely employs PFGE as a 
subtyping technique, which in 2001 incorporated Campylobacter to its database 
(Taboada et al., 2013). PFGE is based on gel electrophoresis separation of DNA 
fragments resulting from restriction enzyme digestion of genomic DNA, typically by 
kpnI or SmaI restriction enzymes for C. jejuni strains (Noormohamed and Mohamed, 
2014; UK Standards for Microbiology Investigations, 2015). The high discriminatory 
power of PFGE was successfully exploited to track Campylobacter species in poultry 
farms (Taboada et al., 2013). However, majority of human Campylobacter cases are 
sporadic; therefore the use of PFGE would be laborious with limited benefits as far 
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as the detection of Campylobacter clusters in concerned (Taboada et al., 2013). The 
limitation of the technique as far as human cases are concerned is that 
epidemiologically-defined outbreak isolates could not entirely be distinguished from 
non-outbreak strains in one study. However, other studies have reported significant 
clustering of human isolates (Taboada et al., 2013). Due to the technique’s time 
consuming-nature, and its requirement for special equipment and training, it is not 
widely used outside the reference laboratories (Taboada et al., 2013; Noormohamed 
and Mohamed, 2014). 
 
 
II. Microarray comparative genomic hybridization (MCGH) 
MCGH is a technique which enables the determination of the presence or absence 
of genes (Taboada et al., 2013). This is achieved through the use of competitive 
fluorescence in situ hybridization. The generated signals can be used to identify copy 
number changes and/or sequence divergence (Taboada et al., 2013). MCGH has 
been used in studies aimed to determine the genetic diversity of C. jejuni, which 
demonstrated evidence for significant genomic diversity in C. jejuni strains attributed 
to carriage of accessory genes which are not conserved across the entire species 
(Pearson et al., 2003; Klena et al., 2004; Quińones et al., 2008; Taboada et al., 
2013). One study showed MCGH to have a higher resolution power compared to 
MLST in an epidemiological study suggesting transmission between cattle and 
human clinical cases (Taboada et al., 2013). Significant differences in gene content 
between isolates that were indistinguishable by MLST were revealed through 
comparative genomic analysis using MCGH and similar observations have been 
evident from whole-genome sequencing (WGS) data. Limitations that precluded the 
use of MCGH in molecular typing include low throughput and high cost (Taboada et 
al., 2013). 
 
III. Multi-locus sequence typing (MLST) 
Molecular differentiation of microbial isolates by the relative comparison of 
housekeeping gene sequence fragments involves MLST (Dingle et al., 2001; Dingle 
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et al., 2002; Sails et al., 2003; Schouls et al., 2003; Taboada et al., 2013). The 
technique primarily involves the sequencing of approximately 500 bp fragments of 
usually six and eight loci (Jolley et al., 2004; Dingle et al., 2005). The resulting 
unique fragment sequences are assigned an allele marker, and subsequently each 
allelic combination or the generated allelic profile for each isolate is then assigned a 
sequence type (ST) (Jolley et al., 2004). Isolates with related STs can be further 
grouped into clonal complexes, which are thought to be groups of organisms derived 
from a common progenitor (Dingle et al., 2002; Noormohamed and Fakhr, 2014). 
MLST allele sequences and ST profile tables are stored in curated databases at 
different geographical locations globally. Data from all databases is collected and 
made readily accessible through the Pubmlst website (Jolley et al., 2004; 
Noormohamed and Fakhr, 2014). 
 
Following the successful implementation of MLST for Neisseria meningitidis, MLST 
has since been considered the “gold standard” of molecular typing, with schemes 
developed that cover the bacterial and fungal species (Larsen et al., 2012; Maiden et 
al., 2013). MLST has enabled the characterization of hypervariable genomes of 
Campylobacter species, (Dingle et al., 2001; Dingle et al., 2002; Dingle et al., 2005; 
Noormohamed and Fakhr, 2014; Sheppard and Maiden, 2015). Many of the studies 
carried out to understand the molecular epidemiology of campylobacteriosis using 
MLST focused primarily on seven housekeeping genes (Appendix A) of C. jejuni, 
which is the most frequently isolated bacterial pathogen in cases of human 
campylobacteriosis globally compared to C. coli (Dingle et al., 2002). Nevertheless, 
MLST scheme for C. coli has been developed (Dingle et al., 2001; Schouls et al., 
2003; Miller et al., 2005).  
 
C. jejuni species are genetically highly diverse organisms, represented by many 
distinct clonal complexes that vary from host generalist lineages commonly found in 
poultry, livestock, and human disease cases to host-adapted specialized lineages 
primarily associated with livestock or poultry (Sails et al., 2003; Morely et al., 2015). 
MLST has been useful in distinguishing between isolates of C. jejuni subspecies 
jejuni and C. jejuni subspecies doylei, which were determined to be phylogenetically 
distinct (Parker et al., 2007). Predominant clonal complexes accounting for over 60% 
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of human campylobacteriosis attributed to C. jejuni are ST-21, ST-45, ST-206, ST-
61, ST-48, and ST-257 (Dingle et al., 2002; Colles et al., 2003). A study conducted 
by Manning et al., (2003) comparing veterinary and human isolates of C. jejuni using 
MSLT indicated that isolates of animal and of human do overlap. MLST on a total of 
32 clinical C. jejuni isolates from Southern Africa was previously performed to 
determine genetic variation among these isolates, from which 18 different STs were 
identified (Quiñones et al., 2008). Other studies reporting STs of South African 
human C. jejuni isolates have been documented (Manning et al., 2003; Ioannidou et 
al., 2013). 
 
Transmission of C. jejuni from potential sources to hosts is less understood: it is not 
fully known whether only some of the C. jejuni present in environmental reservoirs 
are pathogenic to humans and whether all animals and microenvironments harbour 
the same strains (Colles et al., 2003; Manning et al., 2003; Schouls et al., 2003). 
Although the sources of Campylobacter are well described, the role that these 
sources play in the epidemiology of campylobacteriosis or how transmission from 
potential sources to human hosts would commonly occur remain incompletely 
addressed.  
 
Traditional MLST involves a PCR amplification step using primers that are specific 
for the loci of the MLST scheme, followed by Sanger sequencing (Larsen et al., 
2012). The procedure is both costly and time consuming. The advent of high-
throughput sequencing techniques, tethered with the cost of DNA sequencing 
progressively depreciating has made it favourably less labour intensive to carry out 
whole-genome MLST (wgMLST) which is a gene-by-gene approach as well as MLST 
analysis of the seven housekeeping genes from WGS data (Larsen et al., 2012). In 
addition, MLST analysis from WGS data provides minimal experimental variation, 
enabling direct inter-laboratory sharing and comparison of results (Taboada et al., 
2013). It is crucial that STs generated from WGS data is relatable to other typing 
schemes (Chan et al., 2001; Larsen et al., 2012). There are multiple websites with 
tools and servers to analyze WGS data and identify STs; The Center for Genomic 
Epidemiology (CGE) in Denmark Technical University (DTU) is one example which is 
accessible at www.cbs.dtu.dk/services/MLST (Larsen et al., 2012). 
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1.7.3. Whole genome sequencing (WGS) 
The advent of next generation sequencing (NGS) technologies have resulted in 
rapid, high throughput, and cost effective means to carry out WGS (Loman and 
Pallen, 2008; Jolly and Maiden, 2010; Köser et al., 2012; Taboada et al., 2013). The 
sequencing-by-synthesis NGS technologies, which are already commercially 
available, are gradually precluding the sequencing-by-termination Sanger method. 
WGS technologies include the Illumina MiSeq sequencer (Illumina Inc), aimed for the 
smaller laboratories and the clinical diagnostic market (Quail et al., 2012). Studies 
have shown the remarkable impact made by the high-throughput function of NGS 
technologies on genomic research (Pinard et al., 2006; Morozova and Marra, 2008; 
Reis-Filho, 2009). 
 
According to Cartwright et al., (2011) and Kösier et al., (2012), routine microbial 
sequencing in diagnostic laboratories will aid in delineation, tracking, control of 
hospital-acquired infections, monitoring antibiotic resistance rates and threats of new 
and emerging pathogens. It is being proposed that molecular epidemiology carried 
out for surveillance, outbreak cases, and genotypic antimicrobial susceptibility testing 
for fastidious pathogens best fit the applications of WGS (Köser et al., 2012). Recent 
studies have described WGS as an invaluable tool for understanding the 
epidemiology of Campylobacter in humans, farm animals, and the environment 
(Cody et al., 2013). WGS can resolve bacterial isolates with just a single base pair 
variation, displaying a high discriminatory power ideal for epidemiological subtyping 
of bacterial pathogens (Taboada et al., 2013). Advances in NGS platforms have 
made it possible to apply the technology in outbreak cases, and C. jejuni was one of 
the organisms investigated using these sequencing platforms (Taboada et al., 2013). 
The wgMLST approach carried out to characterise strains of C. jejuni and C. coli 
showed better strain to strain relationships than single-locus based methods (Cody 
et al., 2013; Taboada et al., 2013).  
 
The limiting factor for WGS, which is likely to preclude the use of WGS data for 
routine C. jejuni subtyping, is that the capacity to generate data is somewhat 
surpassed by the ability to analyse and interpret it (Loman and Pallen, 2008; 
Taboada et al., 2013). However, the interpretation part of the limitations is being 
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circumvented by the Bacterial Isolate Genome Sequence Database (BIGSDB) which 
is a bioinformatics platform for evolutionary and functional analysis of genomic 
sequences (Jolley and Maiden, 2010). 
 
 
1.7.3.1. Genomes of sequenced Campylobacter species 
In a quest to best understand the genetics, physiology, and virulence of 
Campylobacter, a clinical human C. jejuni isolate, NCTC11168 was sequenced and 
completed in the year 2000 [Figure 1.6] (Parkhill et al., 2000; Fouts et al., 2005; Poly 
et al., 2005). The genome sequence of C. jejuni NCTC11168 has a circular 
chromosome of 1,641,481 base pair (bp) in length; a guanine (G) and cytosine (C) 
content of 30.6 %; as well as predicted 1,643 open reading frames (ORFs). The C. 
jejuni genome is predicted to encode 1,654 proteins and 54 stable ribonucleic acid 
(RNA) species (Parkhill et al., 2000). According to Fouts et al., (2005) the genome of 
C. jejuni NCTC11168 was insufficient to provide comprehensive aspects founding 
the biology of Campylobacter. The findings drove Fouts and colleagues to sequence 
and complete the genome of a second C. jejuni strain, RM1221, isolated from a 
chicken carcass (Fouts et al., 2005). The genome of C. jejuni RM1221 is a circular 
chromosome that is 1,777,831 bp in length, with a G+C content of 30.31% (Price, 
2007). The predicted coding regions in the genome are approximately 1,884 with an 
estimated ORF length of 885 bp. The coding region is represented by 94% of the 
genome (Fouts et al., 2005).  
 
Comparison made between C. jejuni NCTC11168 and C. jejuni RM1221 revealed 
unique characteristics not identified in C. jejuni NCTC11168. The unique features 
identified through experimental work in C. jejuni RM1221 include the colonization of 
chicken skin ceca, invasion of Caco-2 cells, unique lipooligosaccharide (LOS) and 
capsule loci, and other unique ORFs (Fouts et al., 2005). Another strain of C. jejuni 
that has been sequenced is C. jejuni 81-176, originally isolated from a patient during 
an outbreak associated with raw milk (Fouts et al., 2005; Hofreuter et al., 2006). This 
strain has been described to be highly virulent, comprising unique pathogenic 




The C. jejuni 81-176 genome is a circular chromosome that is 1,616,554 bp in 
length, along with a G+C content of 30.6%, and it encodes 1779 genes (Price, 2007). 
Other species of Campylobacter that have been sequenced include C. coli (RM2228; 
multi-drug chicken isolate), C. lari (RM2100), and C. upsaliensis (RM3195) which 
were both clinical isolates, with C. upsaliensis isolated from a patient with Guillain-
Barrè Syndrome (GBS). For in vitro and in vivo experiments, the C. jejuni 81116 
(NCTC11828) genome has been suggested to be a genetically stable strain 
compared to previously described sequenced genomes of C. jejuni, rendering it 
more reliable for studies aimed at understanding the biology of Campylobacter 
(Pearson et al., 2007). The genome size of Campylobacter is relatively smaller than 
that of Escherichia coli (E. coli) and Salmonella and the reduced genome size 
pertains to the reduced metabolic capabilities of this organism (Pendleton et al., 
2013).  
 
Figure 1.6: Model representation of a sequenced human C. jejuni NCTC11168 
genome (1 641 481 bp). The outer most circle from the origin of replication 
represents coding sequences in both the clockwise (dark green) and anticlockwise 
(light green) directions. The positions of hypervariable sequences in the genome are 
represented in black. The genes involved in the biosynthesis of surface structures 
are represented in dark red (clockwise) and pale red (anticlockwise). Annotated in 
the innermost sphere are clusters of genes responsible for the biosynthesis of 
extracellular polysaccharide (EP), LOS, and flagella modification. Image adopted 
from Parkhill et al., (2000).  
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1.8.  Treatment 
Campylobacteriosis is often a self-limiting disease, with symptoms typically 
disappearing within one to three weeks (Schielke et al., 2014).  For short-lived 
infections, fluid and electrolyte replacement are the cornerstone for treatment 
(Perez-Perez and Blaser, 1996; Silva et al., 2011). When Campylobacter-induced 
enteritis is severe and prolonged, particularly in young and immunosuppressed 
individuals, antimicrobial therapy is recommended for treatment of patients 
(Wagenaar et al., 2013; Galate and Bangde, 2015). The first-line choice of treatment 
involves macrolides (erythromycin), followed by fluoroquinolones, where 
ciprofloxacin is predominantly administered (Acheson and Allos, 2001; Gaudreau 
and Gilbert, 2003; Luber et al., 2003; Luangtongkum et al., 2007; Luangtongkum et 
al., 2009; Pollet et al., 2012). Other alternative drugs, depending on the severity of 
campylobacteriosis, include tetracylines, chloramphenicol, and serious systemic 
infections may be treated with aminoglycoside such as gentamicin (Acheson and 
Allos, 2001; Ge et al., 2002; Luangtongkum et al., 2007). All Campylobacter species 
are inherently resistant to vancomycin, rifampicin, and trimethoprim (Taylor and 
Courvalin, 1988; Acheson and Allos, 2001). In contrast, Campylobacter species are 
generally susceptible to aminoglycosides, chloramphenicol, clindamycin, nitrofurans, 
and imipenem (Acheson and Allos, 2001; Luangtongkum et al., 2007). In severe 
cases where antibiotic treatment is mandatory, appropriate and timely treatment is of 
importance in the light of antibiotic resistance (Moore et al., 2005). 
 
1.8.1. Antimicrobial mode of action 
 
I. Fluoroquinolones against Campylobacter species 
Fluoroquinolones are a chemically modified form of the quinolone nalidixic acid 
(Ketley and Konkel, 2005). This class of antimicrobials are bactericidal agents; they 
impede DNA replication by targeting two bacterial enzymes [DNA gyrase (type II 
topoisomerase) and DNA topoisomerase IV] which play a significant role in DNA 
replication (Ketley and Konkel, 2005). 
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A few years ago fluoroquinolones were the first-line of treatment for Campylobacter 
infections requiring antimicrobial therapy (Acheson and Allos, 2001; Wimalarathna et 
al., 2013). During those years, administering these drugs empirically was 
advantageous because symptoms of campylobacteriosis are clinically 
indistinguishable from other gastrointestinal diseases caused by other organisms 
such as Salmonella or Shigella (Acheson and Allos, 2001; Wimalarathna et al., 
2013), which were generally susceptible to fluoroquinolones. Resistance to 
quinolone treatment was first identified in the early 1990’s in Asia and in the 
European countries such as Sweden, the Netherlands, Finland, and Spain (Acheson 
and Allos, 2001; Luber et al., 2003). The increase in quinolone resistance was 
tethered to licensing of the fluoroquinolone, enrofloxacin, in 1996 for veterinary use 
in Europe as well as the United Kingdom. As a result, the number of domestically-
acquired fluoroquinolone resistant human Campylobacter isolates increased from 
1.3% in 1992 to 10.2% in 1998 (Acheson and Allos, 2001; Ketley and Konkel, 2005).  
 
 
II. Macrolides against Campylobacter species 
Macrolides are bacteriostatic agents which inhibit protein synthesis by binding 
reversibly to the 50S subunit of the 70S bacterial ribosome and cause dissociation of 
the peptidyl-tRNA and subsequently terminating the elongation cycle of protein 
synthesis (Ketley and Konkel, 2005).  
 
For campylobacteriosis that requires antimicrobial treatment, a macrolide, 
particularly erythromycin, has in the recent years become the first-line of treatment 
(Wimalarathna et al., 2013). The rate of erythromycin resistance has remained low 
and stable over the years since its introduction, particularly in developed countries 
(Acheson and Allos, 2001; Coker et al., 2002). In addition to its low and stable 
resistant rate properties, the drug is clinically useful in that it is of low cost, safe 
(children and pregnant women), allows ease of administration, and narrow spectrum 
activity properties. Moreover, erythromycin stearate is acid-resistant, stable, and 
incompletely absorbed which allows the drug to exert a contact effect throughout the 
bowel where most of these gastrointestinal microbes colonize (Acheson and Allos, 
2001). Among many other newer macrolides, azithromycin is one of the drugs which 
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is effective against C. jejuni. However, erythromycin is chosen over these drugs 
because they are costly with no clinical advantage (Acheson and Allos, 2001).  
 
 
III.      Tetracycline against Campylobacter species 
Tetracyclines are broad spectrum antimicrobials that also act as protein synthesis 
inhibitors at the bacterial ribosome level just as macrolides (Ketley and Konkel, 
2005). High rates of tetracycline resistance make it a poor choice for treatment of 
campylobacteriosis, particularly infections caused by C. jejuni (Acheson and Allos, 
2001; Bester and Essack, 2012).  
 
 
1.9. Antimicrobial Resistance 
Antimicrobial resistance is the inherent or acquired de novo mutation or through 
horizontal gene transfer (HGT)] ability of bacteria to subsist in an environment 
enriched with antimicrobial agent(s) (Acar and Röstel, 2001; Kumarasamy et al., 
2010). The ability of bacteria to have mechanisms which results in higher inhibitory 
concentration (MIC) in comparison to the wild-type bacteria describes the definition 
of antimicrobial resistance in a microbiological and molecular concept (Acar and 
Röstel, 2001; Livermore, 2003). Mechanisms by which bacteria can achieve 
antimicrobial resistance include inactivation or modification of the antimicrobial, 
alteration of antimicrobial target site thereby reducing its binding efficacy, increased 
efflux or decreased influx of the antimicrobial, as well as gene duplication and 





Figure 1.7: Mechanisms through which antimicrobial resistance can be achieved for 
the different classes of antimicrobials. Image adopted from Grasso et al., (2016). 
 
1.9.1. Epidemiology of antimicrobial-resistant Campylobacter  
Since the 1980’s, there has been a growing concern of increased incidence of 
Campylobacter species being resistant to clinically used antimicrobials, particularly 
C. jejuni and C. coli in many European countries  and other developing countries (Ge 
et al., 2002; Chokboonmongkol et al., 2013). The on-going use of antimicrobials in 
food animals has raised a concern as this could select for antimicrobial-resistant 
Campylobacter species which may ultimately reach and pose a major health-threat 
to humans through the food chain [Figure 1.8] (Luber et al., 2003; IFT, 2006; 
Chokboonmongkol et al., 2013). The fact that humans are considered to be the 
dead-end host necessitates the recommendation to identify the reservoirs for the 
acquisition of antimicrobial-resistant Campylobacter in poultry farms (Wimalarathna 
et al., 2013). The study of the antimicrobial resistance, as well as the resistance 
determinants, and their genetic composition is vital for zoonotic bacteria as this may 
help alleviate resistance dissemination and contribute to the understanding of the 
relationships that exist between bacterial species (Aarestrup et al., 1997; Sato et al., 




Figure 1.8: Sectors where antimicrobial use is applied and the impact it has in the 
ecosystem which drives the epidemiology of antimicrobial resistance and 
subsequently implicate human health through multiple pathways. Image adopted 
from IFT, (2006). 
 
 
1.9.2. Prevalence of antimicrobial resistance in Campylobacter 
As far as Campylobacter is concerned, resistance to erythromycin has been reported 
more in C. coli than C. jejuni, and coherently, many developed countries have 
reported low and stable rates of erythromycin resistance in C. jejuni strains 
(Aarestrup et al., 1997; Ge at al., 2002; Gaudreau and Gilbert, 2003). However, an 
increasing erythromycin resistance trend has been reported in developing countries 
(Coker et al., 2002). In the United States resistance to ciprofloxacin exists in almost 
25% of Campylobacter tested and approximately 2% for azithromycin (Coker et al., 
2002). From the year 1997 to 2011, Campylobacter drug resistance to 
fluoroquinolones has increased from 13% to 25% and as the rate of resistance 
increases, the clinical usefulness of recommended antimicrobials is compromised 
(Coker et al., 2002; Gouvêa et al., 2015). This trend is more recently seen in 
ciprofloxacin, where resistance to ciprofloxacin in human isolates of C. jejuni is 
increasing (Aarestrup et al., 1997; Acheson and Allos, 2001; Sato et al., 2004; 











A study conducted in England and Wales by Nichols et al., (2012) involving one 
million cases of campylobacteriosis from 1989 to 2009, demonstrated an increase in 
the percentage of Campylobacter isolates that were fully or intermediately resistant 
to ampicillin, ciprofloxacin, nalidixic acid, tetracycline and erythromycin. The 
percentage of strains that were resistant to ciprofloxacin was higher in people who 
had recently travelled abroad (1042/1601; 65%) compared with those who had not 
(2005/6530; 31%) and where travel status was not recorded (28646/ 90095; 32%). 
Isolates with a high prevalence rate of resistance to ciprofloxacin were found in 
people who had travelled to India (79%), Egypt (79%), Spain (78%) and Thailand 
(80%) (Nichols et al., 2012). 
 
There is insufficient data describing antimicrobial patterns of Campylobacter species 
isolated from humans in RSA. Majority of the Campylobacter studies are carried out 
in farm and agricultural sectors. A study conducted by Jonker and Picard, (2010) 
which examined antimicrobial susceptibility profiles of Campylobacter species 
isolated from pigs and poultry in RSA revealed that C. jejuni strains from poultry 
origin were more resistant to fluoroquinolones, macrolides, and lincosamides. Four 
multi-drug resistant (MDR) Campylobacter strains were detected in the Western 
Cape region, RSA (Jonker and Picard, 2010). Another study carried out in KwaZulu-
Natal, RSA in different poultry production systems showed that isolates from rurally 
raised chickens were significantly less resistant against ciprofloxacin (7.9%), 
erythromycin (0%), and tetracycline (21.6%) than isolates from industrially raised 
broiler and egg-laying chickens. High rate of tetracycline resistance (98.9%-100%) 
was detected in isolates from industrially raised chickens (Bester and Essack, 2012). 
 
Historically, antimicrobials have been used in animal husbandries either for 
therapeutic use or as growth promoters, with the latter use banned in certain parts of 
the world. The therapeutic use of certain antimicrobials, particularly in poultry 
production systems has been licensed, which include, but not limited to macrolides, 
fluoroquinolones and tetracyclines (Wimalarathna et al., 2013). Variation between 
poultry production systems, which encompasses the use of antimicrobials, plays a 
role in selected antimicrobial resistance profiles of Campylobacter colonizing poultry 
(Bester and Essack, 2012). 
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1.9.3.  Mechanisms of antimicrobial resistance in Campylobacter 
 
1.9.3.1. Quinolone resistance 
The quinolone resistance-determining region (QRDR) of the gyrA gene is the region 
driving quinolone resistance in Campylobacter species (Ketley and Konkel, 2005; 
Luangtonkum, et al., 2009; Wieczorek and Osek, 2013). The most predominant of 
the described mutations is the Thr88Ile which gives rise to high MIC values. Other 
mutations implicated with the gyrA gene include point mutations at the same codon: 
Thr86Val, Thr86lys, and Thr86Ala. Mutations in other codons include Ala87Pro, 
Asp90His, and Asp90Tyr which confer quinolone resistance at different MIC values 
(Pérez-Boto et al., 2014). 
 
1.9.3.2. Macrolide resistance 
Two mechanisms have been described to be the driving force of macrolide 
resistance in Campylobacter species. The most predominant mechanisms are 
represented by the mutations that occur in the rrn gene which encodes the 23S 
rRNA component of the large subunit (50S) of the bacterial ribosome (Ketley and 
Konkel, 2005; Luangtonkum, et al., 2009; Wieczorek and Osek, 2013). The positions 
of the rrn gene where mutations occur are 2074 and 2075. The most commonly 
found is the transversion A2075G in which the three copies of the rrn gene have 
mutations. This phenomenon is implicated with high MIC values against macrolides. 
The second mechanism through which macrolide resistance is achieved in 
Campylobacter involves mutations in specific regions of the rp/D (amino acids 55-77) 
and rp/V genes (amino acids 109-142). These two genes encode L4 and L22 
ribosomal proteins respectively (Pérez-Boto et al., 2014). 
 
1.9.3.3. Tetracycline resistance 
Different mechanisms have been described for tetracycline resistance, however, for 
C. jejuni and C. coli in particular, the protection of the ribosomal site of the 16 SrRNA 
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gene carried out by the Tet (O) protein is of importance in mediating tetracycline 
resistance (Ketley and Konkel, 2005; Luangtonkum, et al., 2009; Wieczorek and 
Osek, 2013). The Tet (O) protein is encoded by the tet (o) gene, a gene that can be 
carried on the chromosome and plasmids. This renders the dissemination of 
tetracycline resistance to be highly carried out by exchange of conjugative 
transmissible genetic material such as plasmids containing the tet (o) gene between 
and within species of bacteria (Ketley and Konkel, 2005; Pérez-Boto et al., 2014). 
 
1.10. Postinfectious manifestations of Campylobacter infection 
1.10.1. Guillain-Barrè Syndrome (GBS) 
As with other enteropathogenic bacteria, complications may arise following 
campylobacteriosis. Complications that may occur following campylobacteriosis 
include GBS, reactive arthritis, and irritable bowel syndrome (WHO, 2013). GBS is 
the most severe post infectious disease and therefore of public health importance 
(WHO, 2013). 
 
GBS is a reactive, self-limited, autoimmune disease triggered by a preceding 
bacterial or viral infection (Allos, 1997; Yuki and Hartung, 2012; Dimachkie and 
Barohn, 2013). For many decades the link between GBS with a preceding infection 
has been recognised, however, controversy lies in pointing out the primary 
mechanism by which GBS is elicited mainly due to the fact that a vast number of 
agents which include bacterial species, viruses, and strains of mycoplasma have 
been implicated as aetiological agents of infection preceding GBS (Aspinall et al., 
1994). With polio almost eradicated globally, GBS has now become the most 
common cause of acute flaccid paralysis (AFP) with an annual incidence of 0.6–4 
cases per 100,000 populations (Nyati and Nyati, 2013; Kaushik et al., 2014). GBS 
which develops post C. jejuni infection has been investigated and reported in a 
number of studies rendering strains of the C. jejuni subject to renewed interest in 
their mode of pathogenesis (Aspinall et al., 1994; Rees et al., 1995; Wierzba et al., 
2008; Nyati and Nyati, 2013).  
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1.10.2. Campylobacter-induced GBS 
It was 1982 when C. jejuni-induced GBS was first recognized 10 days after infection 
with C. jejuni (Rhodes et al., 1982; Allos, 1997; Allos et al., 1998; Nachamkin et al., 
1998). One of the confounding factors tempering with associating GBS antecedent 
C. jejuni enteritis is that the bacteria are usually eliminated from the body within 16 
days of infection and before the onset of acute neuromuscular paralysis, which 
usually occurs 10 days to 3 weeks after the onset of diarrhoea (Allos, 1997; 
Nachamkin, 1997; Allos et al., 1998; Nachamkin et al., 1998; Acheson and Allos, 
2001; Poropatich et al., 2010). Nevertheless, antibodies against C. jejuni may remain 
elevated for several weeks after enteritis; this has been exploited serologically to 
evaluate the frequency of GBS preceding C. jejuni infection (Allos, 1997). Many 
cases of Campylobacter-induced GBS cases go unrecognized; in part because 
Campylobacter is not routinely diagnosed in resource poor settings, as well as the 
possibility of bacteria having been eliminated by the time the person presents with 
acute neuromuscular paralysis (Allos, 1997; Poropatich et al., 2010). The use of 
antimicrobials also compromises isolating species of Campylobacter in culture 
(Nachamkin, 1997). 
 
The spectrum of disease manifestation following C. jejuni infection, which may 
involve acute inflammatory diarrhoea and the onset of autoimmune neuropathies, 
could be associated with the differential expression of virulence factors in C. jejuni 
strains (Quiñones et al., 2008). The broad variability in the severity and spectrum of 
clinical symptoms in GBS patients suggests that host susceptibility may play a 
substantial role in disease development (Quiñones et al., 2008). Species of 
Campylobacter, other than C. jejuni, have been isolated from GBS patients (Molnar 
et al., 1982); one study reported C. upsaliensis isolated from a GBS patient 
(Nachamkin, 1997; Price, 2007). 
 
C. jejuni-induced GBS is a severe disease which is characterized by acute or 
subacute symmetrical ascending motor weakness, areflexia, and mild-to-moderate 
sensory abnormalities (Acheson and Allos, 2001; Coker et al., 2002; Moore et al., 
2005; Nyati and Nyati, 2013). The sequelae are attributed to sialylated surface 
polysaccharide structures and flagella of some C. jejuni strains, which are thought to 
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be responsible for the ganglioside mimicry leading to GBS (Misawa et al., 1998; van 
Vliet and Ketley, 2001).  Upon infection, immune responses directed towards the 
infecting organism are involved in the pathogenesis of GBS by cross-reaction with 
neural tissues (Acheson and Allos, 2001; Mcarthy and Gieseck, 2001). The adaptive 
immune response comprising the humoral and cellular immune responses is 
triggered upon infection and because of the sharing of homologous epitopes, cross-
reaction with ganglioside surface components of peripheral nerves occurs causing 
axonal degeneration resulting in paralysis [Figure 1.9] (Quińones et al., 2008; van 




Figure 1.9: A model representation of the mechanisms facilitating the pathogenesis 
of C. jejuni-induced GBS. Abbreviations: Alpha C protein (APC); acute motor axonal 
neuropathy (AMAN); acute inflammatory demyelinating polyneuropathy (AIDP). 




1.10.3. Clinical and electrophysiological subtypes of GBS 
For a number of years GBS has been described as a single homogenous clinical 
entity (Dimachkie and Barohn, 2013). With insightful studies carried out, GBS has 
been categorized into heterogeneous clinical and electrophysiological subtypes: 
acute inflammatory demyelinating polyneuropathy (AIDP), acute motor axonal 
neuropathy (AMAN) and in a case where sensory fibres are affected, this axonal 
subtype is called acute motor and sensory axonal neuropathy (AMSAN) (Nachamkin 
et al., 1998; Dimachkie and Barohn, 2013; van den Berg et al., 2014). 
 
1.10.4. Mechanism by which C. jejuni induces GBS 
The mechanism by which autoimmune processes result in neuropathy is by affecting 
different structures (myelin or axons), at different locations (nerve root, nerve cell 
bodies or peripheral nerve) (Dimachkie and Barohn, 2013). Infections with C. jejuni 
are significantly associated with AMAN form of GBS (children and young adults) and 
not with AIDP (older population in Western countries) (Nachamkin et al., 1998; 
Kuwabara, 2007). Immune responses against C. jejuni have been implicated to 
cause AMAN by the induction of antibodies that cross-react with ganglioside 
structures that are expressed on the peripheral axons. Individuals who have AMAN 
subsequent to C. jejuni infection have been found to have high titers of antibodies 
against gangliosides GM1, GM1b, GD1a or GalNAc-GD1a (Nachamkin et al., 1998; 
Kuwabara, 2007; van den Berg et al., 2014). 
 
1.10.5. Prevalence of Campylobacter-induced GBS  
In spite of the plethora of studies aimed at understanding and elucidating C. jejuni-
induced diarrhoea with subsequent inception of GBS, the specific clinical features 
and epidemiology remains a black box (Rees et al., 1995; Nyati and Nyati, 2013). 
The prevalence of Campylobacter in stool specimens of AFP patients and 
successively the description of the proportion of C. jejuni-induced GBS in RSA has 




In Cape Town, RSA, one study sought to determine the frequency of 
Campylobacter-induced GBS from isolates of patients admitted to the Red Cross 
War Memorial Children’s Hospital during the years 1994-1995 (Quiñones et al., 
2008). Campylobacter species were recovered from three adults and six paediatric 
patients from a total of 14 patients whom submitted stool specimens (Goddard et al., 
1997; Lastovica et al., 1997). A total of six of the nine isolates were identified as C. 
jejuni biotype 2, serotype O:41 (Goddard et al., 1997; Lastovica et al., 1997). The 
other three positive isolates were identified as C. concisus, C. upsaliensis, and C. 
jejuni biotype 1. C. jejuni biotype 1, serotype O:41 was newly associated with GBS, 
the severe form, reflecting a novel isolation of this strain confined to the Cape Town 
region (Goddard et al., 1997; Lastovica et al., 1997; Wassenaar et al., 2000; 
Quiñones et al., 2008). 
 
The risk of developing GBS post C. jejuni infection is seldom, with reported cases of 
less than 1% (1:3000 cases) (Acheson and Allos, 2001; Moore et al., 2005; Nyati 
and Nyati, 2013). The isolation rate of C. jejuni from stool cultures of GBS patients 
range from 8% to 50% (Misawa et al., 1998; Nyati and Nyati, 2013). The Penner 
heat-stable (HS) serotypes of C. jejuni strains attributed to GBS include serotype 
HS:19 which is reported to occur globally, and serotype HS:41 reported to be 
restricted to Cape Town, RSA (Lastovica et al., 1997; Nachamkin et al., 2001; Coker 
et al., 2002; Moore et al., 2005; Poly et al., 2005; Quińones et al., 2008). A study 
carried out by Wassenaar et al., (2000), to genetically characterize C. jejuni 0:41 
isolates in relation to GBS in Cape Town, RSA, indicated that C. jejuni 0:41 isolates 
represented a genetically stable clone for a long time. 
 
Due to the scarcity of the development of the sequelae following C. jejuni enteritis, 
the mortality rate ranges from 2% to about 8% (Moore et al., 2005; Wierzba et al., 
2008; Nyati and Nyati, 2013). Mortality from GBS has been linked with autonomic 
nervous system (ANS) malfunction, respiratory failure, and subsequently 
compromised vital functions (Newswanger and Warren, 2004; Dimachkie and 
Barohn, 2013). The majority of GBS patients experience partial or total recovery 
which can take over a period of weeks to months (Nachamkin et al., 1998; 
Dimachkie and Barohn, 2013). Approximately 20% of patients are left with severe 
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disability with men being more frequently affected than women (Nachamkin et al., 
1998; Nyati and Nyati, 2013). The incidence of GBS increases with age, but some 
studies have shown an early peak among the 15 to 30 years old suggesting a 
possible bimodal distribution of cases by age (Nachamkin et al., 1998). Most GBS 
cases are sporadic; however, a seasonal trend has been reported with a surge in the 
summer months (Dowling et al., 1977; Nachamkin et al., 1998; Dimachkie and 
Barohn, 2013). 
 
1.10.6. General clinical presentation of GBS 
The disease is frequently observed one to three weeks after onset of 
Campylobacter-induced diarrhoea, and it is characterized by ascending paralysis, 
with patients presenting with AFP (Misawa et al., 1998; Acheson and Allos, 2001; 
Dimachkie and Barohn, 2013). Progression of the disease can lead to respiratory 
muscle compromise and subsequently death (Misawa et al., 1998). 
 
1.10.7. Management and treatment of GBS 
With the majority of GBS patients (30%) undergoing respiratory muscle compromise, 
good supportive care is the most fundamental element of management of the 
disease. Patients are admitted to the neurological intensive care unit or an 
intermediary care telemetry unit to allow for close and frequent monitoring of 
respiratory, bulbar and automatic function (Dimachkie and Barohn, 2013). Other 
indicated treatments for GBS include plasma exchange (PE) and intravenous 
immunoglobulin (IVIg). PE treatment directly facilitates the removal of humoral 
factors such as autoantibodies, immune complexes, complement, cytokines, and 
other nonspecific inflammatory mediators (Dimachkie and Barohn, 2013). IVIg 
treatment aids in the initiation of an anti-inflamatory cascade, the end result being 




1.11. Prevention and control measures of Campylobacter infections 
Diarrhoeal diseases remain a leading cause of preventable death, especially among 
children of less than five years of age in developing countries (Keusch et al., 2006). 
Human campylobacteriosis is primarily associated with the consumption or handling 
of poultry. Strategies that aim to eliminate and prevent Campylobacter infections 
consider the multiple pathways through which the pathogen reaches the human host 
from the source (Wagenaar et al., 2013). Mitigation strategies from a public health 
point of view facilitate effective control of food safety, including food production, 
processing, distribution, storage, and food preparation (Mangni and Arvntikis, 2010). 
Poultry contamination with Campylobacter takes place in the slaughterhouse as a 
result of high concentration of Campylobacter in the intestines. During automated 
slaughtering processes, chicken carcasses are almost universally contaminated on 
the surface (Acheson and Allos, 2001). Food and safety authorities sought cost-
effective ways to intervene in the poultry production chain. One of the postulated 
strategies that aims to target the food and environmental pathway for infection is 
reducing the prevalence of Campylobacter colonization in living farm animals, 
decreasing the introduction of high numbers of Campylobacter into the 
slaughterhouse (Acheson and Allos, 2001; Wagenaar et al., 2013). This may either 
reduce or eliminate Campylobacter in the final product, resulting in a better public 
health impact rather than implementing site specific interventions later in the 
production chain (Wagenaar et al., 2013). According to Wagenaar et al., (2013), the 
major issue at hand concerning the risk factors in the production line is the lack of 
biosecurity. In theory, the implementation of biosecurity at animal husbandries 
should prevent the introduction of Campylobacter into flocks. However, the 
ubiquitous nature of Campylobacter in the environment renders biosecurity a non-
eliminating approach. Flies have been found to carry Campylobacter in and out from 
broiler houses (Nylen et al., 2002; Ekdahl et al., 2005). 
 
Control measures to combat human Campylobacter infections place emphasis on 
good hygiene practices throughout production and processing of poultry, not only in 
the slaughterhouse but handling of the final product by the consumers. Failure in 
good food-handling practices is the major pathway for transmission (Acheson and 
Allos, 2001; Wagenaar et al., 2013). Undercooked chicken is one of the underlying 
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causes of infection, but of minor importance because interior contamination of meat 
with Campylobacter is very minimal because campylobacters are unable to multiply 
outside the intestines of warm-blooded animals. By the time the final product 
reaches the consumer, a considerable fraction of Campylobacter would have died, 
and only a small fraction will reach the consumer (Acheson and Allos, 2001).  
 
Cutting boards and utensils used during meat preparation orchestrate cross-
contamination in the kitchen from contaminated meat to foods that are eaten raw 
such as salads. This route is considered the major pathway for human 
campylobacteriosis (Wagenaar et al., 2013). Consumers are required to accept 
some level of risk and to take appropriate precautions (Wagenaar et al., 
2013).Transmission can be avoided by thorough washing of utensils used during 
meat preparation with soap and water. Unpasteurized milk has been linked to C. 
jejuni outbreak cases, and should not be consumed (Acheson and Allos, 2001; Fouts 
et al., 2005; Hofreuter et al., 2006). Other prevention approaches include persons 
with acute diarrhoea avoiding the preparation and handling of food until their illness 
resolves (Acheson and Allos, 2001). Good hygiene dictates that all persons should 
wash their hands after using the bathroom, especially if they have enteritis (Acheson 
and Allos, 2001). Tourists should be cautious against taking antibiotics as 
prophylaxis to prevent campylobacteriosis, and also when travelling to developing 
countries, not to drink untreated water (Acheson and Allos, 2001). 
 
1.11.1. Vaccination 
Despite the burden estimates of human campylobacteriosis globally, a vaccine as a 
preventative approach is still not yet available (Wagenaar et al., 2013). Genetic 
diversity and incomplete understanding of pathogenesis, along with post infectious 
manifestations associated with C. jejuni, which accounts for over 80% of all human 
campylobacteriosis, are some of the factors that impede current approaches aimed 
at developing a vaccine against these species of Campylobacter (WHO PD-VAC, 
2014).  Nevertheless, development of vaccines against C. jejuni for human clinical 




1.12. Study objectives 
To date, there are limited numbers of studies comprehensively describing the 
molecular epidemiology of Campylobacter in South Africa. The current study 
proposed to improve the understanding of the molecular epidemiology of 
campylobacteriosis in South Africa by exploiting molecular diagnostic and subtyping 
tools.  
 
Objectives of the study: 
 
 
 To investigate the prevalence of Campylobacter infections in South Africa through 
screening of clinical isolates and stool specimens from diarrhoeagenic patients. 
 
1. GERMS-SA Campylobacter Surveillance Program 
2. Rotavirus Surveillance Program (stool specimens of children <5 years of age 
with sever acute diarrhoea) 
 
 Furthermore, to investigate the prevalence of Campylobacter in polio-negative 
stool specimens of patients with symptoms of acute flaccid paralysis (AFP) to 
define the proportion of AFP which may be attributed to GBS post Campylobacter 
infection.  
 
3. AFP Surveillance Program 
 
 To identify associated risk factors and risk groups associated with 
campylobacteriosis  
 To investigate antimicrobial susceptibility profiles of Campylobacter isolates 
associated with diarrhoeal diseases  
 To achieve this molecular tools included in our current study were real-time PCR, 
WGS, and MLST; these tools were used to characterize Campylobacter species 
and subtype prevalent strains associated with illnesses to better under the 




Chapter 2:  Materials and Methods 
 
 
2.1. Human bacterial isolates and stool specimens  
2.1.1. Bacterial isolates for Campylobacter surveillance 
The reference centre in South Africa for enteric infections is the Centre for Enteric 
Diseases (CED), National Institute for Communicable Diseases (NICD). The CED 
now also includes surveillance for the enteric pathogen Campylobacter, to better 
understand the epidemiology of this organism in South Africa. Isolates were 
voluntarily sent from approximately 200 clinical microbiology laboratories across 
South Africa as part of the Group for Enteric, Respiratory and Meningeal disease in 
South Africa (GERMS-SA) laboratory-based surveillance program. The study 
focused on all laboratory-confirmed Campylobacter cases from respective 
laboratories sent to the CED-NICD in the years January 2014 to December 2015. 
Bacterial isolates were sent on either Dorset Egg slope transport medium or on 
CCDA selective media (plates or Transwabs) and Trypticase Soy Agar (TSA) + 5% 
sheep blood media. A total of 848 bacterial isolates were submitted during the 
January 2014-December 2015 study period from various South African provinces 
participating in the GERM-SA Campylobacter Surveillance Program. 
 
2.1.2. Stool specimens from the Rotavirus Surveillance Program 
Stool specimens sent to CED (virology division) as part of the Rotavirus Surveillance 
Program (implemented in 2009), which is concerned with identification of the 
aetiology of diarrhoeal disease in children (<5 years of age), were screened for the 
presence of Campylobacter. The Rotavirus Surveillance Program enrolled children 
aged <5 years with sever acute diarrhoea (three or more loose stools within a 24 
hour period) who were admitted to selected sentinel hospitals in RSA. Nucleic acid 
extracted from stool specimens during February 2014 and December 2015 were 
screened for the presence of Campylobacter, where a total of 981 samples formed 
the basis of the study. 
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2.1.3. Stool specimens from the AFP Surveillance Program 
Polio-negative stool specimens from the AFP Surveillance Program in South Africa 
were screened for the presence of Campylobacter. The AFP Surveillance Program is 
based at the NICD and it is concerned with the screening of all AFP cases in South 
Africa for polio. The case definition of a suspected polio case is any case of AFP, 
including GBS, in a person under 15 years of age for any reason other than severe 
trauma, or paralytic illness in a person of any age in which polio is suspected. Raw 
stool samples are collected in universal sample containers and transported to the 
World Health Organization (WHO) accredited Regional Polio Reference Laboratory 
(National Institute for Communicable Diseases) for processing and testing. For 
optimal isolation, two stool samples, 24 – 48 hours apart and within 14 days of onset 
of paralysis must be collected from each case and transported between 2-8°C. The 
first stool specimen for each non-polio case in RSA was screened for the presence 
of Campylobacter to investigate the proportion of AFP attributed to GBS post 
Campylobacter infection. A total of 512 polio-negative stool specimens were 




2.2. Bacterial isolates of animal origin 
Veterinary institutes in RSA were requested to send Campylobacter bacterial 
cultures upon isolation from animals from January 2014-December 2015. Animal 
isolates were received from the Western Cape Veterinary institute (n=6) and from the 
University of Pretoria in Gauteng (n=12) between January 2014 to December 2015. 
The Western Cape animal isolates were from chicken (n=2), sheep (n=2), and 




2.3. Detection of Campylobacter from bacterial isolates 
2.3.1. Phenotypic identification of Campylobacter  
All received bacterial isolates were streaked onto selective media; CCDA agar plates 
[Diagnostic Media Products (DMP), National Health Laboratory Service (NHLS), 
Johannesburg, RSA] and TSA + 5% blood agar plates (DMP, NHLS, RSA), followed 
by incubation at 42°C microaerophilically [GENBox microaer, (BioMèrieux, Marcy-
L’Etoile, France)] for 48 hours. Colonial morphology, microscopy, Hippurate 
hydrolysis, catalase, and an oxidase test were performed on all culturable isolates as 
rapid presumptive identification of positive or negative Campylobacter isolates. 
Definite identification of Campylobacter from culturable and non-culturable isolates 
was carried out using a molecular characterization tool (multiplex real-time PCR) 
according to Best et al., (2003). 
 
2.3.2. Genomic DNA extraction for the detection of Campylobacter 
 
a. Crude genomic DNA preparation from bacterial cultures 
 
A total of 400 microliters (µL) autoclaved Tris-Ethylenediaminetetraacetic acid (TE) 
buffer (Appendix B) was aliquoted into 1.5 mL eppendorf tubes. A sterile loop (1 µL) 
was used to collect and transfer a half loopfull of bacterial culture from agar plates 
into 1.5 mL eppendorf tubes containing 400 µL TE buffer. The bacterial culture 
suspension in each tube was vortexed for 5 seconds and the tubes were placed on a 
heating block set at 95°C for 25 minutes (min). After incubation the tubes were 
vortexed for 10 seconds and centrifuged [Eppendorf MiniSpin; (Eppendorf, Hamburg, 
Germany)] at 13400 revolutions per minute (rpm) for 3 min at 4°C to pellet the 
cellular debris and obtain the DNA in the supernatant. A 20 µL of supernatant was 
diluted into new 1.5 mL eppendorf tubes containing 80 µL TE buffer and mixed by 
vortexing for 5 seconds, followed by pulse centrifugation to collect the contents at the 




b. Crude genomic DNA preparation from non-culturable bacterial isolates  
In situations where bacterial isolates submitted [Dorset Egg slope transport media 
(DMP, NHLS, Johannesburg, RSA)/CCDA plate or transwab/TSA + 5% sheep blood 
plate] were non-culturable, a loopfull of bacterial culture was collected from the 
dorset slope or agar plate using a 1 µL sterile loop and suspended into a 1.5 mL 
eppendorf tube containing 200 µL autoclaved TE buffer and processed as described 
in section a. Non-culturable bacterial isolates sent on CCDA transport swabs were 
extracted by suspending the swab into a 1.5 mL eppendorf tube containing 200 µL 
autoclaved TE buffer and processed as described in section a. 
 
c. Genomic DNA preparation from stool specimens 
QIAamp Fast DNA Stool Mini Kit (06/2012) [QIAGEN®, Hilden, Germany] was used 
to extract DNA from stool specimens received as part of the AFP Surveillance 
Program. The preliminary preparations of the reagents in the kit and the validation of 
extraction are outlined in Appendix C. DNA extraction was performed according to 
the manufacturer’s instructions. The initial step involved suspending a pea sized 
stool sample (~200 mg) in a 2 mL microcentrifuge tube with 1 mL InhibitEX Buffer. 
The tubes were vortexed until the stool sample was thoroughly homogenized. The 
suspension was incubated at 70°C for 5 min on a heating block, followed by 
vortexing for 15 seconds. The Eppendorf 5415R centrifuge (DJB Labcare, UK) was 
used at 13200 rpm to pellet the stool suspension and 200 µL of the supernatant was 
transferred into a new 1.5 mL centrifuge tube containing 15 µL of proteinase K. Two 
hundred microliters of lysis buffer (Buffer AL) was added into the proteinase K-
supernatant mixture. The tubes were vortexed for 15 seconds and incubated at 70°C 
for 10 min. Furthermore 200 µL of absolute ethanol (Merck Chemicals Ltd., 
Nottingham, England and Wales) was added to the lysate which was vortexed and 
spun down.  
 
Six-hundred microliters of the lysate was transferred into a QIAamp spin column in a 
2 mL collection tube and centrifuged at 13200 rpm for 2 min. The QIAamp spin 
column was transferred into a new 2 mL collection tube and 500 µL of wash buffer 
(Buffer AW1) was added into the QIAamp spin column and centrifuged at 13200 rpm 
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for 2 min. The QIAamp spin column was again placed into a new 2 mL collection 
tube and 500 µL of a second wash buffer (Buffer AW2) was added into the QIAamp 
spin column and centrifuged at 13200 rpm for 3 min. To eliminate the chance of 
possible Buffer AW2 carryover, the QIAamp spin column was transferred into a new 
2 mL collection tube and centrifuged at 13200 rpm for 3 min. The QIAamp spin 
column was transferred into a new, labelled 1.5 mL eppendorf tube and 200 µL of 
elution buffer (Buffer ATE) was added and incubated for 5 min at room temperature 
(RT). Subsequently, the DNA was eluted into the 1.5 mL microcentrifuge tube by 
centrifuging at 13200 rpm for 3 min and stored at -20°C.  
 
2.3.3.   Genotypic detection of Campylobacter using multiplex real-time PCR 
A previously described multiplex real-time PCR assay (Best et al., 2003; Lund et al., 
2004; Botteldoorn et al., 2008) was performed to identify Campylobacter at species 
level from genomic DNA and nucleic acid prepared from bacterial isolates and stool 
specimens. The assay detected the presence of C. jejuni and C. coli by targeting 
genes that are specific for each species. The targeted genes were mapA gene 
specific for C. jejuni and the ceuE gene specific for C. coli. A 16SrRNA gene unique 
to all Campylobacter species was also targeted which served as both an internal 
amplification control and for the identification of non-C. jejuni/C. coli species of 
Campylobacter. A non-template control (NTC) was also incorporated to rule out 
possible false positive tests as a result of contamination. Target gene sequences, 
primers, and probes used for Campylobacter multiplex real-time PCR are indicated 
in Appendix D. 
  
A multiplex real-time PCR was performed in an Optical 96-well Reaction Plate 
(Applied Biosystems® by Life Technologies, Shanghai, China). For each sample the 
following reagents were added: 25 µL TaqMan Gene Expression Master Mix 
(Applied Biosystems®, Foster City, USA); 3 µL Campylobacter primer/probe mix 
(Appendix D); 12 µL internal positive control (IPC) mix (Applied Biosystems®, Foster 
City, USA); 1-7 µL genomic DNA (Appendix D); and autoclaved deionized water to 
make up to a final PCR reaction volume of 50 µL. The control strains (WHO) used for 
each run are outlined in Appendix D. 
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After adding all the reagents the wells were capped with Optical caps (Applied 
Biosystems® by Life Technologies, Shanghai, China) and the plate was briefly 
centrifuged using the Allegra™ X-22R centrifuge (Beckman Coulter™, Fullerton, USA) 
at 13000 rpm for 5 seconds to settle the fluid at the bottom of the reaction wells. The 
PCR reaction was carried out on the Applied Biosystems (AB) 7500 real-time PCR 
machine (Applied Biosystems®, Foster City, USA) and the cycling conditions for a 50 
µL reaction were set as follow: initial heating stage at 50°C for 2 min (1 cycle); 
second stage invovled two denaturation steps at 95°C for 10 min (1 cycle), followed 
by 95°C for 15 seconds. The third stage was conducted at 60°C for 1 min (40 cycles) 
and  the results were viewed and analyzed using the 7500 System SDS Software 
after 90 min. Interpretations of real-time PCR results for Campylobacter are outlined 
in Appendix D. 
 
2.4. Antimicrobial susceptibility testing of Campylobacter isolates 
Antimicrobial susceptibility profiles of viable bacterial cultures that were positive for 
Campylobacter were examined and a total of 229 Campylobacter isolates [C. jejuni 
(n=185), C. coli (n=40), and other non-C. jejuni/C. coli species (n=4)] were tested 
against erythromycin, azithromycin, ciprofloxacin, and tetracycline (BioMèrieux, 
Marcy-L’Etoile, France). Antimicrobial susceptibility profiles of the isolates were 
determined using the Epsilometer test (Etest) method and analyzed according to the 
Clinical and Laboratory Standards Institute (CLSI) guidelines issued for the year 
2014 and 2015 (CLSI, 2014 suppl 24; CLSI, 2015 suppl 25). 
 
Upon initial use of a new Etest batch, the Etest strips were validated by using control 
strains (E. coli ATCC 25922 and K. Pneumonia ATCC700608). The controls strains 
ought to be susceptible to all tested antimicrobials in order to deem the Etest and 
antimicrobial susceptibility test valid. Campylobacter isolates were sub-cultured on 
TSA + 5% Sheep blood for 48-72 hours at 42°C microaerophilically. When growth 
was obtained after 48-72 hours on TSA + 5% Sheep blood plates, a 0.5 MacFarland 
bacterial suspension was prepared and measured using a Microscan Turbidity Meter 
(Dade Behring, Deerfield, USA) for each isolate in sterile saline (DMP, NHLS, 
Johannesburg, RSA). A sterile swab was immersed in the bacterial suspension with 
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the subsequent release of excess suspension on the inside wall of the tube. By using 
a rotating plate holder (BioMérieux, Askim, Sweden), the swab was uniformly 
swabbed on the surface of a pre-incubated (RT) 10% blood agar plate (DMP, NHLS, 
Johannesburg, RSA). 
 
Subsequently, two different Etest strips [erythromycin and azithromycin; ciprofloxacin 
and tetracycline (BioMèrieux, Marcy-L’Etoile, France) were placed in each plate, with 
the Etest strips facing in opposite directions. The plates were then incubated for 48 
hours at 42˚C microaerophilically. The bactericidal or bacteriostatic nature of each 
antimicrobial dictated how the minimum inhibitory concentration (MIC) was read. 
Bactericidal antimicrobial MIC was read at the point of complete (100%) inhibition of 
growth and bacteriostatic antimicrobial MIC was read at 80% growth inhibition. The 
results were reported as being susceptible, intermediate or resistant according to 
CLSI guidelines for each antimicrobial (CLSI, 2014 suppl 24; CLSI, 2015 suppl 25). 
 
2.5. Molecular subtyping of C. jejuni isolates using MLST  
2.5.1. Genomic DNA extraction 
Extraction of genomic DNA was carried out using the QIAamp DNA Mini Kit 
(QIAGEN®, Hilden, Germany) as outlined by the manufacturer. Preparation of 
reagents was carried out as indicated in Appendix E. Using a sterile 1 µL inoculating 
loop, bacterial cultures of pure C. jejuni isolates cultured on TSA + 5% Sheep blood 
agar microaerophilically were collected (loop full) and resuspended in 180 µL tissue 
lysis buffer (Buffer ATL) and vortexed. Twenty microliters of proteinase K was added 
into the culture suspension and mixed by vortexing, followed by incubation at 56°C 
for 90 min. Following the incubation step, 200 µL of lysis buffer (Buffer AL) was 
added to the suspension, mixed by a pulse vortex step and incubated at 70°C for 10 
min. A total volume of 200 µL absolute ethanol (Merck Chemicals Ltd., Nottingham, 




The lysate was transferred to a QIAamp Mini spin column and centrifuged at 8000 
rpm for 2 min. The QIAamp Mini spin column was transferred to a clean 2 mL 
collection tube, where 500 µL of wash buffer (Buffer AW1) was added into the spin 
column and centrifuged at 8000 rpm for 2 min. Subsequently, the QIAamp Mini spin 
column was transferred once again to a clean 2 mL collection tube, where 500 µL of 
a second wash buffer (Buffer AW2) was added into the spin column and centrifuged 
at 13400 rpm for 3 min. An additional centrifugation step was performed to remove 
excess AW2 buffer. The QIAamp Mini spin column was then transferred into a newly 
labelled 1.5 mL microcentrifuge tube and 200 µL of elution buffer (Buffer AE) was 
added into the QIAamp Mini spin column and incubated for 5 min at RT. DNA was 
eluted into the 1.5 mL microcentrifuge tube by centrifuging at 13200 rpm for 3 min 
and stored at -20°C. 
 
2.5.2. Quantification of extracted genomic DNA    
Extracted genomic DNA for MLST was quantified using the Qubit™ dsDNA BR Assay 
kit (Life Technologies Corporation, Carlsbad, USA). Once the reagents had reached 
RT, the Qubit™ Working Solution was prepared (Appendix E) for each standard and 
sample and the quantification assay was carried out in 0.5 mL tubes. Following the 
preparation of the assay tubes, the tubes were mixed by pulse vortexing and 
incubated for 2 min at RT. The standards (Standard #1 and Standard #2) were 
initially inserted in the Qubit® 2.0 Fluorometer (Life Technologies Corporation, 
Carlsbad, USA) respectively to calibrate the fluorometer, followed by reading the 
DNA samples. The dilution feature of the Qubit® 2.0 Fluorometer was used to 
determine the stock concentration of each sample in nanogram per mole (ng/mol). 
The accepted minimum genomic DNA concentration for WGS was 10 ng/mol. 
 
2.5.3. WGS and analysis of WGS data 
Purified and quantified genomic DNA of 111 C. jejuni isolates [human hosts (n=99), 
and animal hosts (n=12)] were sequenced by the technicians at the NICD 
Sequencing Core Facility (NSCF) using the Illumina MiSeq genome analyzer 
(StarSeq, Mainz, Germany). Following DNA extraction, Nextera XT DNA sample 
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preparation kit (Illumina San Diego, CA, US) was used to generate multiplexed 
paired-end libraries which required 1 ng of extracted DNA as starting material (48 
samples per run).  During the library preparation input DNA was tagmented (tagged 
and fragmented) by Nextera XT transposome. The Nextera XT transposome 
simultaneously fragmented the input DNA and added adaptor sequences to the end, 
allowing amplification by PCR in subsequent steps.  The resulting DNA was 
amplified using Nextera XT Indexing tags, to generate multiplexed paired-end 
libraries which allowed pooling of samples on the MiSeq. Genome sequencing was 
carried out using an Illumina Miseq instrument to generate 300 bp paired-end reads 
with 100x genome coverage. The resultant reads were checked for quality, trimmed 
and de novo assembled using the CLC Genomics Workbench software version 7.5.2 
(CLC Bio-Qiagen, Aarhus, Denmark) at the CED. 
 
2.5.4. MLST from WGS data of C. jejuni isolates 
The resultant genomic assemblies of C. jejuni isolates were analyzed on the basis of 
molecular subtyping using MLST targeting the seven housekeeping genes from 
generated WGS data. MLST pipelines developed at CGE in DTU based on the 
seven housekeeping genes for C. jejuni (Appendix A) were used to define allele 
sequences and STs for the C. jejuni isolates in our current study (accessible at 
https://cge.cbs.dtu.dk//services/MLST/).  Clonal complex assignment for the isolates 
was carried out using tools available on the Bacterial Isolate Genome Sequence 
Database (BIGSDB) accessible at http://pubmlst.org/software/database/bigsdb/. 
 
2.6. Data analysis  
Results (phenotypic, real-time PCR, and antimicrobial susceptibility testing) of all 
bacterial isolates and stool specimens included in the study were illustrated by using 
tables on Microsoft Excel 2010 and statistical analysis was performed using Epi Info 
7 (CDC). Demographic data for case-patients from the various surveillance programs 
included in the study were obtained from the Access Database at the NICD. Testing 
for statistical significance was performed using Chi-squared and Fisher’s Exact tests 
from which a p-value of <0.05 was taken to be statistically significant. 
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The analysis of subtyped C. jejuni isolates by MLST from WGS data was carried out 
by collecting generated MLST profile data in BioNumerics Software version 6.5 
(Applied Maths, Sint-Martens-Latem, Belgium). Phylogenetic relationships between 
strains of C. jejuni were calculated and defined on the basis of STs by using 
unweighted pair group method with arithmetic mean (UPGMA) cluster analysis and 
Minimum Spanning Trees (MSTs) were generated on the basis of the allele 
sequence profiles of the seven housekeeping genes of C. jejuni. The generated 
dendrogram was performed using the categorical coefficient with a zero (0) tolerance 
and the MSTs were constructed using the MST categorical coefficient on 
Bionumerics. The Simpson’s index of diversity was calculated for all typable C. jejuni 
isolates with defined STs to statistically determine the extent of diversity that exist 






Chapter 3: Results 
 
 
3.1. Campylobacter Surveillance Program 
3.1.1. Submission of bacterial isolates during 2014 and 2015 
During the course of the study, which commenced from January 2014 to December 
2015, a total of 848 bacterial cultures were submitted from various GERMS-SA 
participating laboratories in South Africa [Table 3.1]. The results obtained were 
stratified by year (2014 and 2015) of submission, during which 320 isolates were 
submitted in 2014 and 528 were submitted in 2015 [Table 3.1]. Testing for statistical 
significance by year, demographic characteristics, and specimen type respectively 
was performed using Chi-squared and Fisher’s Exact tests. The difference in the 
number of received isolates based on age categories, sex, and specimen type during 
the two study years were not statistically significant (p-value >0.05) [Table 3.1]. 
However, annual occurrences of infections, and submission of isolates by province, 
as well as culture viability of isolates was significantly different between 2014 and 
2015 (p-value <0.05) [Table 3.1]. 
 
The age range of individuals from whom bacterial cultures were submitted in this 
study was less than one years to 90 years [Table 3.1]. Majority of these case 
patients were male (53%; 452/848) children of less than five years of age (35% 
(297/848). The provinces that highly participated in the Campylobacter Surveillance 
Program during 2014 and 2015 were the Gauteng and Western Cape Provinces, 
with a prominent year to year increase (p-value <0.01) in the number of isolates 
submitted. These provinces accounted for an overall of 47% and 45% respectively, 
while 8% was accounted for by the remaining provinces, with the exception of the 
Eastern Cape. Majority of the submitted bacterial isolates were from stool cultures 
(99%; 840/848), with only 1% (8/848) representing those bacterial isolates from 
blood cultures [Table 3.1]. Overall, 52% of the submitted bacterial isolates were non-
viable following submission, 45% were viable, and the remaining 3% was accounted 
for by contaminated isolates and those lost in transit [Table 3.1]. 
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Table 3.1: Demographic information of the study population collected during the 




Overall (n=848) (%) 
 
2014 (n=320) (%) 
 




Age (years)      
Median (
€
IQR)   20 (2-45) 20 (2-40) 19 (2-47) 0.99 
 Range <1-90 <1-90 <1-90 
Age category      
           <1-4 297 (35) 108 (34) 189 (36)   
 
 









  5-14   94 (11)   38 (12)   56 (11) 
15-24     71 (8)     30 (9)     41 (8) 
25-34   96 (11)   39 (12)   57 (11) 
35-44     72 (8)   35 (11)     37 (7) 
45-54     65 (8)     19 (6)     46 (9) 
55-64     57 (7)     17 (5)     40 (8) 
≥65    93 (11)   33 (10)   60 (11) 
*Unk     3 (<1)     1 (<1)    2 (<1) 
Sex      
Female 393 (46) 149 (46) 244 (46)  
0.88 Male 452 (53) 169 (53) 283 (53) 
Unk     3 (<1)    2 (<1)     1 (<1) 
Ø
Province      
Free State    3 (<1)   3 (<1)      0  
<0.0001 
Gauteng           405 (47)          189 (59)          216 (41) 
KwaZulu-Natal    26 (3)   17 (5)      9 (2) 
Limpopo    28 (3)     4 (1)    14 (3) 
Mpumalanga    6 (<1)   3 (<1)    3 (<1) 
North West    2 (<1)   1 (<1)    1 (<1) 
Northern Cape    7 (<1)     5 (2)    2 (<1) 
Western Cape 381 (45)             98 (30) 283 (53) 
ᶲ
Annual quarter      
Jan-Mar (Q 1) 257 (30)            56 (18) 201 (38)  
 
<0.0001 
Apr-Jun (Q 2) 151 (18)              20 (6) 131 (25) 
Jul-Sep  (Q 3) 166 (20)            71 (22)   95 (18) 
Oct-Dec (Q 4) 274 (32)          173 (54) 101 (19) 
Specimen type      
Stool 840 (99)         318 (99) 522 (99) 0.72 
 Blood culture       8 (1)             2 (<1)       6 (1) 
Culture viability      





Missing     1 (<1)  0     1 (<1) 
Non-viable  438 (52)         145 (45)  293 (55) 
Viable  387 (45)         166 (52)   221 (42) 
 
Number of isolates (n); Percentage (%); 
€
Interquartile range (IQR); 
ᶲ





p-value <0.05 statistically significant.  
Footnote: Findings were stratified by year of study, therefore p-value represents whether or not findings in year 
2014 were significantly different from findings in year 2015. For all statistical analysis unknowns were omitted. 
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3.1.2. Proportion of real-time PCR positive isolates for Campylobacter  
Ninety-four per cent (801/848) of all submitted bacterial isolates during January 2014 
to December 2015 were positive for Campylobacter by a multiplex real-time PCR 
assay [Table 3.2]. Of the positive isolates, 38% were those isolates submitted in the 
year 2014, and 62% were those submitted in the year 2015. Collectively, 6% 
(47/848) represented those isolates that were negative for Campylobacter species in 
both study years. A total of 94% of the isolates submitted were accurately identified 
by GERMS-SA participating laboratories in the Campylobacter Surveillance 
Program.  
 
3.1.3. Detected species of Campylobacter by real-time PCR 
Of the total real-time PCR positive Campylobacter isolates (801/848), C. jejuni was 
the most predominant species detected in this study, accounting for an overall 
positivity rate of 83% (665/801) [Table 3.2]. C. coli was infrequently detected, 
accounting for only 12% (97/801) of the total positive cases. Coinfection with both C. 
jejuni and C. coli was identified 16 times throughout the study period, accounting for 
2% (16/801). Several cases of Campylobacter species other than C. jejuni or C. coli 
were detected, which accounted for 3% (23/801). The detection of Campylobacter 
species by year of isolation was slightly higher in the year 2014 (86%; 260/303) for 
C. jejuni as compared to the year 2015 (81%; 405/81). C. coli was slightly more 
detected in the year 2015 (14%; 69/498) as compared to the year 2014 (9%; 
28/303), whereas the detection of coinfections and non-C. jejuni/C. coli cases was 
the same in both respective study years (3%). However the differences seen by year 
were not statistically significant (p-value 0.28). 
 
3.1.4. Sex distribution of characterized species of Campylobacter 
Males were slightly more frequently associated with all detected species of 
Campylobacter infections compared to females, with an overall positivity rate of 53.6% 
(429/801) for males, and 46% (369/801) for females in both study years [Table 3.3]. 
Patients of unknown sex with isolates positive for Campylobacter were <1% (3/801). 
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Table 3.2: Distribution of real-time PCR confirmed Campylobacter isolates during the 
2014-2015 study period.  
 
*January (Jan) and December (Dec). 
£
Campylobacter spp.: mixed (positive for both C. jejuni and C. coli); Other 
(positive for non-C. jejuni/C. coli). 
£







(Jan 2014-Dec 2015) 2014 2015 
£
p-value Overall positive (%) 
n=801 
Total positive (%)  
n= 303 
Total positive (%) 
n=498 
Specimen type     
Stool 796 (99)   302 (99.7)   494 (99) 
0.41 
Blood culture    5 (<1)          1(<1)        4 (1) 
Age group 
(years) 
    
<1-4              281 (35)      104 (34)   177 (36) 
0.40 
5-14                90 (11)        35 (12)     55 (11) 
15-24               67 (8.4)        29 (10)       38 (8) 
25-34                95 (12)        39 (13)     56 (11) 
35-44               68 (8.5)        33 (11)       35 (7) 
45-54               62 (7.7)          18 (6)       44 (9) 
55-64               52 (6.5)          16 (5)       36 (7) 
≥65                84 (10)        29 (10)     55 (11) 
Unk                  2 (<1)            0 (0)      2 (<1)  
Province     
Free State     3 (<1)           3 (1)       0 (0) 
<0.001 
Gauteng            379 (47)      180 (59)          199 (40) 
KwaZulu-Natal     25 (3)         16 (5)       9 (2) 
Limpopo     17 (2)          4 (1)     13 (3) 
Mpumalanga     4 (<1)          3 (1)     1 (<1) 
North West     6 (<1)          5 (2)     2 (<1) 
Northern Cape     2 (<1)        1 (<1)     1 (<1) 
Western Cape            364 (45)       91 (30) 273 (55) 
Annual quarter     
Jan-Mar (Q 1) 233 (28)      52 (17) 181 (36) 
<0.001 
Apr-Jun  (Q 2) 146 (18)        19 (6) 127 (26) 
Jul-Sep  (Q 3) 161 (20)      68 (22)   93 (19) 
Oct-Dec (Q 4) 261 (33)    164 (54)   97 (19) 
£
Campylobacter spp.    
C. jejuni 665 (83)  260 (86) 405 (81) 
0.28 
C. coli              97 (12)      28 (9)   69 (14) 
Mixed                16 (2)        7 (2)       9 (2) 
Other     23 (3)        8 (3)     15 (3) 
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3.1.5. Detection of Campylobacter by age groups 
Case patients in this study displayed a median age of 20 years and an Interquartile 
Range (IQR) of 2-40 in the year 2014 and a median age of 19 years (IQR=2-47) in 
the year 2015; of which the difference between 2014 and 2015 was not significant 
(p-value 0.99) [Table 3.1]. The difference in the number of submitted bacterial 
isolates based on age groups in year 2014 and 2015 respectively were not 
statistically significant (p-value 0.57) [Table 3.1] as well as the detection of 
Campylobacter in those respective years (p-value 0.40) [Table 3.2].The age 
categories chosen for the study population displayed three peaks for both study 
years combined [Table 3.2]. The peaks were represented by individuals in the 0-4 
age group, 25-34 age group, and those aged ≥65 in years. In this study, children in 
the 0-4 age group were more implicated with campylobacteriosis and they accounted 
for an overall positivity rate of 35% (281/801). The second most implicated group 
were young adults aged 25-34 in years, accounting for 12% (95/801) of the total 
positive cases. The elderly (≥65 years) were another group of individuals who 
showed a Campylobacter infection fraction of note following the young adults, 
accounting for 10% (84/801) of the total Campylobacter positive cases.  
 
 Table 3.3: The overall distribution of real-time PCR positive Campylobacter isolates 
submitted in the years 2014-2015 by age-group and sex. 
 
Age group 
Sex                                                                        




0-4 113 166 2        281 (35) 
0.02 
5-14 37 53 0          90 (11) 
15-24 29 38 0         67 (8.4) 
25-34 54 41 0          95 (12) 
35-44 39 29 0         68 (8.5) 
45-54 30 31 1         63 (7.9) 
55-64 22 30 0         52 (6.5) 
≥65 44 40 0          84 (10) 
Unk 1 1 0            2 (<1) 
Total positive (%) 369 (46) 429 (53.5) 3 (<1)         801 (94)   
 
£The total number of positive isolates for females and males per age category were evaluated for any variation; the overall 
differences for sex per age-group was of statistical significance (p-value of 0.02). 
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3.1.6. Detection of Campylobacter by both sex and age groups 
Overall males were slightly more associated with the positive cases of 
Campylobacter in this study, however, instances where females were slightly more 
associated with campylobacteriosis than males were seen in age groups 25-34, 35-
44, and those aged ≥65 years [Table 3.3]. Overall there was a difference in sex 
distribution which was significant (p-value 0.02). 
 
3.1.7. Invasive cases of Campylobacter 
During January 2014 to December 2015, a total of eight (1%; 8/848) invasive 
isolates attributed to Campylobacter infection were submitted [Table 3.1]. In the year 
2014, two invasive isolates (1%; 2/320) were submitted, of which only one of the two 
cases (0.3%; 1/320) were positive for Campylobacter species, which was other than 
C. jejuni/C. coli by real-time PCR. In the year 2015 six invasive isolates (1%; 6/528) 
of Campylobacter infection were submitted, and less than 1% (4/528) of these 
isolates were positive for Campylobacter [C. jejuni (n=3); and non-C. jejuni/C. coli 
(n=1)] based on real-time PCR results. Collectively, less than 1% (5/848) of the 
submitted isolates was invasive cases that were positive for Campylobacter by real-
time PCR in this study.  
 
3.1.8. Annual occurrences of Campylobacter infections 
In the years 2014 and 2015 [Table 3.1] the total number of isolates submitted during 
the first annual quarter were represented by 18% and 38% for the year 2014 and 
2015 respectively. This was followed by a decrease in the number of submitted 
isolates during the second annual quarter (6% in 2014 and 25% in 2015). In 2014 
the total number of submitted isolates increased from 6% (quarter two) to 22% 
(quarter three) and then to 54% (quarter four). In 2015 the submitted isolates further 
decreased from 25% (quarter two) to 18% (quarter three) and then increased to 19% 
(quarter four). The difference in annual occurrences of Campylobacter by year were 
significant (p-value <0.01). 
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This trend by year held true for the number of detected Campylobacter species in 
those respective annual quarters using real-time PCR [Table 3.2]. Collectively, 28% 
(233/801) of the positive cases of Campylobacter by real-time PCR were submitted 
during the first annual quarter, followed by a decrease in the number of positive 
Campylobacter cases in the second quarter, represented by 18% (146/801) of the 
positive cases. The number of positive Campylobacter cases increased from the 
third quarter, represented by 20% (161/801), to 33% (261/801) in the fourth quarter. 
Notably, the majority of the Campylobacter positive isolates were submitted during 
the fourth quarter of 2014 and the first quarter of 2015, represented by 20% 
(164/801) and 23% (181/801) respectively [Table 3.2]. 
 
3.1.9. Antimicrobial susceptibility profiles of Campylobacter  
During January 2014 to December 2015, only 59% (229/387) of the viable isolates 
represented in Table 3.1 remained viable and therefore were tested against the 
antimicrobials: erythromycin, azithromycin, ciprofloxacin, and tetracycline. Isolates 
showed the highest sensitivity to erythromycin, with 90% (207/229) of the isolates 
being sensitive against the antimicrobial and only 10% (22/229) representing those 
isolates that were resistant [Figure 3.1]. Eighty-six per cent (198/229) of the isolates 
were sensitive against azithromycin and only 14% (31/229) were resistant. The 
isolates showed high resistance against ciprofloxacin, represented by 53.3% 
(122/229) and only 42.4% (97/229) accounted for isolates sensitive against 
ciprofloxacin, while intermediate resistance was seen in eight isolates, which 
accounted for 4.3% (10/229) of the total isolates. The isolates displayed a similar 
resistance pattern against tetracycline as for ciprofloxacin; 53% (121/229) were 
resistant against tetracycline, while only 43% (99/229) were sensitive. A total of 4% 
(9/229) of the isolates were intermediately resistant against tetracycline. Of the total 
isolates, 3.1% (7/229) were resistant against all antimicrobials tested in the study. 
 
I. Species-specific antimicrobial susceptibility profile: C. jejuni 
Of the total isolates tested, 81% (185/229) were C. jejuni [Table 3.4]. C. jejuni 
isolates were sensitive against the tested antimicrobials as follows: erythromycin 
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(92%; 170/185), azithromycin (88%; 163/185), ciprofloxacin (42%; 77/185), and 
tetracycline (44%; 81/185). Resistance against antimicrobials were lower for 
macrolides [erythromycin (8%; 15/185); and azithromycin (12%; 22/185)], however, 
higher for ciprofloxacin (54%; 100/185) and tetracycline (52%; 97/185). A few cases 
of intermediate resistance against both ciprofloxacin and tetracycline were seen, 
which accounted for 4% (8/185) and 4% (7/185) respectively. 
 
II. Species-specific antimicrobial susceptibility profile: C. coli 
Seventeen per cent (40/229) of the tested isolates were C. coli [Table 3.4]. C. coli 
isolates were sensitive to the tested antimicrobials as follows: erythromycin (82.5%; 
33/40), azithromycin (77.5%; 31/40), ciprofloxacin (47.5%; 19/40), and tetracycline 
(45%; 18/40). Resistance to antimicrobials was lower for macrolides [erythromycin 
(18%; 7/40); and azithromycin (23%; 9/40)]. C. coli isolates that were resistant 
against ciprofloxacin (48%; 19/40) were equal to susceptible C. coli isolates against 
the antimicrobial, with only two cases (5%; 2/40) of intermediate resistance. Fifty per 
cent (20/40) of the isolates were resistant against tetracycline, and only 5% (2/40) 
were intermediately resistant against the antimicrobial. 
 
III.   Antimicrobial susceptibility profile of non-C. jejuni/C. coli  isolates 
Only 2% (4/229) of the total isolates tested against antimicrobials were species of 
Campylobacter other than C. jejuni/C. coli [Table 3.4]. These species of 
Campylobacter showed 100% (4/4) sensitivity against both the macrolides 
(erythromycin and azithromycin). Only one (25%; 1/4) isolate was susceptible to 
ciprofloxacin, and the remaining 75% (3/4) were resistant. One hundred per cent 
(4/4) resistance against tetracycline was seen in these isolates and intermediate 




          Table 3.4: Species-specific antimicrobial susceptibility profiles of detected Campylobacter in the years January 2014 to     
          December 2015 (n=229).  
Class of ATB ATB 
 
 
C. jejuni (n=185)      
 
 





























































































                 
             Abbreviations:  Antibiotic (ATB), Susceptible (S), Intermediate (I), and Resistance (R). 
             Footnote: Etest Break points (µg/mL):  Erythromycin [S≤16; R≥16], Azithromycin [S≤16; R≥16], Ciprofloxacin [S≤1; I=2; R≥4], Tetracycline [S≤4; I=8; R≥16].    







Figure 3.1: Antibiogram of the total viable Campylobacter species (n=229) tested against various antimicrobial agents during the 
years 2014-2015. Depicted on the vertical axis are the antimicrobial agents (erythromycin, azithromycin, ciprofloxacin, and 
tetracycline) tested against the Campylobacter isolates. The horizontal axis shows the generated 



















3.2. Animal isolates 
 
3.2.1. Detected Campylobacter species 
During January 2014-December 2015 Campylobacter species from animal isolates 
recovered in Gauteng [n=12 chicken isolates] and Western Cape [n=2 chicken 
isolates; n=2 sheep isolates; n=2 bovine isolates] were characterized using real-time 
PCR. Of the 12 isolates received from Gauteng, 58% (7/12) were C. jejuni and 42% 
(5/12) were C. coli. Five of the Western Cape isolates were C. jejuni (83%; 5/6) with 
one isolate positive for C. coli (17%; 1/6). 
 
3.2.2. Antimicrobial susceptibility profiles of Campylobacter  
All isolates from Gauteng and Western Cape were susceptible against erythromycin 
and azithromycin. Two chicken isolates from Gauteng (17%; 2/12) were susceptible 
against ciprofloxacin with the remaining 83% (10/12) being resistant. Four of the 
Western Cape isolates were susceptible to ciprofloxacin (67%; 4/6), with one 
intermediately resistant isolate recovered from chicken, as well as one isolate with 
full resistance against ciprofloxacin recovered from sheep. Eleven of the Gauteng 
chicken isolates were resistant against tetracycline (92%; 11/12) with only one 
susceptible isolate. Four of the Western Cape isolates were resistant against 
tetracycline while the remaining two isolates were susceptible (chicken isolate) and 
intermediately resistant (bovine isolate) against tetracycline respectively. 
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Table 3.5: Campylobacter species of animal origin recovered in Western Cape and Gauteng Provinces during January 2014 to   
December 2015. 
 
         
        
          
ᶲ
Province: Western Cape (WC), Gauteng (GP). 
€




Additional information Campylobacter spp. 
WC                                                 
Sheep Aborted fetus; stomach content C. jejuni 
Chicken Carcass ; organ pool C. jejuni 
Chicken Organic farm layer chicken; caecal content C. coli 
Bovine Dairy farm;  calf ; diarrhoea; small intestine C. jejuni 
Sheep Neonatal; liver presented with a multifocal necrotic hepatitis C. jejuni 
Bovine Aborted fetus; commercial dairy; cotyledon C. jejuni 
GP 
Chicken NS C. jejuni 
Chicken NS C. jejuni 
Chicken NS C. jejuni 
Chicken NS C. jejuni 
Chicken NS C. jejuni 
Chicken NS C. jejuni 
Chicken NS C. coli 
Chicken NS C. coli 
Chicken NS C. coli 
Chicken NS C. coli 
Chicken NS C. jejuni 
Chicken NS C. coli 
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3.3. MLST characterization of C. jejuni isolates in South Africa 
Human C. jejuni isolates from the Campylobacter Surveillance Program which were 
viable and pure were then further characterized using MLST to examine the degree 
of clonality that exists within species of C. jejuni. Veterinary C. jejuni isolates [Table 
3.7] were also characterized using MLST for comparison to human C. jejuni isolates 
to determine whether human and animal isolates show similar MLST profiles, which 
may be indicative of transmission from animal to human. In total, the genetic 
relationships of 111 C. jejuni isolates from human hosts (n=99) and animal hosts 
(n=12) were examined [Figure 3.2]. Of the 111 C. jejuni isolates only 93 isolates 
[human (n=84); and animals (n=9)] could be assigned a ST previously represented in 
the Campylobacter MLST database accessible at http://pubmlst.org/campylobacter/. 
Fifty per cent (9/18) of the C. jejuni isolates with unassigned STs represented new 
STs (NST) of novel combinations of previously known alleles (8/9), with a single 
case (1/9) of novel alleles not previously represented in the PubMLST database. The 
remaining 50% represented isolates that were non-typable (NT) due to incomplete 
allele sequences [the allele length did not equal the high-scoring segment pair (HSP) 
length]. These isolates were given a zero digit in Figure 3.2 under allele profiles, 



































































































9 25 2 10 22 3 6
9 25 2 10 22 3 6
9 25 2 10 0 3 6
9 17 52 10 10 3 1
7 17 2 15 23 3 12
7 17 2 15 23 3 12
14 17 5 2 11 3 6
14 17 5 2 11 3 6
7 112 5 2 10 3 475
3 1 5 10 11 68 6
24 171 2 2 89 59 6
24 30 2 2 89 120 6
8 10 2 2 11 12 6
8 10 2 2 11 12 6
8 10 2 2 11 12 6
8 10 2 2 11 12 6
0 17 2 2 2 0 6
9 2 4 62 4 5 6
9 2 4 62 4 5 6
9 2 4 62 4 5 6
9 2 4 62 4 5 6
9 2 4 62 4 5 6
9 2 4 62 4 5 6
9 4 5 62 2 5 6
7 396 5 62 4 61 44
62 4 5 2 2 1 5
62 4 5 2 2 1 5
62 4 5 2 2 1 5
62 4 5 2 2 1 5
62 4 5 2 2 1 5
62 4 5 2 2 1 5
62 4 5 2 2 1 5
62 4 5 2 2 1 5
62 4 5 2 2 1 5
14 4 5 2 2 1 5
14 4 5 2 2 1 5
2 4 5 2 2 1 5
2 4 5 2 2 1 5
2 4 5 2 2 1 5
2 4 5 2 2 1 5
2 4 5 2 2 1 5
2 4 5 2 2 1 5
2 4 5 2 2 1 5
2 4 5 2 2 1 5
2 4 5 2 2 1 5
2 4 5 2 2 1 5
2 4 5 2 2 1 5
2 4 5 2 2 1 5
2 4 1 2 2 1 5
2 4 1 2 2 1 5
62 4 154 2 2 1 5
62 4 5 2 11 1 5
2 4 5 4 2 1 5




















































































































































































































































































Figure 3.2: Dendrogram demonstrating phylogenetic relationships of 111 C. jejuni 
isolates on the basis of MLST profiles which were grouped by UPGMA clustering. 
The C. jejuni isolates were from human hosts and animal hosts (chicken, sheep, and 
bovine). For each isolate an allele profile, Sequence type (ST), clonal complex, 
province, source of isolate, and year of isolation was presented. Non-typable (NT) 
isolates and isolates with new combinations of previously known alleles (NST) were 
presented. An allele digit of zero (0) represented an incomplete allele sequence. 
ᶲProvinces: Gauteng (GP), Western Cape (WC), KwaZulu-Natal (KZN), North West 
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2 1 5 2 0 1 5
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2 1 5 3 2 1 5
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2 1 1 3 2 1 5
2 4 5 3 2 1 5
2 84 12 3 2 1 5
2 84 12 3 2 1 5
2 84 12 3 2 1 5
2 84 12 3 2 1 5
2 84 12 3 2 1 5
2 1 12 3 2 1 5
2 1 12 3 2 1 5
2 17 2 3 2 1 5
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2 1 1 3 11 1 5
2 4 5 25 11 203 5
9 309 5 10 2 0 5
2 1 2 2 6 3 5
2 4 2 4 19 3 6
2 4 2 4 19 3 6
2 4 5 0 2 3 6
2 4 2 68 11 58 6
2 4 1 4 19 62 5
2 4 1 4 19 62 5
2 4 1 4 19 62 5
2 4 1 4 19 62 5
2 4 1 4 19 62 5
2 4 1 4 19 62 5
2 4 1 4 19 62 5
2 4 1 4 19 1 5
2 4 0 4 0 1 5
1 3 6 4 3 3 3
1 3 6 4 3 3 3
1 3 6 4 0 3 3
1 3 6 4 167 3 1
2 2 42 4 0 25 8
4 7 10 4 42 51 1
4 7 10 4 42 51 1
166 7 10 4 42 51 1
166 7 10 4 42 51 1
166 7 10 4 42 51 1
4 7 10 4 42 0 1
4 7 10 4 1 7 1
4 7 10 4 1 7 1
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33 39 30 82 113 43 17
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3.3.1. Distribution of STs and clonal complexes of C. jejuni isolates 
The 93 typable C. jejuni isolates (for which MLST STs could be assigned) were 
represented by a total of 33 different STs which were illustrated on the MST in Figure 
3.3. The STs that were represented by ≥5 C. jejuni isolates were ST-7997, ST-257, 
ST-19, ST-475, ST-572, and ST-227 in the order of increasing number of isolates 
found in each ST respectively [Figure 3.3]. These STs accounted for 51% (47/93) of 
the total C. jejuni isolates. ST-227 which accounted for 13% (12/93) of the total C. 
jejuni isolates was the most common ST, followed by ST-572 which accounted for 
10% (9/93) of the isolates. The ST distribution of the isolates was highly diverse with 
the remaining 27 STs representing C. jejuni isolates that were ≤4 in each ST; this 
diversity was also evident from the dendrogram [Figure 3.2] with many isolates 
represented by a single branch. Isolates with new combinations of previously known 
alleles as well as the single case of novel allele combinations were submitted to the 
PubMLST database to be assigned new allele numbers, STs, and clonal complexes. 
 
Sixteen different clonal complexes grouped all the typable C. jejuni isolates in the 
study, with the exception of the two human isolates represented by ST-6091 and ST-
881, which were not previously assigned to any clonal complex in the PubMLST 
database. The typable C. jejuni isolates were predominantly grouped into ST-45 
complex; ST-257 complex; ST-48 complex; ST-21 complex; and ST-206 complex in 
the order of increasing number of isolates into each respective clonal complex. 
These five predominant clonal complexes were represented by ≥5 C. jejuni isolates, 
while the remaining 11 clonal complexes were represented by C. jejuni isolates that 




Figure 3.3: Phylogenetic analysis (minimal spanning tree) of South African C. jejuni 
isolates from humans and of veterinary origin (chicken, sheep, and bovine). Each 
coloured node (circle) represents one ST along with the ST number. STs 
representing one strain appear small in diameter, with or without the nodes being 
shaded in colour. The diameter of the node represents the number of strains within 
one ST; the bigger the node, the higher the number of strains found within the ST. 
The connecting lines between the different STs depict the number of allelic 
differences between them; one allele difference (black bold lines); two allele 
difference (grey bold lines or thin lines); three alleles difference (grey hatched lines); 
more than three alleles difference (grey dotted lines). 
 
3.3.2. Province distribution of STs 
Majority of the typable C. jejuni isolates [Figure 3.4] were from Gauteng [human 
(n=54), and animal (n=6)] followed by the Western Cape Province [human (n=25), 
and animal (n=3)]. Mpumalanga, KwaZulu-Natal, Free-State, and the North West 
Provinces were represented by ≤2 typable C. jejuni isolates. The majority of the STs 
were represented by C. jejuni isolates from Gauteng; where they branched as 
singletons, clustered together, as well as clustered with other isolates from other 
provinces as seen in ST-572 (Gauteng and Western Cape), ST-19 (Gauteng, 
 72 
 
Western Cape, and Free-State) and ST-227 (Gauteng, Mpumalanga, and North 
West). STs only representing C. jejuni isolates (≥3) from a specific province were 
identified; such as ST-475, ST-4063, and ST-4063 for Gauteng isolates. STs 
representing C. jejuni isolates (≥3) from Western Cape only were ST-354 and ST-
7997. The single isolate from KwaZulu-Natal had three allele differences from ST-52 
(Gauteng) and more than three allele differences from ST-2109 (Mpumalanga). For 
the typable Gauteng isolates (n=60), a total of 24 different STs were identified which 
were further grouped into 14 clonal complexes. The most predominant ST and clonal 
complex for the Gauteng isolates was ST-227 and ST-206 complex. The typable 
Western Cape isolates (n=28) were represented by 16 different STs and 10 clonal 
complexes of which ST-7997 and ST-21 complex were predominant. 
 
Figure 3.4: Minimal spanning tree of 111 C. jejuni isolates based on STs and the 
province distribution thereof. Each node represents a ST and the segments found 
within some of the nodes represent ≥2 C. jejuni strains belonging to the same ST, 
while un-segmented nodes represents a single C. jejuni strain. The shade of colour 
found in each node represents the province of the isolate(s) as stipulated in the keys. 
Keys: Provinces 
Gauteng (n=72)  













3.3.3. STs of animal isolates  
A total of eight different STs were identified for C. jejuni isolates of animal origin 
(n=9) which were further grouped into six different clonal complexes. The six 
Gauteng isolates which were all from chicken were represented by five different STs 
and five clonal complexes. ST-227 which falls under ST-206 clonal complex was 
represented by two chicken isolates. The three Western Cape isolates [chicken 
(n=1), and bovine (n=2)] had different STs, however, they all belonged to the same 
ST-21 complex. 
 
Human and animal C. jejuni isolates that shared homologous MLST profiles were 
represented by ST-227, ST-257, ST-7997, ST-21, and ST-52. ST-227 was 
represented by 10 isolates from human hosts and two chicken isolates [Figure 3.5]. 
ST-21 represented a human C. jejuni isolate and a bovine C. jejuni isolate, whereas 
the previous shared STs represented human and chicken isolates. The three STs 
found in animal isolates but not in human isolates were ST-381, ST-613, and ST-
1932. However, all the six clonal complexes of animal isolates overlapped with clonal 
complexes of human isolates. Allele similarities between isolates of human and 
animal origin were identified, although they respectively represented different STs; 
this was noted particularly between human and chicken isolates. ST-381 
represented an isolate of bovine origin which had six homogenous alleles with ST-21 
representing an isolate from a human and another bovine isolate.  
 
3.3.4. Diversity of C. jejuni isolates 
The Simpson’s index of diversity for C. jejuni isolates on the basis of MLST loci was 
calculated [Table 3.8]. The diversity index at each locus for the set of samples 
ranged from 0.692 [confidence interval (CI), 0.569 - 0.815] to 0.828 [CI, 0.745 - 
0.911]. Loci associated with the highest number of different repeats were aspA, glnA, 
and tkt, with a K-value of 13, while the locus with lowest number of different repeats 
was uncA with a max (pi) value of 0.485. The MLST loci for the sample set showed 




Figure 3.5: Minimal spanning tree of 111 C. jejuni strains illustrating shared STs 
between human hosts and animal hosts. Each node represents a ST and the shade 
of colour within each node represent the sources, depicted in the keys, from which 
C. jejuni strains belonging to a specific ST were isolated.  
 
Table 3.6: Diversity indices of South African C. jejuni isolates. 
  95% ^Confidence Interval (CI)   





aspA 0.786 0.662 0.91 13 0.424 
glnA 0.828 0.745 0.911 13 0.333 
glytA 0.817 0.75 0.884 10 0.303 
glyA 0.826 0.764 0.889 12 0.242 
pgm 0.826 0.743 0.91 12 0.333 
tkt 0.771 0.652 0.891 13 0.424 
uncA 0.692 0.569 0.815 8 0.485 
*Diversity index: measure of the variation of the number of repeats at each locus. Ranges from 0.0 (no diversity) 
to 1.0 (complete diversity). 
^Confidence interval: Precision of Diversity Index at 95% upper and lower boundaries. 
£
K: Number of different repeats found at a locus in the sample set. 
ᶲ
Max (pi): proportion of isolates with commonly repeated number in each locus (range 0.0 to 1.0). 
(Simpson, 1949; Hunter and Gaston, 1988). 
Keys: Sources of isolates 
Human 
       Chicken  
Animal      Sheep 
  Bovine 
                 








3.4. Rotavirus Surveillance Program 
  
3.4.1. Demographic information 
A total of 981 nucleic acid samples extracted from stool specimens submitted for the 
Rotavirus Surveillance Program were screened for the presence of Campylobacter 
from February 2014 to December 2015 [Table 3.5]. These samples were from 
children of less than five years of age (range <1-60 months), with a median age of 10 
months (IQR=5-16). Fourty-four per cent (436/981) of these stool samples were from 
females, and 55% (535/981) were from males, with the remaining 1% (10/981) 
representing specimens with unspecified sex. Eight different study sites formed the 
basis of the study, each site representing a hospital(s) in a specific province in South 
Africa (Appendix F). Majority of the specimens were submitted during the first three 
quarters of the year, with a few specimens submitted during the fourth quarter [Table 
3.5]. 
 
3.4.2. Detection of Campylobacter from children <5 years of age with diarrhoea 
Of the total submitted and screened nucleic acid samples from stool specimens, 
Campylobacter species were detected in 7% (69/981) of the samples using real-time 
PCR [Table 3.5]. C. jejuni was the most commonly detected species of 
Campylobacter, accounting for 81% (56/69), while C. coli was detected in nine 
samples, accounting for 13% (9/69). Four cases of coinfection with both C. jejuni and 
C. coli were detected, which accounted for 6% (4/69). Other species of 
Campylobacter were not detected from these samples. The positive samples were 
more frequently detected from children belonging to the <1-12 age group (months), 
represented by 62% (43/69), followed by those aged 13-24 months, accounting for 
23% (16/69). Case patients from the remaining age groups were represented by 
≤6% detection of Campylobacter. Majority of the positive cases were slightly more 
from males (54%; 37/69) than females (46%; 32/69) but the difference was not 
statistically significant (p-value 0.22). However, C. coli was detected more in females 
(6/9) in comparison to males (3/9) in this study. The Campylobacter positive samples 
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were mostly from Chris Hani Baragwanath Hospital (45%; 31/69), Red Cross 
Childrens Hospital (14%; 10/69), Edendale Hospital (13%; 9/69), and Mapulaneng 
Hospital (10%; 7/69). Annual occurrences of detected Campylobacter were as 
follows; quarter 1 (26%; 19/69), quarter 2 (20%; 14/69), quarter 3 (38%; 26/69), and 
quarter 4 (13%; 9/69). Quarter 3 had the highest number of submitted stool 
specimens and subsequently the highest detection of Campylobacter throughout the 
study. 
 
Table 3.7: Stool specimens of children under five years of age with diarrhoea 
screened for the presence of Campylobacter in the years February 2014 to 
December 2015.  
Characteristic Overall submitted 
(%) 
Total positive  
(%) 
Campylobacter spp.  
(%) 
   C. jejuni C. coli Mixed 
Specimen type      
Stool 981     69 (7) 56 (81) 9 (13) 4 (6) 
Age (months)      
Median (IQR) 10 (5-16)     
Range <1-60     
Age category 
(months) 
     
  <1-12 615 (63) 43 (62) 32 (57) 8 (89) 3 (75) 
  13-24 239 (24) 16 (23) 14 (25) 1 (11) 1 (25) 
  25-36     83 (8)     4 (6)  4  (7) 0 0 
  37-48     28 (3)     4 (6)  4  (7) 0 0 
    ≥49     12 (1)     1 (1)  1  (2) 0 0 
   Unk     4 (<1)     1 (1)  1  (2) 0 0 
Sex      
Female 436 (44) 32 (46) 25 (45) 6 (67) 1 (25) 
Male 535 (55) 37 (54) 31 (55) 3 (33) 3 (75) 
Unk     10 (1) 0 0 0 0 
*p-value       0.22    
^Study sites      
Site 1 493 (50) 31 (45) 26 (46) 4 (44) 1 (25) 
Site 2     78 (8)   7 (10)  5  (9) 2 (22) 0 
Site 3     63 (6)     4 (6)  2  (4) 0 2 (50) 
Site 5     81 (8)   9 (13)    6  (11) 3 (33) 0 
Site 6           108 (11) 10 (14)    9  (16) 0 1 (25) 
Site 8    48 (5)     4 (6)  4  (7) 0 0 
Site 9    27 (3)     1 (1)  1  (2) 0 0 
Site10    83 (8)     3 (4)  3  (5) 0 0 
£
Annual quarter      
Feb-Mar 257 (26) 19 (26) 17 (30) 2 (22) 0 
Apr-Jun 285 (29) 14 (20) 12 (21) 1 (11) 1 (25) 
Jul-Sep 292 (30) 26 (38) 18 (32) 6 (67) 2 (50) 
Oct-Dec 145 (15)   9 (13)   8 (14) 0 1 (25) 
Unk     2 (<1)     1 (1)   1  (2) 0 0 
 ^
Study sites (refer to Appendix F) 
£
Annual quarter: February (Feb), March (Mar), April (Apr), June (Jun), July (Jul), 
September (Sept), October (Oct), December (Dec). 




3.5. Acute Flaccid Paralysis Surveillance Program 
 
3.5.1. Polio-negative stool specimens of AFP patients 
A total of 512 stool specimens were submitted from October 2014 to December 2015 
from all South African provinces participating in the AFP Surveillance Program 
[Table 3.6]. Specimens from AFP patients with polio negative results were screened 
for the presence of Campylobacter species, particularly C. jejuni which has been 
reported to elicit GBS. The age range of AFP patients in this study was <1-67 years, 
with a median age of four years (IQR=2-12). Fifty-three per cent (271/512) of the 
specimens were from males, 47% (239/512) from females, and less than 1% (2/512) 
from patients with unspecified sex. These isolates were submitted from all South 
African provinces, particularly Gauteng (20%), Eastern Cape (18%), KwaZulu-Natal 
(18%), Limpopo (13%), and Mpumalanga (12%), while the remainder (19%) were 
distributed across the remaining provinces [Table 3.6]. 
 
3.5.2. Campylobacter detected from AFP patients 
Campylobacter species were detected in 12% (62/512) of the submitted stool 
specimens using real-time PCR, of which C. jejuni accounted for majority of detected 
species with 77.4% (48/62), C. coli accounted for 19.4% (12/62), and mixed 
infections accounted for 3.2% (2/62) [Table 3.6]. The detection of Campylobacter 
species was notable in the 0-2 age group (37%; 23/62), 3-5 age group (32%; 20/62), 
and the 6-9 age group (18%; 11/62) [Table 3.13]. Majority of the detected species of 
Campylobacter in these age groups were C. jejuni, accounting for ≥19%. Other age 
groups from which Campylobacter was detected (≤6%) were those aged 10-19 years 
(6%; 4/62), 40-49 years (2%; 1/62), and those with unknown age groups (5%; 3/62). 
  
Campylobacter species were slightly more frequently detected in females than 
males, accounting for 55% (34/62) and 45% (28/62) respectively (p=value 0.22). 
Females accounted for 54% (26/48) of the detected C. jejuni and males accounted 
for 46% (22/48). C. coli was detected equally in both females and males, accounting 
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for 50% (6/12) respectively. Coinfection with both C. jejuni and C. coli were detected 
in females only. The Eastern Cape, Gauteng, Limpopo, and KwaZulu-Natal 
Provinces had the highest number of detected Campylobacter species in this study, 
each province accounting for 32 % (20/62), 24% (15/62), 15% (9/62), and 13% 
(8/62) respectively [Table 3.6]. In the Eastern Cape Province, 85% (17/20) of the 
detected Campylobacter species were C. jejuni, as well as 73% (11/15) of the 
detected Campylobacter species in Gauteng. Overall, C. jejuni was the most 
common species of Campylobacter detected from each province with the exception 
of the Northern Cape, from which Campylobacter was not detected. Specimens 
positive for both C. jejuni and C. coli were from the North West and Gauteng 
Province. The majority of the Campylobacter positive specimens were submitted 
during the fourth quarter of the year (34%; 21/62), followed by the first quarter (29%; 
18/62), and lastly the third quarter (24%; 15/62). Campylobacter species were 




Table 3.8: Stool specimens from polio-negative AFP case patients screened for the 
presence of Campylobacter species during October 2014 to December 2015. 




Campylobacter spp.  
(%) 
    C. jejuni C. coli Mixed 
Specimen type 











Age (years)         
Median (IQR)   4(2-12)        
Range    <1-67        
Age category      
    (years) 
         
0-2 140 (27) 23 (37) 20 (42) 3 (25) 0 
3-5 188 (37) 20 (32) 13 (27) 5 (42) 2 (100) 
6-9   85 (17) 11 (18)   9 (19) 2 (17) 0 
10-19   68 (13)     4 (6)  3 (6) 1 (8) 0 
20-29       6 (1)        0        0 0 0 
30-39     4 (<1)        0        0 0 0 
40-49     3 (<1)     1 (2)   1 (2) 0 0 
50-59     2 (<1)        0        0 0 0 
≥60     1 (<1)        0        0 0 0 
Unk     15 (3)     3 (5)   2 (4) 1 (8) 0 
Sex      
Female 239 (47) 34 (55) 26 (54) 6 (50) 2 (100) 
Male 271 (53) 28 (45) 22 (46) 6 (50) 0 
Unk     2 (<1)      0 0 0 0 
£p-value     0.22    
Province      
Eastern Cape   94 (18) 20 (32) 17 (35) 3 (25) 0 
Free State     21 (4)      3(5)   3  (6) 0 0 
Gauteng         104 (20) 15 (24) 11 (23) 3 (25) 1 (50) 
KwaZulu-Natal    93 (18)   8 (13)   7 (15) 1 (8) 0 
Limpopo    64 (13)   9 (15)   5 (10) 4 (33) 0 
Mpumalanga    63 (12)     1 (2)  1  (2) 0 0 
North West      24 (5)     1 (2)       0 0 1 (50) 
Northern Cape      11 (2)        0       0 0 0 
Western Cape      36 (7)     4 (6)  4 (8) 0 0 
Unk      2 (<1)     1 (2)       0 1 (8) 0 
Annual quarter      
Jan-Mar 107 (21) 18 (29) 13 (27) 3 (25) 2 (100) 
Apr-Jun 106 (21)     5 (8)       3  (6) 2 (17) 0 
Jul-Sep 122 (24) 15 (24) 11 (23) 4 (33) 0 
Oct-Dec 164 (32) 21 (34) 19 (40) 2 (17) 0 
Unk     13 (3)     3 (5)       2  (4) 1 (8) 0 
£






Chapter 4: Discussion 
 
 
4.1. Campylobacter Surveillance Program 
 
4.1.1. Submission of bacterial isolates 
From when the Campylobacter Surveillance Program began in January 2014, 
laboratories participating in the GERMS-SA surveillance program were continuously 
motivated to submit laboratory confirmed Campylobacter species at CED. This 
progressive participation was seen from the total number of submitted bacterial 
isolates in 2015 (62%; 528/848), which was greater (p-value 0.04) than the total 
number of isolates submitted in 2014 (38%; 320/848). However, the quality of 
submitted bacterial isolates in terms of viability, upon arrival at CED, did not improve; 
in the year 2014, 45% of the submitted isolates were non-viable with only 52% viable 
isolates, whereas in the year 2015 55% were non-viable and only 42% were viable. 
The remaining 3% in the year 2014 was constituted by both missing and 
contaminated isolates, and in the year 2015, the remaining 3% represented 
contaminated isolates only. Campylobacter species are fastidious organisms that 
can enter a VNC state (Cappelier et al., 1997; van Vliet and Katley, 2001), which 
may explain the frequency of non-viable cultures even under optimal growth 
conditions in this study. The difference seen in the number of isolates submitted in 
2014 and 2015 was only a reflection of improved participation of laboratories in the 
GERMS-SA Campylobacter Surveillance Program. This improvement was facilitated 
by continuous requests that laboratories send isolates to the CED. 
 
Due to the short study years, seasonality of Campylobacter infections could not be 
extrapolated in this study, however, annual occurrences of submitted cases showed 
an overall (2014-2015) suggestive trend of more Campylobacter cases occurring in 
the warmer months (quarter 1), followed by a decrease during the cooler months 
(quarter 2), with a subsequent increase from the third quarter, which progresses all 
the way to the fourth quarter, characterized with warmer months. The seasonal 
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suggestive trend is inconsistent with previously ‘unrecognized’ seasonal patterns for 
Campylobacter infections in developing countries, nevertheless, the trend is 
consistent to what has been reported in temperate countries, where the number of 
Campylobacter cases reported increase with increasing temperature (Nylen et al., 
2002; Ekdahl and Andersson, 2004; Louis et al., 2005; Galate and Bangde, 2013). 
However, longer systematic studies would need to be carried out to deem what was 
observed in this study true. The weather in Africa can largely be classified as 
tropical; the lack of extreme temperature fluctuations, as well as the lack of 
surveillance for epidemics may be a contributing factor for the unrecognized 
Campylobacter seasonal peaks (Nylen et al., 2002; Ekdahl and Andersson, 2004; 
Galate and Bangde, 2013). In temperate regions, risk factors that are associated 
with campylobacteriosis in the summer months include animal contact, eating 
barbequed meals, drinking untreated water from streams and other natural sources, 
and most recently, flies have been postulated to be a risk factor, functioning as a 
mechanical vector (Nylen et al., 2002; Ekdahl et al., 2005). Studies have shown 
transfer of Campylobacter from the environment to flies with relative ease; in one 
such study, Campylobacter was isolated from 8% (4/49) of flies caught outside a 
broiler house in Denmark (Ekdahl et al., 2005). 
 
 
4.1.2. Campylobacter positive isolates and the detected species 
Overall, majority of the bacterial isolates submitted from the various laboratories 
were identified correctly as Campylobacter, with only 6% representing those isolates 
that could not be characterized as Campylobacter using real-time PCR. The most 
predominant species of Campylobacter detected in this study was C. jejuni, 
represented by over 80% of the tested isolates in 2014 and 2015 respectively, and 
C. coli was the second most frequently detected species of Campylobacter, 
accounting for 9% of the isolates submitted in 2014, and 14% of the isolates 
submitted in 2015. The detection of coinfection with both C. jejuni and C. coli, as well 
as the detection of non-C. jejuni/C. coli was the same in both study years, 
accounting for 2% and 3% respectively. The findings coincided with previous reports 
of C. jejuni accounting for over 80% of human infections and C. coli accounting for 
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most of the remainder (Acheson and Allos, 2001; Sheppard et al., 2009; Wagenaar 
et al., 2013; Schielke et al., 2014; Vidal et al., 2016 ). Various studies from 
developing countries have reported on high rates of mixed or polymicrobial infections 
involving Campylobacter (Glass et al., 1983; Rajendran et al., 2012; Mason et al., 
2013): this occurrence was also seen in our study, with a prevalence of 2% among 
the isolates. The detection of non-C. jejuni/C. coli suggests that there are species of 
Campylobacter other than C. jejuni/C. coli in circulation in South Africa, which may 
also cause infection, but these are present in very low numbers. Reports of species 
of Campylobacter other than C. jejuni/C. coli recovered from patients with diarrhoea 
in developing countries have been documented, such as C. concisus, C. fetus, and 
C. upsaliensies (Mason et al., 2013; Wagenaar et al., 2013; Platts-Mills and Kosek, 
2014). The isolation of non-C. jejuni/C. coli species has been facilitated primarily by 
the use of less-selective isolation techniques and culture-independent diagnostic 
tests (Platts-Mills and Kosek, 2014). In South Africa, efficient isolation of non-C. 
jejuni/C. coli species of Campylobacter has been facilitated by the adoption of non-
selective isolation techniques, where C. concisus and C. upsaliensies were 
recovered with a frequency close to that of C. jejuni from diarrhoeal stools of children 
(Lastovica and Rouxe, 2000; Platts-Mills and Kosek, 2014). According to Platts-Mills 
and Kosek, (2014) the incidence and pathogenicity of these species of 
Campylobacter recovered in developing countries stands subject for investigation, 
because they may well be of public health importance. The 3% representing non-C. 
jejuni/C. coli isolates could only be identified to genus level for the purpose of this 
study which only looked at predominant species associated with high incidence rates 
of campylobacteriosis.   
 
In South Africa, reports of the recovery of Campylobacter species from pigs and 
chickens from various poultry production systems as well as retailers have been 
documented (van Nierop et al., 2005; Suzuki and Yamamoto, 2009; Jonker and 
Picard, 2010; Bester and Essack, 2012). C. jejuni is commonly recovered from 
poultry and poultry by-products, whereas C. coli isolation is associated with pigs 
(Jonker and Picard, 2010; Wagenaar et al., 2013). It is conceivable that the high 
incidence of campylobacteriosis associated with C. jejuni may reflect on poultry and 
possibly other ruminants (e.g. bovine intestine) being a cheaper affordable food 
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source for South Africans than porcine, which may explain why C. coli was less 
frequently recovered from patients. However, due to the less understood 
epidemiology of Campylobacter, and the lack of literature in South Africa, there are 
still uncertainties how each possible pathway contributes to human infections, 
because all known risk factors only explain less than 50% of human cases (Nylen et 
al., 2002; Müllner et al., 2010; MacRitchie et al., 2013). One of the few studies in 
Soweto, South Africa, showed the relative ease of C. jejuni acquisition by families as 
a result of eating chicken, which is the cheapest meat available for these 
communities, and their custom of keeping flocks in their backyards (Richardson et 
al., 1983). In the same study by Richardson et al., (1983) C. jejuni was recovered in 
86% of the tested fowl faeces, some samples of bovine intestine, which is another 
cheap popular food source, as well as from pet dog faeces, which are usually fed 
poultry scraps (Richardson et al., 1983). 
 
4.1.3. Sex-specific occurrences of Campylobacter infections  
Of the total submitted isolates, it was males from whom more Campylobacter 
species were detected in both study years, accounting for 53.6% (429/801) as 
compared to  females (46%; 369/801), and individuals of unknown gender with 
Campylobacter positive results (<1%; 3/801). This observation of male infections 
being slightly more than females is consistent to previously documented findings, 
with sex-specific differences in food handling practices being a risk factor (Acheson 
and Allos, 2001; Strachan et al., 2008; Cody et al., 2012). According to Samuel et 
al., (2004) the prevalence of males amongst infected individuals is explained by 
unsafe food handling, preparation, and consumption practices than females. High 
risk foods for foodborne diseases have been reported to be frequently consumed by 
males more than females, including foods that may be risky for Campylobacter 
contamination (Samuel et al., 2004). Sex-specific immunity described by Olivier and 
William, (2010) could in part explain the slightly high incidence of Campylobacter 




4.1.4. Age-related occurrences of Campylobacter infections 
The age-related data from this study showed campylobacteriosis to commonly occur 
amongst those aged 0-4 years, whom accounted for 35% (281/801) of the total 
infections, which was a common observation from previous reports (Miller et al., 
2005; Mshana et al., 2009). The high incidence rate in this group of individuals is 
attributed to Campylobacter risk factors such as a lack of a developed immune 
system amongst the young, living in close proximity to animals, particularly in 
developing countries where children can easily come into contact with and ingest 
bacteria that have been shed by animals into the environment, as well as drinking 
contaminated milk (Richardson et al., 1983; Sibbald and Sharp, 1985; Fernandes et 
al., 2015). According to Lund and O’Brien, (2011) for children of less than five years 
of age to be implicated, smaller infective doses are required for infection, as a result 
of lack of developed immune system. 
 
Another factor taken into account for these individuals is overreporting, where the 
young are more likely to receive medical care and have stools cultured compared to 
adults who are most likely to have short lived, and less severe diarrhoeal episodes 
(Miller et al., 2005; Weinberger et al., 2013). The precise infection pathway 
implicated with the high incidence rate of campylobacteriosis among children of less 
than five years of age has not yet been identified (Miller et al., 2005; MacRitchie et 
al., 2013), this was inferred from studies that showed that greater exposure to risk 
factors does not particularly coincide with greater incidence for age groups.  
 
A study in Australia investigating risk factors for sporadic Campylobacter infection in 
infants and young children aged 0-2 years proposed that children of less than three 
years of age are at risk of Campylobacter infection if residing in a household which 
has puppies or chicken as pets (Tenkate and Stafford, 2001). These findings were 
similar to the findings of Richardson et al., (1983) conducted in Soweto, South Africa, 
for children under two years with C. jejuni infections. According to Tauxe et al., 
(1988) sources of C. jejuni infection among infants have not been examined 
systematically. Consumption of unpasteurized/incorrectly pasteurized raw milk from 
dairy (Acheson and Allos, 2001), particularly in developing countries, could be a 
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possible risk factor, which may in part explain the high rates of C. jejuni seen 
amongst the young in South Africa (O’Ferrall-Berndta, 2003). 
 
Individuals aged 5-14 and 15-24 in years showed a marked reduction of 
Campylobacter infections, accounting for 11% (90/801) and 8.4% (67/801) 
respectively. According to previous reports, the reduction is attributed to a change in 
behavioural patterns, such as improved hygiene which subsequently reduces the risk 
of environmental exposure and infection (Miller et al., 2005). A second peak ensued 
in the 25-34 age group, accounting for 12 % (95/801). This trend then reversed with 
a decline for those individuals falling within the 35-44; 45-54; and 55-64 age groups. 
The observed second peak in the young adults (25-34 age group) has been 
previously recognized (Miller et al., 2005; Schielke et al., 2014), however, it was 
reported to be more pronounced in the urban than rural populations (Sibbald and 
Sharp, 1985). The risk factors associated with young adults include international and 
national travel, where individuals harbour different strains of Campylobacter species 
from visited geographical location. According to Tauxe et al., (1988) 
campylobacteriosis associated with young adults may be related to their food 
handling practices following leaving their childhood homes and beginning to cook for 
themselves. Diseases, stress, pregnancy, eating habits and hygiene practices are 
some of the life experiences that impact individuals entering young adulthood. All 
these factors increase the risk of foodborne infections or severity of the disease 
(Lund and O’Brien, 2011). Stress which leads to changes in metabolism results in 
reduced resistance to infections such as campylobacteriosis. Pregnancy generally 
alters the mother’s immune system, making pregnant women susceptible to 
foodborne illness. Consuming fatty foods (Lund and O’Brien, 2011), undercooked 
meats (Acheson and Allos, 2001), and unhygienic habits of preparing raw foods, like 
salads (Acheson and Allos, 2001; Wagenaar et al., 2013) may in part explain the 
incidence peak observed in young adults. 
  
The global pandemic of Human Immunodeficiency Virus/Acquired Immunodeficiency 
Syndrome (HIV/AIDS) which result in weakened immunity, particularly affecting 
young female adults, could also account for the peak observed. Gastrointestinal tract 
infections are common among HIV/AIDS individuals; enteric pathogens recovered 
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from stool specimens of HIV/AIDS patients include Campylobacter, amongst many 
other pathogens (Prasad et al., 2000; Lund and O’Brien, 2011). C. jejuni has been 
recovered more frequently from HIV/AIDS patients than in the healthy population 
(Snijders et al., 1997; Altekruse et al., 1999).  A study carried out by Snijders et al., 
(1997) indicated that species of Campylobacter, other than C. jejuni, are frequently 
recovered from HIV infected individuals than previously recognized. However, the 
HIV status for the case patients in this study was not provided, thus HIV/AIDS being 
a contributing factor amongst the young adults could only be speculated.  
 
According to Sibbald and Sharp (1985), the lower incidence rate observed in adults 
from developing settings reflects on widespread immunity which results from post 
Campylobacter exposure during infancy. Immunity may confer protection against 
Campylobacter infections or symptomatic infections all together (Miller et al., 2005). 
The latter further substantiates the report from Acheson and Allos, (2001) that in 
developing countries asymptomatic infections occur in both the young and adults. 
This might in part explain the decrease observed from those adults aged ≥35≤64 in 
years. According to Miller et al., (2005) reduced incidence of campylobacteriosis 
might be explained by reduced exposure to the infection pathways more common in 
younger age groups, pathways which still stand subject for investigation (Weinberger 
et al., 2013). Following this decrease seen in adults in this study, there was an 
increase in the number of infections for those aged 65 and older in years.   
 
The elderly with positive Campylobacter results accounted for 10% (84/801) in this 
study. A study conducted in England and Wales (Gillespie et al., 2009a; Gillespie et 
al., 2009b), where age-related changes in the incidence of campylobacteriosis was 
investigated, showed a shift, with individuals aged 60 years and older found to be the 
emerging at-risk group for campylobacteriosis as compared to children who 
displayed a reduced incidence rate. The increase in incidence rate for those aged 60 
and older in years was in part attributed to increased life expectancy in both England 
and Wales, from which it was hypothesized that the incidence of campylobacteriosis 
in the elderly will continue to increase, as with other chronic illnesses affecting the 
elderly, thus weakening their immune system. Risk factors for campylobacteriosis 
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associated with this group of individuals still needs to be investigated (Gillespie et al., 
2009a; Gillespie et al., 2009b).  
 
South Africa has the lowest average life expectancy in the world; however, recently, 
the South African Medical Research Council (SAMRC) and Statistics South Africa 
have released latest reports which show a steady improvement in life expectancy in 
the country which has increased by 8.5 years since 2005 to an average of 62 years 
in 2013 (SAMRC, 2015; Statistics South Africa, 2015). As life expectancy increases 
in South Africa, as seen in England and Wales, the number of individuals living with 
chronic conditions, and subsequently weakened immunity, are likely to increase as 
reflected by the Campylobacter peak amongst the elderly (Gillespie et al., 2009a; 
Gillespie et al., 2009b).  The phenomenon of acquired immunity in developing 
countries as a result of exposure during infancy is not reflected in the elderly age 
group (≥60 years) with an increased number of infections. This could be as a result 
of a decrease in serum antibodies against Campylobacter species previously 
exposed to or new species exposed to as an individual ages. According to Lund and 
O’Brien (2011), age-related deterioration of the immune system and comorbidity 
result in increased susceptibility to infections such as Campylobacter. The incidence 
rate of campylobacteriosis three peaks, resulting from the three identified age risk 
groups in this study (0-4; 24-34; and >65 age groups). The resulting curve coincided 
with the previously reported U-shaped curved by Miller et al., (2005) and Weinberger 
et al., (2013) observed in developing countries for children and young adults, 
furthermore, our results showed the elderly to be the third emerging at risk group for 
campylobacteriosis. 
 
4.1.5. Gender and age distribution of positive Campylobacter cases 
The distribution of positive Campylobacter cases was examined by both sex and age 
to investigate any possible variation. The number of males with Campylobacter 
positive isolates was greater in all age groups, with the exception of those aged 25-
35 years, 35-44 years, and individuals ≥65 years of age, where the number of 
positive Campylobacter cases in females were higher than males (p-value 0.02). A 
similar trend of females being slightly more infected than males in the 25-35 age 
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group (young adults) has been reported in England, Wales, the Netherlands, and 
Germany (Louis et al., 2005; Schielke et al., 2014).  
 
Possible risk factors associated with women of this age group may include: (1) 
weakened immunity due to diseases such as HIV/AIDS which is prevalent in young 
female adults in South Africa, (2) exposure as a result of human-to-human 
transmission from young children they take care of, (3) or they handle/prepare and 
eat chicken more frequently than males in the same age group, which could lead to 
campylobacteriosis if chicken is undercooked, or from possible cross contamination 
in the kitchen (Schielke et al., 2014). What was observed for females in the elderly 
(≥65 years) age group associated with more campylobacteriosis cases than males 
conflicted with the report from California, United States of America (USA), by Samuel 
and colleagues (2004) where sex-related incidence was highest among males 
across all age groups, even the elderly. More studies would need to be carried out to 
deem this current observation for South African Campylobacter cases true. 
 
4.1.6. Province distribution of detected Campylobacter  
The distribution of positive Campylobacter cases throughout the study period was 
not interpreted as a true reflection of which province had the highest burden of 
disease or where the detected species of Campylobacter were most prevalent. The 
results were perceived as a reflection of which province participated the most in the 
Campylobacter Surveillance Program. Throughout the study period, bacterial 
isolates were submitted the most from the Gauteng Province followed by Western 
Cape Province; as a result the majority of positive Campylobacter cases were seen 
from these two provinces. In order to mitigate the existing research gap as far as 
Campylobacter infections are concerned in South Africa, all provinces would need to 
show participation which will enhance the Campylobacter Surveillance Program and 
subsequently contribute to strategies aimed at controlling and preventing human 




4.1.7. Detection of invasive Campylobacter species  
Overall the positive invasive cases of Campylobacter remained as low as 1% (5/848) 
throughout both the study years, an observation seen globally (Acheson and Allos, 
2001; Moore et al., 2005; Wagenaar et al., 2013). Five invasive isolates of 
Campylobacter were identified, 60% (3/5) were C. jejuni, while 40% (2/5) were 
species other than C. jejuni/C. coli. In this study bacteraemia was associated more 
with children of less than five years of age (80%; 4/5) compared to young adults 
(20%; 1/5), an observation that is consistent with previous reports (Acheson and 
Allos, 2001). Age-related lack of immunity may be the underlying cause of 
bacteraemia for children in this study, whereas the young adult case may be due to 
weakened immune system as a result of other underlying medical conditions, or an 
encounter with a very virulent strain of Campylobacter (Acheson and Allos, 2001; 
Moore et al., 2005). 
 
4.1.8. Antimicrobial susceptibility profiles of detected Campylobacter species 
Bacterial cultures submitted as part of the Campylobacter Surveillance Program that 
were positive for Campylobacter species as well as viable during January 2014-
December 2015 were 387 of a total of 848 submitted isolates. However, only 59% 
(229/387) of the bacterial cultures remained viable following sub-culturing for 
antimicrobial testing. The remainder (41%) was accounted for by non-culturable 
isolates and the few cases of mixed Campylobacter isolates. The ability of 
Campylobacter to enter a VNC state (Cappelier et al., 1997; van Vliet and Katley, 
2001), may partly explain the high number of isolates that lose viability even under 
optimal growth conditions as well as the inherent fastidious nature of the genus 
Campylobacter in culture. Mixed Campylobacter isolates were omitted in this 
analysis as a result of difficulty encountered in separating these two species in 
culture due to their spread out growth form. The overall results of the 229 isolates 
combined (C. jejuni, C. coli, and other species of Campylobacter) showed 
considerable sensitivity to the macrolides (erythromycin and azithromycin) and 
considerable resistance to ciprofloxacin and tetracycline. These findings coincide 




In developing countries increase in resistance to both erythromycin and ciprofloxacin 
have been documented (Coker et al., 2002; Moore et al., 2005; Galate and Bangde, 
2013), which is largely influenced by the use of antimicrobials for infections other 
than gastrointestinal diseases and the pressing issue of self-medication (Coker et al., 
2002; Tafa et al., 2014; Rastyani et al., 2015). Conversely the increase in resistance 
seen in developed countries is associated with the use of the antimicrobials in food 
animals and travel to developing countries (Coker et al., 2002; Galate and Bangde, 
2013). Resistance to azithromycin was found in 7% to 15% of Campylobacter 
isolates in Thailand (Coker et al., 2002) which is similar to the findings of our study, 
where resistance to azithromycin was accounted for by 14% (31/229) of all the 
Campylobacter isolates combined. 
 
In 2009 Campylobacter species isolated from the Vhembe district, South Africa, from 
diarrhoeic and non-diarrhoeic patients showed significant prevalence of resistance 
against erythromycin; with susceptibility of less than 30% (Samie et al., 2009). Over 
90% of the isolates showed susceptibility to ciprofloxacin, and 34% of the isolates 
were resistant to tetracycline (Samie et al., 2009). Susceptibility data in our present 
study were not comparable to the study reported from the Vhembe district; in our 
study, isolates were least susceptible to ciprofloxacin and tetracycline, with an 
overall susceptibility of less than 43%. Moreover, isolates showed the highest 
susceptibility to erythromycin, with an overall susceptibility of 90%, followed by 
azithromycin, with an overall susceptibility of 86%. 
 
4.1.8.1.    Antimicrobial susceptibility patterns of C. jejuni 
 
Of the total 229 Campylobacter isolates tested against the different antimicrobials in 
the study, 185 were C. jejuni.  These isolates showed the highest susceptibility to 
erythromycin (92%) and azithromycin (88%). Over 50% of the C. jejuni isolates were 
resistant to both ciprofloxacin and tetracycline with only a small fraction of these 
isolates intermediately resistant to both the antimicrobials. Susceptibility against 
ciprofloxacin and tetracycline was accounted for by 41% and 44% of the C. jejuni 
isolates respectively. This renders tetracycline the third treatment option for C. jejuni 
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infections over ciprofloxacin, while erythromycin may be the first treatment option 
against C. jejuni infections in South Africa, followed by azithromycin.  
 
4.1.8.2.    Antimicrobial susceptibility patterns of C. coli 
According to Best et al., (2003) antimicrobial susceptibility profiles of C. jejuni and C. 
coli differ, particularly for erythromycin and ciprofloxacin. Species-specific 
association of erythromycin resistance has been linked to C. coli, whereas 
tetracycline and quinolone resistance showed no affinity for either species of 
Campylobacter (Wimalarathna et al., 2013). In our current study, resistance against 
erythromycin and azithromycin for the 40 C. coli isolates was slightly higher than 
seen for C. jejuni isolates; a similar observation has been reported by Jonker and 
Picard, (2010) for animal isolates in the Western Cape region. A total of 18% of the 
C. coli isolates were resistant to erythromycin and 23% were resistant to 
azithromycin. Nonetheless, majority of the C. coli isolates were sensitive to both the 
macrolides, accounting for 82.5% and 77.5% for erythromycin and azithromycin 
respectively. Susceptibility, intermediate resistance, and complete resistance against 
ciprofloxacin and tetracycline were similar for the C. coli isolates; a binomial pattern 
of antimicrobial resistance previously reported by Jonker and Picard, (2010) for 
macrolides was seen for ciprofloxacin and tetracycline in our current study. 
Distribution of these isolates between being susceptible and resistant against 
ciprofloxacin and tetracycline was virtually equally distributed. Macrolides are more 
clinically useful to combat C. coli infections as compared to ciprofloxacin and 
tetracycline whose clinical usefulness has been compromised for isolates in our 
current study with almost 50% of the isolates being resistant. 
 
4.1.8.3.   Antimicrobial susceptibility patterns of non-C. jejuni/C. coli  
Complete susceptibility against erythromycin and azithromycin was observed for all 
four non-C. jejuni/C. coli isolates. One of these isolates was susceptible against 
ciprofloxacin, while the remaining showed complete resistance to both ciprofloxacin 
and tetracycline.  As seen for infections caused by C. jejuni and C. coli, macrolides 
prove to be a better treatment option; while antimicrobial treatment of Campylobacter 
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infections is infrequent, as majority of human infections are self-limiting, macrolides 
are recommended for the treatment of laboratory confirmed Campylobacter cases 
(Wimalarathna et al., 2013). 
 
4.1.8.4.    MDR Campylobacter species 
MDR Campylobacter was accounted for by 3.1% of the 229 isolates tested against 
antimicrobials included in the study. Four of these isolates were C. jejuni and three 
were C. coli. Only one of these isolates was from a child of less than five years of 
age, while the remaining six were individuals aged >19 years. It is plausible that this 
may be an underreporting of the actual number of MDR Campylobacter cases in 
South Africa because over 40% of the Campylobacter isolates in the study were non-
culturable for antimicrobial testing. Nevertheless, studies reporting the emergence 
and mechanisms of MDR Campylobacter have been documented (Wieczorek and 
Osek, 2013). The global resistance to fluoroquinolones together with the increase in 
macrolide resistance, particularly in developing countries, poses a great threat for 
human health (Aarestrup and Engberg, 2001; Wieczorek and Osek, 2013; Wang et 
al., 2014). Resistance stemming from inappropriate use or failure to complete the 
prescribed course of antimicrobials does not sufficiently explain the increasing 
burden of antimicrobial-resistant Campylobacter because many of these infections 
resolve on their own. In addition, human-to-human transmissions are uncommon, 
providing minimal opportunity for resistant strains of Campylobacter to propagate 
(Wimalarathna et al., 2013). The epidemiology of antimicrobial-resistant 
Campylobacter in South Africa still stands subject for investigation. 
 
Globally, studies conducted to compare antimicrobial resistance patterns of human 
Campylobacter clinical isolates with that recovered from chicken meats have found 
patterns of human isolates and chicken meats to be comparable (Jonker and Picard, 
2010; Silva et al., 2011; Bester and Essack, 2012; Wimalarathna et al., 2013). 
Robust molecular characterizing techniques such as MLST have shown association 
between clinical isolates of human Campylobacter with that recovered from poultry, 
which suggests that is it plausible that antimicrobial resistance patterns from poultry 
will therefore also be prevalent in human clinical isolates (Gormley et al., 2010; Vidal 
et al., 2016) but the precise pathways stands subject for investigations. Events that 
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result in favour of resistant strains occur potentially on poultry farms and HGT has 
been described to have a major role in these events (Wimalarathna et al., 2013). 
 
 
4.2. Animal isolates 
As seen from the surveillance programs concerned with human health included in 
our study, C. jejuni was the most commonly detected species of Campylobacter from 
animal isolates submitted from the Gauteng and the Western Cape Provinces, with 
the remaining few isolates accounted for by C. coli. Animal isolates were not 
submitted in a systematic manner and therefore the sample size was too small to 
make substantial comparisons with isolates from human hosts as far as transmission 
from animal to human is concerned. 
 
Animal Campylobacter isolates from Gauteng (n=12) and Western Cape (n=6) tested 
against azithromycin and erythromycin showed complete susceptibility against these 
macrolides. However, the number of received animal isolates was small to reflect 
plausible antimicrobial patterns of animal isolates in South Africa. Studies reporting 
macrolide resistance have been documented in different poultry and pig production 
systems in South Africa where they are the recommended drugs in veterinary 
medicine to treat infections of Mycoplasma and Spirochaete (Jonker and Picard, 
2010).  
 
Fluoroquinolone resistance in animal husbandries has been associated with bird 
treatment of resistant E. coli infections, which may possibly be the treatment method 
used in South Africa, reflected by the high resistance patterns (61%; 11/18) noted for 
the animal isolates. However, it is worth noting that the sample size was small in our 
current study. Only two of the Gauteng chicken isolates were susceptible to 
ciprofloxacin while four of the Western Cape isolates were susceptible, with one 
intermediately resistant isolate and one isolate with complete resistance against 
ciprofloxacin. This may reflect different antimicrobial therapies administered in 
different provinces (Jonker and Picard, 2010). In South Africa tetracyclines are 
extensively used both in the poultry and pig farms (Jonker and Picard, 2010; Bester 
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and Essack, 2012), which may explain the high level of resistance (83%) obtained 
for this class of antimicrobial agents against the tested animal isolates in our study. A 
similar case of isolates from commercially raised chickens showing high rates of 
resistance against tetracycline was reported in KwaZulu-Natal (Bester and Essack, 
2012). In Gauteng and Western Cape similar resistance patterns have been reported 
for tetracycline resistance (Jonker and Picard, 2010). 
  
 
4.3. Population structure of C. jejuni isolates defined by MLST 
MLST was performed on viable pure cultures of South African C. jejuni isolates from 
human hosts (n=84) and animal hosts (n=9). These isolates (n=93) proved to be 
highly diverse with a total of 33 different sequence types belonging to 16 different 
clonal complexes. The identified STs for these isolates were comparable to 
frequently identified C. jejuni STs associated with human infections (Colles et al., 
2003; Manning et al., 2003; Dingle et al., 2005; Sheppard et al., 2009; Nielsen et al., 
2010; Vidal et al., 2016). The most predominant STs identified in this study were ST-
7997, ST-257, ST-19, ST-475, ST-572, and ST-227 in the order of increasing 
number of isolates found in each ST respectively. ST-227 and ST-572 were the most 
frequently identified STs for the C. jejuni isolates in the study accounting for 13% and 
10% respectively for all typable C. jejuni isolates with defined STs. These STs have 
been reported in many European countries, and in the USA in association with 
human disease (Colles et al., 2003; Manning et al., 2003; Sails et al., 2003; Kinana 
et al., 2006; Sheppard et al., 2009). Two human isolates represented by ST-474 
were identified in the study; ST-474 has been reported to be rare in other countries, 
but highly prevalent in New Zealand, associated with isolates of human and poultry 
origin (Biggs et al., 2011). 
 
All typable isolates could be grouped into clonal complexes with the exception of 
isolates belonging to ST-6091 and ST-881 which were not assigned to any clonal 
complex in the PubMLST database. Five clonal complexes frequently associated 
with the typable isolates in the study were ST-45 complex, ST-257 complex, ST-48 
complex, ST-21 complex, and ST-206 complex in the order of increasing number of 
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isolates in each clonal complex. ST-206 complex was represented by 25 isolates, 
accounting for 27% (25/91) of all the typable isolates with defined clonal complexes. 
ST-21 complex was the second common clonal complex, followed by ST-48 
complex, accounting for 23% (21/91) and 13% (18/91) respectively. These clonal 
complexes fall amongst previously described clonal complexes associated with over 
60% of human disease isolates (Dingle et al., 2002; Colles et al., 2003; Best et al., 
2005). Many studies report a predominance of ST-21 complex (Colles et al., 
2003;Manning et al., 2003; Nielsen et al., 2010), an observation not seen in this 
study; with ST-206 complex taking precedence. Nevertheless, it could be that the 
isolates that were non-viable (>40%) represent some of the clonal complexes 
reported to be common among human disease isolates. 
 
Province distributions of STs between Gauteng and Western Cape varied, with a few 
shared STs and clonal complexes. ST-227 complex and ST-206 complex 
represented the most common strains of C. jejuni in Gauteng, and ST-7997 complex 
and ST-21 complex represented the most common strains of C. jejuni in Western 
Cape. However, diversity within isolates of the respective provinces was still 
substantial.  
 
Shared STs and clonal complexes between isolates of human hosts and animal 
hosts was observed, they were represented by ST-227, ST-257, ST-7997, ST-21, 
and ST-52. All the STs were common in human isolates and isolates of chicken 
origin, with the exception of ST-21 which was common between a human isolate and 
an isolate of bovine origin. These findings were consistent with previous reports of 
human isolates overlapping with veterinary isolates which may signify potential 
transmission from animal to human through the food chain (Colles et al., 2003; Sails 
et al., 2003; Kinana et al., 2006; Sheppard et al., 2009; Cody et al., 2015; Fernandes 
et al., 2015; Vidal et al., 2016). ST-21 complex, which was the most common clonal 
complex for the animal isolates, and the second most common clonal complex 
amongst human isolates, has been reported to be the most stable cluster of isolates 




Although three STs (ST-381, ST-613, and ST-1932) found in animal isolates [bovine 
(ST-381); and chicken (ST-613 and ST-1932)] were not found in human isolates in 
our current study, these isolates had common clonal complexes with human isolates 
(ST-21 complex, ST-48 complex, and ST-460 complex). Studies carried out to 
subtype Campylobacter have reported that isolates from human hosts and animal 
hosts are not totally congruent; suggesting that some isolates colonizing chickens do 
not infect humans, and conversely, some isolates infecting humans do not colonize 
chickens (Manning et al., 2003). The reported observation may in part explain the 
three STs of animal origin that do not overlap with the human isolates in our current 
study. Moreover the association of poultry samples with human Campylobacter 
infections have not been consistent, and of ruminants are less well defined (French 
et al., 2005). The genetic diversity observed in human disease isolates has also 
been reported in veterinary isolates; particularly in poultry samples (French et al., 
2005; Vidal et al., 2016). This reported observation held true for isolates in our 
current study, which was represented by 25 different STs for human isolates (n=84) 
and 8 different STs for animal isolates (n=9). However, in our current study the 
comparison (STs of animal isolates and STs of human isolates) was done to see if 
there are STs that were identified from our animal isolates (small sample number) 
that were not present in our human Campylobacter isolates (large sample number), 
not necessarily to emphasize that there are unique STs found in animals and not in 
humans, as our animal sample number was small to draw such conclusions. 
Although the sample size of animal isolates in the study was small to extrapolate 
substantial conclusions, potential existing diversity between the isolates could be 
seen by the number of sequence types and clonal complexes defining these isolates. 
Nevertheless, distinguished STs and clonal complexes appeared to be predominant 
between isolates of human origin and animal origin regardless of the small number 
of C. jejuni isolates. Other STs and clonal complexes of C. jejuni may still be present 
in South Africa. Manning et al., (2003) reported on three human South African C. 
jejuni isolates which had STs not represented by isolates in this study; these STs 
were ST-497, ST-631, and ST-442. This may reflect that isolates in the study have 
not covered all the possible C. jejuni STs in circulation in South Africa, which can 
only be unravelled through more molecular epidemiological studies of the genus 
Campylobacter. One ST identified in the study which was previously documented in 
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the PubMLST database originating from a South African (Cape Town) human C. 
jejuni isolate in 1994 (sporadic case) was ST-1471 belonging to ST-406 complex; the 
case patient was from Gauteng Province in our current study. Majority of the South 
African Campylobacter isolates documented in the PubMLST database are 
represented by ST-362 complex, a complex which was not identified for isolates in 
this study. C. jejuni isolates that could not be subtyped due to confounding factors 
such as difficulty obtaining growth and purity of bacterial cultures could represent 
other STs that were not represented presently in our current study. 
 
Non-typable isolates and isolates with new combinations of previously represented 
alleles, as well as the single case of novel alleles were included in the phylogenetic 
analysis to determine how they relate to typable isolates. Isolates with novel 
combinations of previously known alleles (NST) had one to three allele differences 
with typable isolates in the study, with the exception of NST.3 and NST.9, which had 
more than three allele differences with isolates in the study. The human isolate 
(NST.6) with novel allele combinations had more than three allele differences (glnA, 
gltA, tkt, and uncA) to ST-227. Majority of the NT C. jejuni isolates had one to three 
allele differences with the typable isolates in the study; e.g. NT.9 isolate from sheep 
had two allele differences (glnA and pgm) to ST-227. These isolates may not 
necessarily represent new clonal complexes as they do not have significant allele 
differences from typable isolates in this study. 
 
The Simpson’s diversity index of C. jejuni showed a significant degree of genetic 
diversity and a weakly clonal lineage ranging from 0.692 to 0.828 with a 95% 
confidence interval. The uncA locus was found to be the less diverse allele 
associated with less different repeats as compared to aspA, glnA, and tkt, associated 
with significant number of different repeats. These findings coincided with a study by 
Kinana et al., (2006) and conversely opposed the findings by Colles et al., (2003) 
describing high diversity in the uncA locus. The population structure of isolates in the 
study resembled that of high genetic diversity and weak clonality, as with C. jejuni 
isolates from previous studies (Meinersmann et al., 2002; Colles et al., 2003; 
Manning et al., 2003; Sails et al., 2003; Kinana et al., 2006; Vidal et al., 2016). The 
driving force influencing the evolution of C. jejuni is primarily intraspecific 
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recombination (Suerbaum et al., 2001; Biggs et al., 2011; Sheppard et al., 2011; 
Sheppard and Maiden, 2015).   
 
4.4. Rotavirus Surveillance Program   
The detection rate of Campylobacter was 7% (69/981) for children of less than five 
years of age with diarrhoea in South Africa.  Majority of the positivity was accounted 
for by children aged less than two years, represented by 85% (59/69) of the positive 
samples. The results coincided with previous reports showing the prevalence of 
campylobacteriosis to be hyperendemic among the young in developing countries, 
particularly those aged less than two years of age (Acheson and Allos, 2001; 
Mshana et al., 2009). However, the detection of Campylobacter could not confidently 
be associated with the resultant diarrhoea as this could be asymptomatic carriage; 
other untargeted enteropathogenic bacteria could be the underlying cause of 
diarrhoea. For both the young and adults residing in developing countries, 
asymptomatic infections with Campylobacter occur (Acheson and Allos, 2001) due to 
recurrent Campylobacter infections as residents are repeatedly exposed (Wierzba et 
al., 2008). 
 
The most predominant species of Campylobacter identified was C. jejuni, accounting 
for 81% of the positive samples for Campylobacter. The high detection of C. jejuni 
was similar to what was observed from the Campylobacter Surveillance Program, 
which coincided with previous reports of C. jejuni being the most ubiquitous species 
of Campylobacter associated with human infections, followed by C. coli, which in this 
study accounted for 13% of the positive samples (Moore et al., 2005; Persson and 
Olsen, 2005; Chokboonmongko et al., 2013; Ioannidou et al., 2013; Mason et al., 
2013; Wagenaar et al., 2013; Schielke et al., 2014; Vidal et al., 2016). In 1990, 
Konkel and Joens postulated a possible synergistic relationship between C. jejuni 
and other enteric pathogens to exist in developing countries. Other enteric 
pathogens, particularly viruses, which mediate virus-induced alterations in cell 
membrane receptors, may contribute to Campylobacter colonization and penetration; 
this possibility was considered because these samples were from a Rotavirus 
Surveillance Program aimed at identifying aetiological agents associated with 
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childhood diarrhoea, primarily viruses. Children coinfected with both C. jejuni and C. 
coli were identified (6%), while other species of Campylobacter (non-C. jejuni/C. coli) 
were not detected from this study group, as seen from the 0-4 age group from the 
Campylobacter Surveillance Program. 
 
Majority of the positive samples were slightly more from males (54%) than females 
(46%), proportions which were similar to what was observed from the Campylobacter 
Surveillance Program.  
 
Campylobacter was detected throughout February 2014 to December 2015, during 
which the third annual quarter had the highest number of positive cases (38%), 
followed by the first and second quarter accounting for 26% and 20% respectively. 
The fourth annual quarter had the lowest number of screened samples, and 
subsequently the lowest number of detected Campylobacter, accounting for 13%.  
There was synergy between the number of screened samples and the frequency of 
detected Campylobacter; the higher the number of screened samples, the higher the 
likelihood of detecting Campylobacter.  
 
Majority of the detected Campylobacter were from Chris Hani Baragwanath Hospital 
(45%), followed by Red Cross Childrens Hospital (14%), Edendale Hospital (13%), 
and lastly Mapulaneng Hospital (10%). Provinces represented by these study sites 
were Gauteng, Western Cape, KwaZulu-Natal, and Mpumalanga respectively. As 
with isolates from the Campylobacter Surveillance Program, detected 
Campylobacter species from the respective provinces is only a reflection of which 
hospitals sent in more specimens for the Rotavirus Surveillance Program, and not 







4.5. Acute Flaccid Paralysis Surveillance Program 
 
4.5.1.  Detection of Campylobacter from AFP patients  
The most predominant species of the 12% (62/512) detected Campylobacter from 
the AFP Surveillance Program was C. jejuni; accounting for 77.4% and C. coli was 
the second most frequently detected species of Campylobacter, accounting for 
19.4%, while coinfection with both C. jejuni and C. coli was the least detected, 
accounting for 3.2%. C. jejuni is a well-documented trigger of GBS; however, an 
interesting finding was the detection of C. coli from stool specimens of AFP patients. 
According to Nachamkin (1977), it is unknown whether C. coli is also an elicitor of 
GBS. C. coli was also detected as a coinfecting pathogen with C. jejuni. In 
developing countries, asymptomatic infections with Campylobacter occur (Acheson 
and Allos, 2001) due to recurrent Campylobacter infections as residents are 
repeatedly exposed (Wierzba et al., 2008). This could in part explain the detection of 
species of Campylobacter from AFP patients which have not yet been documented 
as elicitors of the sequelae. If C. coli remains overruled as a trigger of GBS, 
pathogens documented as triggers of GBS (Aspinall et al., 1994), other than 
Campylobacter, may be the underlying cause of AFP in those patients with positive 
C. coli results and those from which Campylobacter was not detected, which remains 
considerably high (88%; 452/512).  
 
The detection of C. jejuni from specimens of AFP patients can only be interpreted as 
possible elicitors of the resultant AFP. Not all serotypes of C. jejuni trigger GBS; 
specific serotypes of C. jejuni found globally and in Cape Town, RSA, have been 
documented (Goddard et al., 1997; Lastovica et al., 1997; Wassenaar et al., 2000; 
Quiñones et al., 2008). To ascertain that the detected C. jejuni were a trigger of 
GBS, a PCR-based serotyping technique targeting serotypes frequently associated 
with GBS would need to be designed to screen all the C. jejuni positive samples from 




4.5.2. Annual occurrences of detected Campylobacter 
Specimens from which Campylobacter was frequently detected were submitted 
during quarter one, three, and four which are characterized by warmer months 
compared to quarter two (with low number of detected Campylobacter) characterized 
by cooler months. Most GBS cases are reported to be sporadic; however, a 
seasonal trend has been reported with a surge in the summer months according to 
Nachamkin et al., (1998) as well as Dimachkie and Barohn (2013). Studies 
describing the precise seasonal distribution of GBS are still lacking, however, 
summer peaks of GBS have been reported in China, Mexico, and Spain (Nachamkin 
et al., 1998; Nyati and Nyati, 2013). In 2008, Wierzba and colleagues reported GBS 
to lack a marked seasonal variation in Egypt, a developing country. Seasonal trends 
of GBS in South Africa have not yet been documented and the study period was 
short to define seasonal trends for positive cases in this study.  
 
4.5.3. Distribution of detected Campylobacter by sex 
Sex distribution has in almost all reports shown males to be more frequently 
associated with Campylobacter-induced GBS in comparison to females (Nachamkin 
et al., 1998; Desai et al., 2010; Islam et al., 2012; Nyati and Nyati, 2013). Most of 
these studies investigating Campylobacter-induced GBS are conducted in developed 
countries. One study conducted in Egypt, a developing country, showed the frequent 
association of GBS cases with males which coincides with what is observed in 
developed countries (Wierzba et al., 2008). However, in our study, although not 
statistically significant (p-value <0.22), it was specimens from females from whom 
more Campylobacter was detected than males, accounting for 55% and 45 % 
respectively. This observation was the inverse of what was observed for isolates 
from the Campylobacter Surveillance Program and samples from the Rotavirus 
Surveillance Program where there were more males among infected persons.  
To further substantiate the findings, polio negative specimens screened for the 
presence of   mpy ob  te  during the October 2014-December 2015 were more 
frequently from males (53%; 271/512) than females (47%; 239/512). According to 
Lastovica et   ., (1997) the nine GBS patients from which   mpy ob  te  species 
 102 
 
were recovered from Groote Schuur and Red Cross hospital (Cape Town, RSA), five 
were males and four were females. Therefore, sex distribution of   mpy ob  te  
positive specimens of GBS patients in this study was not comparable with previous 
reports of GBS being slightly more common in males than females (Lastovica et   ., 
1997; Nachamkin et   ., 1998; Nyati and Nyati, 2013). 
 
 
4.5.4. Distribution of detected Campylobacter by age category 
AFP patients from whom Campylobacter was frequently detected were those aged 
0-2 years (37%), 3-5 years (32%), and those aged 6-9 years (18%). Campylobacter 
species were not detected in all age groups, other age groups with relatively few 
specimens from which Campylobacter was detected were those aged 10-19 years 
(6%), and the single adult case (40-49 age group) accounting for 2%, as well as the 
5% represented by patients of unspecified age groups. Age-specific trends in this 
surveillance program were similar to what was observed previously (Campylobacter 
and Rotavirus Surveillance Programs) and the risk factors associated with these age 
groups described previously were applicable for the AFP case patients. 
 
According to Khuzwayo et al., (2013) a case definition of AFP in South Africa is 
defined as any child of less than 15 years of age presenting with acute onset of focal 
weakness or paralysis which is characterized as flaccid, including GBS, without any 
other obvious cause. This explains why majority of the Campylobacter positive cases 
in this study were accounted for by children and teenagers, which are individuals 
forming part of the AFP case definition. A study conducted in Egypt by Wierzba et 
al., (2008) showed the incidence of C. jejuni-induced GBS to be higher in children 
from developing countries; an observation which contrasts reports from developed 
countries where the prevalence of GBS is commonest among adults (Nachamkin et 
al., 1998; Desai et al., 2010; Islam et al., 2012). According to Nyati and Nyati, (2013) 
all age groups are implicated with GBS, however, reports have shown incidence of 
GBS to increase with age, and according to Islam et al., (2012) C. jejuni-induced 
GBS incidence is lower in children. Nevertheless, results from our study coincided 




Given that gastroenteritis due to C. jejuni infections are hyperendemic among young 
children (<5 years) in tropical resource-poor settings, it is expected that the 
prevalence of C. jejuni-induced GBS would be prevalent among individuals of less 
than five years of age. Reports of bimodal distribution of GBS cases by age, with 
more identified cases in young adults (15-30) and the elderly (significantly higher) 
have been document (Nachamkin et al., 1998; Desai et al., 2010; Islam et al., 2012; 
Nyati and Nyati, 2013). However, an increase in the detection of Campylobacter with 
age, as well as the bimodal distribution (AFP case definition: <15 years) of positive 
cases by age in this AFP study group was not observed. 
 
4.5.5. Province distribution of detected Campylobacter 
The majority of detected C. jejuni was from stool specimens submitted from the 
Eastern Cape and Gauteng Province respectively. The difference in the total number 
of screened stool specimens submitted from Eastern Cape and KwaZulu-Natal, as 
well as between Limpopo and Mpumalanga was one; however, the number of 
detected C. jejuni did not correlate between the compared provinces. The Eastern 
Cape Province had ten more detected C. jejuni than KwaZulu-Natal, and Limpopo 
had four more detected C. jejuni than Mpumalanga. The synergy observed from the 
Rotavirus Surveillance Program where the more samples screened the higher the 
likelihood of detecting Campylobacter did not hold true for AFP stool specimens. For 
example, stool specimens were submitted the most from the Gauteng Province, 
however, only 11/104 were positive for C. jejuni, whereas in the Eastern Cape 
Province 17/94 were positive for C. jejuni. The detection of C. jejuni from the 
respective provinces may be largely compromised by the fact that many 
Campylobacter-induced GBS cases go unreported because by the time patients 
present with AFP the bacteria has already been eliminated from the body (Allos, 
1997; Nachamkin, 1997; Poropatich et al., 2010). According to Nechamkin, (1997) 
history of antimicrobial use from patients with GBS should be clarified, as their use 





The GERM-SA surveillance program is laboratory-based which means that bacterial 
cultures were submitted only for patients from whom stool specimens were collected. 
Laboratory-based surveillance may not best represent the burden of Campylobacter 
in South Africa, especially because this was the first study ever to investigate the 
prevalence of Campylobacter at a national level. Furthermore, only the Western 
Cape and Gauteng Provinces showed participation in the Campylobacter 
Surveillance Program, therefore data in this study are not representative of South 
Africa as far as Campylobacter infections are concerned, as many laboratories from 
the rest of the provinces did not show substantial submission of isolates. 
Nevertheless, the focus of this study was not to describe the incidence rate of 
Campylobacter in South Africa, but rather to characterize Campylobacter isolates 
using molecular tools utilized in the our current study. The fastidious nature of 
Campylobacter species made it challenging to maintain culture viability; the majority 
of isolates lost viability during transportation to CED, and some of the isolates lost 
viability upon storage. This compromised obtaining antimicrobial susceptibility 
profiles as well as subtyping some of the isolates using MLST. The possibility of 
Campylobacter asymptomatic carriage rendered the detection of Campylobacter 
from samples from the Rotavirus Surveillance Program and the AFP Surveillance 
Program inconclusive with respect to the fact that we could not definitely link disease 
(diarrhoea or AFP) to the Campylobacter organism, i.e., we could not say for sure 
that Campylobacter was causing the disease. However the findings are highly 
suggestive that Campylobacter might be associated with the resulting diarrhoeal 
diseases and AFP cases.  In addition, information on history of diarrhoea for AFP 
patients was not available and the detected C. jejuni were not further characterized 
to determine their serotypes, therefore could not be confidently associated with AFP 
because only certain serotypes of C. jejuni elicit AFP. The AFP analysis was also 
limited by the absence of non-AFP control group, which makes it challenging to 
interpret these finding without knowing the background prevalence of Campylobacter 




There was insufficient published literature describing the epidemiology of 
Campylobacter infections in South Africa or developing countries, therefore findings 
in this study were more concluded upon based on what has been reported in 
developed countries, a situation which may disqualify unique Campylobacter 
patterns in South Africa.  
The multiplex real-time PCR assay used in this study only targeted C. jejuni and C. 
coli, which compromised the species detection other campylobacters in the study. 
The use of PCR to detected Campylobacter directly from specimens of AFP patients 
compromised obtaining the detected species in culture, where more phenotypic tests 
could be conducted to further characterize the isolates, which could help reveal if 
there was an association of Campylobacter to GBS for AFP patients in our study. 
Majority of the patients enrolled in the AFP Surveillance Program were aged <15 
years, which narrowed down other potential at risk age groups for AFP, which could 
be caused by Campylobacter. As part of the objectives, the identification of potential 
transmission routes of Campylobacter from non-human isolates (food sources from 
animals) to humans was investigated; however, despite many appeals, veterinary 
sectors did not send isolates to the CED systematically for such investigations to be 
conducted. Thus potential sources of Campylobacter infections in South Africa could 
not be identified in our current study. 
 
4.7. Future prospects 
This study produced preliminary data on Campylobacter infections in South Africa. 
Therefore, surveillance of Campylobacter needs to be expanded in order to establish 
the incidence of Campylobacter infections in South Africa. This will aid in the 
monitoring of emerging Campylobacter strains and MDR Campylobacter since 
macrolides were more clinically effective against the isolates as compared to 
ciprofloxacin and tetracycline with high resistance profiles. An established 
surveillance which is representative of South African Campylobacter isolates will 
help encourage molecular epidemiological studies, which will help identify patterns of 
important strains, as well as motivate vaccine developments. Subsequently, such 
efforts will help fill the current existing research gaps for Campylobacter through new 
published literature in South Africa. Participation of more veterinary laboratories is 
 106 
 
necessary in order to investigate possible transference between animals and 
humans. The use of MLST in such studies will enable us to identify common strains 




Chapter 5: Conclusions 
 
 
This study represented the first comprehensive study looking at the molecular 
epidemiology of Campylobacter in South Africa. The baseline data provided by this 
study included: prevalent species of Campylobacter characterized by real-time PCR, 
possible risk factors and risk groups of infection, antimicrobial susceptibility profiles, 
and the genetic population structure of predominant species of Campylobacter in 
circulation in South Africa using MLST. The burden estimate of Campylobacter was 
further investigated by screening specimens from various surveillance programs; 
which included specimens from the Rotavirus Surveillance Program, which is 
concerned with aetiology of childhood diarrhoea (<5 years) as well as polio negative 
stool specimens from the AFP Surveillance Program to determine the proportion of 
AFP possibly associated with species of Campylobacter, particularly C. jejuni.  
 
The burden of Campylobacter infection in South Africa may have been 
underestimated as a result of lack of Campylobacter surveillance; 94% (801/848) of 
the isolates submitted for the Campylobacter Surveillance Program were positive for 
species of Campylobacter and real-time PCR proved useful characterizing these 
isolates. The most predominant species of Campylobacter identified from all 
surveillance programs included in this study was C. jejuni, which collectively 
accounted for over 80% of all Campylobacter positive cases and C. coli was the 
second most detected species of Campylobacter. Coinfection with both C. jejuni and 
C. coli was identified in some case patients in the respective surveillance programs. 
Non-C. jejuni/C. coli species were detected only from the Campylobacter 
Surveillance Program, which signifies that other species of Campylobacter, although 
presently low in numbers, are causing disease and should be monitored. 
Campylobacter positive samples from the Rotavirus and AFP Surveillance Programs 
could not, with utmost certainty, be associated with campylobacteriosis; due to the 
high level of asymptomatic cases of Campylobacter reported in developing countries, 
as a result of repeated exposure which stems from living in close proximity with 
animals. There is a pressing need for the public to be educated about the 
ramifications associated with living in close proximity with animals and to raise more 
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awareness of Campylobacter infections, which are currently still under reported in 
South Africa as a common disease which affects many people. Emphasis on good 
hygiene practices should be motivated, which includes good food handling practices, 
particularly after being in contact with animals, handling raw meats, and after using 
the toilet. 
 
C. jejuni detected from the AFP Surveillance Program could not be attributed to GBS 
with confidence because specific serotypes of C. jejuni are associated with the 
development of GBS; a serotyping test was not performed for these isolates. The 
detected percentage of C. jejuni could only serve to motivate future studies that will 
examine the true proportion of GBS attributed to Campylobacter infection, and to 
readdress the potentially undiscovered or underreported cases of C. jejuni-induced 
GBS in South Africa. 
 
The detection of   mpy ob  te  by sex showed males to be slightly more associated 
with campylobacteriosis as compared to females, represented by 54% for case 
patients from the   mpy ob  te  Surveillance Program, and by 54% for case 
patients from the Rotavirus Surveillance Program respectively. Conversely, it was 
females from the AFP Surveillance Program from which   mpy ob  te  was more 
frequently detected, accounting for 55%. Extended studies involving the screening of 
stools of AFP patients for   mpy ob  te  would need to be conducted to ascertain 
whether or not females are the risk group for GBS than males (documented risk 
group for GBS) in South Africa. Statistically, the sex-specific differences noted in all 
surveillance programs included in the study were not significant (p>0.05). The 
precise risk factors associated with sex-specific differences for campylobacteriosis in 
South Africa can only be addressed by continued long-term epidemiological studies. 
 
For age of patients, three age-groups were identified as the highest risk groups as 
concluded by data from the   mpy ob  te  Surveillance Program; at risk groups 
were children (35%; <5 years), young adults (12%; 25-34 years), and the elderly 
(10%; >65 years). At risk groups identified from the Rotavirus Surveillance Program 
were children aged <1-12 months (62%) and 13-24 months (23%), and those aged 
<1-2 years (37%) and 3-4 years (32%) from the AFP Surveillance Program. The high 
incidence of   mpy ob  te  among these age risk groups requires interventions that 
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will control and prevent the persistent burden of disease in these age groups. 
Although sex-related differences of incidence held true with previous reports of men 
being more frequently implicated than females; age- and sex-related patterns of 
campylobacteriosis in this study revealed female infections to surpass those of 
males at certain age groups and the findings were statistically significant (p-value 
0.02). Female at risk age-groups were those aged 25-34; 35-44; and >65 in years 
from the   mpy ob  te  Surveillance Program, an observation which requires further 
investigation to determine risk factors associated with these groups in South Africa 
for control and prevention strategies to be put in place. 
 
A pseudo-seasonal pattern for   mpy ob  te  infections was identified for isolates 
from the   mpy ob  te  Surveillance Program; a pattern that was characterized by a 
surge in the warmer months, followed by a rapid decline in the winter months. 
Summer, autumn, and spring may be seasons associated with incidence of 
  mpy ob  te ; however, further studies would need to be carried out to deem these 
preliminary findings valid, because seasonal patterns for   mpy ob  te  in 
developing countries are not well defined. Isolates from the Rotavirus and AFP 
Surveillance Programs lacked a marked seasonal pattern, with identified peaks even 
during winter. 
 
All isolates from the   mpy ob  te  Surveillance Program were sporadic cases, with 
no reported outbreaks during the course of the study, however, one questionable 
significant peak during the fourth quarter of 2014 and first quarter of 2015 was 
observed, accounting for 54% and 36% respectively, particularly in the Gauteng 
province. Significant conclusions to such observations can only be answered once a 
baseline study, with a suitable denominator is established, from which meaningful 
conclusions can be made, whether or not these numbers reflected an outbreak. 
 
 
Cases of invasive   mpy ob  te  infections were rare, remaining as low as 0.6% 
and associated more with children than adults. Other emerging   mpy ob  te  
species should in future be monitored, as some of the identified non-   jejun /    o   





Antimicrobial-resistant   mpy ob  te  species are a growing concern, an 
observation dictating the pressing need for control strategies and strict regulations of 
antibiotic use.   mpy ob  te  isolates in this study were extensively resistant against 
ciprofloxacin and tetracycline, but showed more susceptibility to the macrolides 
(erythromycin and azithromycin), particularly erythromycin, with a total of 90% 
susceptible isolates. The monitoring of   mpy ob  te  antimicrobial susceptibility 
profiles is essential, in order to continually assess the clinical usefulness of 
recommended drugs; such as macrolides which are gradually gaining resistance, 
and to put regulations in place to control and prevent the spread of resistant isolates. 
Cases of MDR   mpy ob  te  were identified which was accounted for by 3.1%, 
however, more MDR   mpy ob  te  species may be in circulation, current 
observations may be underreporting   mpy ob  te  MDR cases due to difficulties 
encountered when growing cultures for antimicrobial testing. 
 
Although the collection of animal isolates to source attribute   mpy ob  te  
infections was not successful, with only 18 isolates received between January 2014-
December 2015, species of   mpy ob  te  identified were the same as those from 
human isolates, with a predominance of    jejun  and less of     o  . The generated 
antimicrobial susceptibility profiles were similar to those of human isolates; extensive 
ciprofloxacin and tetracycline resistance was observed, with isolates showing 
complete susceptibility against the macrolides. MDR   mpy ob  te  isolates were 
not identified from the animal sample set. A systematic approach of collecting animal 
isolates may form preliminary data that will aid in source attributing human 
  mpy ob  te  infections in South Africa, and to reveal if there is a link between 
antimicrobial resistance patterns seen in isolates from animal husbandries and 
human clinical isolates.  
 
MLST based on WGS data analysis was employed to study the genetic population 
structure of    jejun , which was the most prevalent species of   mpy ob  te . MLST 
proved to be an effective typing tool, discriminating strains based on their relative 
difference in their MLST loci on the basis of seven conserved housekeeping genes. 
High diversity and a weakly clonal lineage defined the molecular biology of    jejun  
isolates detected from the   mpy ob  te  Surveillance Program study; the diversity 
was further substantiated by the discovery of isolates with new alleles and STs yet to 
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be assigned in the PubMLST database. Of all the identified STs, ST-227 and ST-572 
were the most predominant STs, and ST-206 complex and ST-21 complex were the 
most predominant clonal complexes grouping the    jejun  strains in our current 
study. MLST aided in the identification of clones from geographically different 
regions; ST-227 and ST-206 complex represented the most common strains of C. 
jejuni in the Gauteng Province; ST-7997 and ST-21 complex represented the most 
common strains of C. jejuni in the Western Cape Province. Isolates of animal hosts 
and human hosts were compared using MLST, which revealed a few shared STs 
and clonal complexes between animal isolates (chickens and bovine) and human 
isolates, represented by ST-227, ST-257, ST-7997, ST-21, and ST-52. However, 
transmission of   mpy ob  te  from animal to human could not be deduced in our 
current study because the animal study was not well established. STs of animal C. 
jejuni strains that did not overlap with human C. jejuni strains were also identified, 
represented by ST-381, ST-613, and ST-1932.  
 
Although animal isolates were relatively of a small sample size, the diversity that 
exists between these isolates could be established by the number of identified 
sequence types and clonal complexes. These findings can form a foundation from 
which large scale feasible studies comparing veterinary and human C. jejuni isolates 
in South Africa can further be carried out to source track infections and alleviate the 
problem of limited data explaining the molecular epidemiology of Campylobacter in 
both the clinical and veterinary sectors in South Africa. Furthermore such findings 
may help guide the development of vaccines against the most virulent and prevalent 
species of Campylobacter.  
 
In South Africa, there are still research gaps regarding Campylobacter and studies 
such as this emphasise the importance of this organism in the public health domain. 
Although data in this study is still preliminary, with the possibility of epidemiological 
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Appendix A: Housekeeping genes for Campylobacter MLST 
 
The MLST scheme for Campylobacter is based on the sequence identification of 
multiple loci located in seven housekeeping genes. The following seven loci were 
chosen for C. jejuni MLST scheme (protein products are shown in parentheses): 
aspA (aspartase A), glnA (glutamine synthetase), gltA (citrate synthase), glyA (serine 
hydroxymethyl- transferase), pgm (phosphoglucomutase), tkt (transketolase), and 
uncA (ATP synthase alpha subunit) (Dingle et al., 2001; Schouls et al., 2003). 
 








(Dingle et al., 2001).











Appendix B: TE buffer for crude genomic DNA extraction 
TE buffer (10mM Tris, 1mM EDTA pH 8.0) 
10 mL 1M *Tris (pH 8.0) 
 2 mL 0.5M ᶲEDTA (pH 8.0) 
       
Two milliliters (mL) of 0.5 molar (M) EDTA at pH 8.0 was added to 10 mL of 1 M Tris  
at pH 8.0 and  the solution was diluted to final volume of 1000 mL with 988 mL sterile 
water and autoclave. 
 
*Tris (Merck, Darmstadt, Germany) 




Appendix C: Preparation and validation of QIAamp Fast DNA Stool Mini Kit 
 
Preparation of reagents in QIAamp Fast DNA Stool Mini Kit for extraction 
  
 The precipitants in Buffer AL and InhibitEX Buffer were dissolved by 
incubating in a water bath set at 55 °C and each of the buffers were 
thoroughly mixed by vortexing.  
 
 Buffer AW1 supplied as a concentrate was prepared to a working solution by 
adding of 25 mL absolute ethanol (100 %) to the concentrate and thoroughly 
mixed by vortexing. 
 
 Buffer AW2 supplied as a concentrate was prepared to a working solution by 
adding of 30 mL absolute ethanol (100 %) to the concentrate and thoroughly 
mixed by vortexing. 
 
 Buffer ATE was mixed by vortexing before use. 
 
 Proteinase K was mixed by inverting the tube up and down. 
 
To validate the extraction kit, a stool specimen from a healthy individual was spiked 
with 0.5 McFarland bacterial lysate in normal saline [Diagnostic Media Products 
(DMP), NHLS, RSA] prepared from C. jejuni (strain C12.2 - WHO EQA 2012) and C. 
coli (strain C9.1 - WHO EQA 2009) control strains respectively (100 µL bacterial 
lysate into ~200 mg stool specimen), following which DNA was extracted as outlined 
by the extraction protocol. Extracted DNA from spiked stool specimens yielded the 
expected PCR results for each control strain. 
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Appendix D: Campylobacter real-time PCR 
 
Table: Campylobacter target gene sequences and primer/probe sequences. 
 
*All primers were synthesized by Inqaba, Pretoria, RSA. 
ᶲAll probes were synthesized by Roche, Johannesburg, RSA. 
€ Target gene sequences were obtained from Best et al., (2003); Lund et al., 2004; 
and Botteldoorn et al., 2008. 
 
Campylobacter primer/probe mix preparation 
 
 70 µl of PCR/molecular grade water 
 30 µl of 100 µM mapA-F1 primer 
 30 µl of 100 µM mapA-R1 primer 
   6 µl of 100 µM mapA-probe1 probe 
 60 µl of 100 µM ceuE-F1 primer 
 60 µl of 100 µM ceuE-R1 primer 
 12 µl of 100 µM ceuE-probe1 
 60 µl of 100 µM Camp-F2 primer 
 60 µl of 100 µM Camp-R2 primer 
 12 µl of 100 µM Camp-probeP2 
 





sequence (3’-5’) Product   
size 
     
C. jejuni 
 









     
C. coli 
 






Cy5 - TTGGACCTCAATCTCGCTTTGGAATCATT -BBQ 
     
Non-C. 
jejuni/C. coli 






Cy3 - CAGAGAACAATCCGAACTGGGACA - BBQ 
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Primers and probes were received as lyophilized products, which were resuspended 
in TE buffer at pH 8.0 according to instructions outlined by the manufacturer to make 
100 µM working solution. The Campylobacter primer/probe mix for real-time PCR 
was prepared by adding reagents outlined above into a 1.5 mL amber tube and 
vortexed to mix and spun down. The mix was stored at -20°C. 
 
 
Volume of genomic DNA added into a 50 µL real-time PCR reaction. 
 
 Crude genomic DNA from culturable bacterial isolates-1µL 
 Crude genomic DNA extracted from non-culturable bacterial isolates in    
           transport media-4µL 
 Genomic DNA and nucleic acid from clinical specimens-7 µL 
 
Control strains for Campylobacter real-time PCR 
 
i. C. jejuni  positive control - (strain C12.2 - WHO EQA 2012) 
 
ii. C. coli positive control - (strain C9.1 - WHO EQA 2009) 
 
iii. Non-template control (NTC) – (autoclaved water) 
 
 
Interpretation of Real-time PCR results 
Positive results were indicated by an amplification plot showing a typical real-time PCR 
sigmoidal curve with samples showing calculated threshold cycle (Ct) values on the SDS 
7500 software. The ‘C. coli_ceuE’ detector was shown in a grey colour, the ‘C. jejuni_mapA’ 
detector was shown in a blue colour, the ‘Campy_16SrRNA’ detector was shown in a red 
colour, and the ‘IPC’ detector was shown in an orange colour (Figure below). The Ct values 
were interpreted differently for bacterial cultures and clinical specimens. For bacterial 
cultures a Ct value of 15-30 (positive results ranged between Ct values of 15-25) was 
accepted as a positive result, and for clinical isolates a Ct value of 15-38 (positive results 




Figure: Real-time multiplex PCR results showing sigmoidal curves and Ct values of 
amplified target genes. 
 
 






















+ + or – C. jejuni positive 
– + 
 
+ + or – C. coli positive 
– – 
 
+ + or – 
Positive for other non-C. jejuni/C. coli 
Campylobacter spp. 







Appendix E: Extraction and quantification of DNA for WGS 
 
Preparation of reagents in QIAamp DNA Mini Kit for extraction 
 
 The precipitants in Buffer AL were thoroughly mixed by vortexing. 
 Buffer AW1 supplied as a concentrate was prepared to a working solution by   
           adding of 25 mL absolute ethanol (100%) to the concentrate and thoroughly  
           mixed by vortexing. 
 
 Buffer AW2 supplied as a concentrate was prepared to a working solution by  
           adding of 30 mL absolute ethanol (100%) to the concentrate and thoroughly         
           mixed by vortexing. 
 
 Buffer ATE was mixed by vortexing before use. 
 Proteinase K was mixed by inverting the tube up and down. 
 
Preparation of Qubit™ Working Solution 
 The Qubit™ Working Solution was prepared by diluting the Qubit™ reagent    
           1:200 in Qubit™ buffer. 
 
 A total of 200 µL of Working Solution was prepared for each standard and  
           sample. 
 





Volume of Working Solution (Qubit™ 




199  µL 
Volume of Qubit™ Standard  
10  µL 
 
- 
Volume of DNA Sample  
- 
 
1  µL 
Total volume in each Assay Tube  
200  µL 
 
200  µL 
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Appendix F: Rotavirus Surveillance Program study sites 
 
Table: Study sites from the Rotavirus Surveillance Program. 
 
Study sites  Province Hospital Name 
1 Gauteng Chris Hani Baragwanath 
Hospital 
2 Mpumalanga Mapulaneng Hospital 
3 Mpumalanga Matikwana Hospital 
5 KwaZulu-Natal Edendale Hospital 
6 Western Cape Red Cross Childrens Hospital 
8 Northern Cape Kimberley Hospital 
9 Polokwane Polokwane Hospital 
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